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Accelerated  atherosclerosis  and  cardiovascular  disease  are  seen  in  patients  with 
primary  vasculitis  (PSV)  and  rheumatoid  arthritis  (RA).  The  mechanisms  behind  this 
remain  unclear,  but  recent  studies  have  linked  it  to  endothelial  cell  dysfunction  (ECD), 
which may result from the vasculitis also seen in RA, secondary to the joint disease.  TNFα 
has  been  shown  to  induce  ECD  in  vitro  and  in  vivo  through  poorly  understood 
mechanisms,  but  other  pro‐inflammatory  cytokines  can  induce  secretion  of  acid 
sphingomyelinase  (ASM)  from EC. ASM has been shown  to  induce  reduced  intracellular 
Ca2+  (iCa












S‐SMase  was  also  confirmed  in  35  patients  with  RA  (84.1  ±  35  pmol/mL/h‐1)  where 
enzyme  activity  correlated  with  several  CV  risk  factors.  TNFα  directly  induced  the 
secretion  of  a  redox‐sensitive  and  enzymatically  active  S‐SMase  from  human  umbilical 
vein EC (HUVEC), a process blocked by antibody‐mediated inhibition of TNFα. Exposure of 
HUVEC  to ASM  inhibited  iCa





inflammation  could  promote  increased  activation  and  secretion  of  S‐SMase  that would 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Ab      AntiBody 
ACPA      Anti‐Cyclic citrullinated Peptide Antibody 
ACC      Acetyl Coenzyme (A) Carboxylase 
AEBSF      [4‐(2‐aminoethyl)benzenesulfonyl fluoride hydrochloride] 
AICAR      5‐Aminoimidazole‐4‐carboxamide‐1‐βribofuranoside 
AMPK      Adenosine MonoPhosphate‐activated protein Kinase 
AMP/ATP    Adenosine MonoPhosphate/Adenosine TriPhosphate 
ANCA      Anti‐Neutrophil Cytoplasm Antibodies 
AASV      ANCA Associated Systemic Vasculitis 




bFGF      Basal Fibroblast Growth Factor 
BVAS      Birmingham Vasculitis Activity Score 
iCa
2+         Intra‐cellular molecular calcium; i[Ca
2+] 
Ca2+        Calcium 
CaM        Calmodulin 
CaMKII        Calcium/Calmodulin‐dependent Kinase II (CaMK2) 
CCA        Common Carotid Artery 
CD        Cluster of Differentiation 
Cer      Ceramide 
CHCC       Chapel Hill Consensus Conference 
CHO        Chinese Hampster Ovary cells 
CNS      Central Nervous System 
CSS      Churg‐Strauss Syndrome   
CSP      Constitutive Secretory Pathway 
CYC      CYcloPhosphamide 
DAN        2,3‐DiAminoNaphthalene 
DAF‐2        DiAminoFluorescein‐2 
DAG        DiAcylGlycerol 
DD        Death Domain 
DMEM        Dulbeco’s Modified Eagles Medium 
DMSO        DiMethyl SulfOxide  
DTT        DiThioThreitol 
EC        Endothelial Cell 
ECD        Endothelial Cell Dysfunction  
EGF        Endothelial Growth Factor 
EGTA        Ethylene Glycol Tetraacetic Acid 
EL        Endothelial Lipase  
eNOS        Endothelial Nitric Oxide Synthase 
EPC        Endothelial Progenitor Cell 
ER        Endoplasmic Reticulum  
   IX 
ERK        Extracellular signal Regulated Kinase 
FAN        Factor‐Associated with Neutral sphingomyelinase 
FCS        Fetal Calf Serum 
GCA      Giant Cell Arteritis 
GPA      Granulomatosis with PolyAngiitis  
GPCR        G‐Protein Coupled Receptor 
GSH        Glutathione (reduced) 
GSSG        Glutathione (oxidised) 
H2O2        Hydrogen eroxide 
HBSS        Hank’s Buffered Saline Solution (not loaded with Mg2+ and Ca2+) 
HBSS‐Ca2+      HBSS loaded with Mg2+ and Ca2+ 
HEPES        4‐(2‐hydroxyethyl)‐1‐piperazine ethane sulphonic acid 
HESFM        Human Endothelial Serum‐Free Medium 
HIFCS      Heat Inactivated Fetal Calf Serum 
HPLC      High Performance/Pressure Liquid Chromatography 
HSP      Henoch‐Schonlein Purpura 
hSerum        Human Serum 
hEGF        Human Endothelial Growth Factor 
hSMase        Human SMase (sphingomyelinase) 
HRP        Horseradish Peroxidise 
iCa
2+        intracellular Molecular Calcium 
Ig        ImmunoGlobulin 
IL         Interleukin 
IP3        Inositol triPhosphate 
kDa      Kilo Dalton 
KLH      Keyhole Limpet Hemocyanin 
LKB1      Liver Kinase B1 
LR      Lipid Raft 
L‐SMase    Lysosomal SphingoMyelinase (ASM splice variant) 
MCF‐7      Michigan Cancer Foundation 7, breast carcinoma cell line 
MHC      Major Histocompatibility Complex 
MI      Myocardial Infarction 
MMP      Matrix MetalloProteinase 
MPA      Microscopic PolyAngiitis 
MPO       MyeloPerOxidase 
MTS  (3‐(4,5‐Dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐2‐(4‐
sulfophenyl)‐2H‐tetrazolium) 
MTX      MeThotreXate 
M199      Medium 199 
M‐6‐P      Mannose‐6‐Phosphate 
NADH      reduced Nicotinamide Adenine Dinucleotide 
NBD      7‐Nitro‐2,1,3‐BenzoxaDiazol‐4‐yl 
NBD‐SM  (NBD‐sphingomyelin); NBD C6-sphingomyelin (6-((N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)amino)hexanoyl) sphingosyl phosphocholine) 
NF kB      Nuclear Factor Kappa B 
NO      Nitric Oxide 
   X 
NPD      Niemann‐Pick Disease 
NSMase    (nSMase) Neutra SphingoMyeliase 
PAN      Polyarteritis Nodosa 
PB      Peripheral Blood  
PBS      Phosphate‐Buffered Saline 
PCR      Polymerase Chain Reaction 
PIP2      PhosphatidylInositol 4,5‐biPhosphate 
PKCδ       Protein kinase C delta 
PKG      cGMP‐dependent protein kinase G (Protein Kinase G) 
PLC      PhosphoLipase C 
PMCA      Plasma Membrane Calcium ATPase (pump) 
PMR      Polymyalgia Nodosa 
PR3      Proteinase 3 
PSV      Primary Systemic Vasculitis 
PTP      Protein Tyrosine Phosphatase 
RA      Rheumatoid Arthritis 
rhASM     Recombinant Human Acid Sphingomyelinase 
Rho      Rho family of GTPases 
ROS      Reactive Oxygen Species  
RPMI      Roswell Park Memorial Institute (medium) 
RIPA      RadioImmunoPrecipitation Assay (buffer) 
SD      Standard Deviation 
SDS PAGE    Sodium Dodecyl Sulphate PolyAcrylamide Gel Electrophoresis 
SEM      Standard Error of the Mean 
SERCA      Sarco/Endoplasmic Reticulum Calcium ATPase (pump) 
SF      Synovial Fluid 
SM      Sphingomyelin 
SMase      Sphingomyelinase 
S‐SMase    Secretory Sphingomyelinase (ASM splice variant) 
STIM      STromal Interacting Molecule  
S1P      Sphingosine‐1‐Phosphate 
TAK      Takayasu’s Arteritis 
TBS      Tris‐buffered Saline 
TEMED    N,N,N’,N’‐Tetramethylethylenediamine 
TGF      Transforming Growth Factor 
TLC      Thin Layer Chromatography 
TNFα      Tumour Necrosis Factor Alpha 
TRAIL      TNF‐Related Apoptosis Inducing Ligand 
v/v      Volume over Volume (volume/volume) 
VDI      Vasculitis Damage Index 
WG       Wegener’s Granulomatosis 
x 3      Three times (referring to repetition of a procedure) 



















































































































































Rheumatoid  arthritis  (RA)  is  an  autoimmune  inflammatory  disease  that  affects 
approximately 1% of the population, it typically occurs in those between 40‐70 years old 
(Harris,  1990,  Hochberg,  1981).  Its  cardinal  features  include  chronic  inflammation  and 
synovial hyperplasia characterised by infiltration of blood‐derived inflammatory cells into 
the  synovial  space.  The  clinical  course  of  RA  varies  from  early  self‐limiting  disease  to 
chronic,  destructive  multisystem  inflammation  (Lee  and  Weinblatt,  2001)  often 




phase  protein  and  the  erythrocyte  sedimentation  rate  (ESR).  More  specific  markers 
include  rheumatoid  factor  (RF), an autoantibody against  IgG and anti‐cyclic  citrullinated 
peptide  antibodies  (ACPA)  (Scott,  2000).  There  is  no  single  diagnostic  test  for  RA  and 
diagnosis  relies on  the presence of RF, ACPA,  raised CRP and ESR  (American College of 
Rheumatology  Subcommitte  on  Rheumatoid  Arthritis,  2002,  Scott,  2000,  Avouac  et  al., 
2006,  Aletaha  et  al.,  2010).  Formal  diagnosis  of  RA  is made  according  to  the American 
Rheumatism Association 1987 revised criteria, which require four of the following to be 
presented  including  1)  morning  stiffness  (>  1  hour),  2)  soft  tissue  swelling  in  three  or 













place  with  macrophage  (MΦ)‐like  and  fibroblast‐like  synoviocyte  proliferation.  This  is 
closely followed by further mononuclear cell  infiltrate including B cells, CD4+ and CD8+ T 
cells, NK cells, and neutrophils found mostly  in the SF while the joint becomes a site for 
increased  angiogenesis  with  generation  of  endothelial  venules  supporting  hyperplastic 
growth  (Lee and Weinblatt, 2001, Bugatti et al., 2007, Cope, 2008, Cascao et al., 2010). 
The hyperplastic synovial tissue (pannus) composed of MΦ and synovial fibroblasts is rich 
in matrix metalloproteinases  (MMP)  invades  the  cartilage  and mediates  its  destruction 








synovial  inflammation  is  thought  to  give  rise  to,  or  propagate  rheumatic  disease.  RA  is 
characterised  by  a  cytokine  disequilibrium  whereby  the  effects  of  pro‐inflammatory 
cytokines and chemokines  (e.g. TNFα,  IL‐1β,  IL‐6,  IL‐8, GM‐CSF) outweigh  those of anti‐
inflammatory cytokines  (e.g.  sTNFR,  IL‐10,  IL‐1ra,  IL‐4)  (Feldmann et al., 1996). MΦ  and 
fibroblasts are considered the richest source of pro‐inflammatory cytokine production in 









relies  on  ruling  out  the  presence  other  diseases  such  as  diabetes,  atherosclerosis, 
infection and primary vasculitides. 
It is often difficult to diagnose or characterise RV and this may reflect perseverance or 
guided  systematic  approach.  However,  if  assessed  post‐mortem  it  is  almost  always 
present in RA (Bacon and Kitas, 1994). The pathogenesis of RV is often associated with RF 
presence (Westedt et al., 1985), anti‐endothelial cell and anti‐CCP antibodies,  (Turesson 




Voskuyl  et  al.,  1998b)  while  the  resulting  thrombus  formation  may  lead  to  ischaemic 
events and infarcts often present in the myocardium and fingertips (Genta et al., 2006).  
 
RV was  proposed  to  significantly  contribute  to  the  accelerated  atherosclerosis  often 
observed in RA (Bacon and Kitas, 1994).  Rheumatoid heart disease is often a sub‐clinical 
manifestation  that  is  rarely  recognised  however,  upon  closer  echocardiographic 
assessment its diagnosis is indeed increased and is best confirmed only by autopsy (Kitas 
et  al.,  2001).  Cutaneous  vasculitis  and  pleuritis  were  initially  shown  to  be  the  most 
common presentations of ExRA and were associated with  increased mortality related to 
heart  disease  (Turesson  et  al.,  1999).  It  was  later  confirmed  however,  that  cutaneous 







the  capillaries.  They  feature  leukocyte  activation  and  infiltration,  endothelial  activation 
and vascular necrosis (Savage, 2002, Watts et al., 2007, Watts et al., 2010). In PSV, vessel 







coupled with  a  laboratory  diagnostic  test  or  supported  by  histological  findings  through 
biopsy. Confirmation of a particular PSV is made through exclusion of mimics of vasculitic 
disease  (e.g.  atheromatous  vascular  disease,  multiple  myeloma)  and  secondary  causes 
such  as  RA  (Jayne,  2009).  The  PSVs  are  a  heterogeneous  group  of  disorders  often 
distinguished by the presence of granulomatous disease and auto‐antibodies such as anti‐
neutrophil  cytoplasmic  antibodies  (ANCA).  PSVs  are  currently  defined  according  to  the 





The  large  vessel  PSVs  not  associated with  ANCA  presence  include  giant  cell  arteritis 
(GCA) and Takayasu’s arteritis (TAK). GCA or temporal arteritis is a granulomatous disease 
of  large  and  medium  sized  vessels  and  is  the  most  common  form  of  PSV  affecting 
branches of the carotid artery, with an incidence up to 35 per 100,000 over 50 years old 
(Watts  and  Scott,  2004,  Mohan  and  Kerr,  2000).  Takayasu’s  arteritis  (TAK)  is  another 




that  predominantly  affects  the  aorta,  carotid,  subclavian  and  associated  branches 
featuring  stenotic  lesions  and  aneurysms  (Maksimowicz‐McKinnon  et  al.,  2007). 
Polyarteritis  nodosa  (PAN)  was  the  first  described  form  of  PSV  in  1866  (Kussmaul  and 
Maier,  1866)  affecting  medium  or  small  size  vessels  and  clinically  manifests  as 
hypertension, fever, myalgia, and systemic vasculitis of skin, heart and renal vessels. It is 
also associated with Hepatitis B infection (HBV‐PAN) (Guillevin et al., 2005, Pagnoux et al., 
2010).  The  last  of  the  non‐ANCA  associated  PSVs  is  Kawasaki’s  disease  (KD),  a  form  of 
idiopathic  juvenile vasculitis  that affects medium sized vessels usually  in children below 
five  years  old,  and  more  often  in  boys.  KD  in  severe  cases  features  coronary  artery 
aneurysms,  which  account  for  the  increased morbidity  and mortality  in  these  patients 
(Lytwyn et al., 2010, Jennette et al., 1994).   
1.2.2   ANCA‐associated systemic vasculitis (AASV) 
There  are  two  types  of  ANCA;  these  are  cytoplasmic  proteinase  3(PR3)  antibodies, 
termed cANCA, and the perinuclear enzyme myeloperoxidase (MPO) antibodies, termed 
pANCA. ANCA are disease specific and are thought to contribute to disease progression in 
AASV  (Savage,  2002).  Patients  with  AASV  are  often  considered  for  plasmapheresis 
(plasma exchange, PEX), and can be used for those with renal failure (Jayne et al., 2007). 
The  most  extensively  studied  AASV  is  Wegener’s  Granulomatosis  (WG),  affecting 
capillaries, venules, arterioles and arteries. WG is a granulomatous disease that presents 
mostly  in  the  respiratory  tract  and  renal  vessels,  while  necrotizing  glomerulonephritis 
develops during the course of the disease (Jennette et al., 1994). Churg‐Strauss syndrome 
(GSS)  is  a  small  vessel  disease  that  features  asthma,  hypereosinophilia  and  necrotizing 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vasculitis  manifesting  with  disease  progression.  It  is  a  poorly  understood  disease  with 
pANCA presence in 40‐75% of patients (Keogh and Specks, 2006, Guillevin et al., 1999a). 
Microscopic  polyangiitis  (MPA)  is  a  PSV  that  was  initially  classified  as  a  type  of  PAN 
however,  is  distinguished  by  the  presence  of  small  vessel  involvement  including 
capillaries,  venules  or  arterioles  (Jennette  et  al.,  1994,  Guillevin  et  al.,  1999b).  Most 
patients with MPA have renal impairment (78%). MPA also has a high frequency of ANCA 
(>70%) and is characterised by a 74% 5‐year survival rate (Guillevin et al., 1999b). Other 
small  vessel  vasculitides  include  cutaneous  vasculitis,  cryoglobulinemic  vasculitis  and 
Henoch‐Schonlein  purpura  (HSP)  all  of  which  have  not  been  shown  to  feature  ANCA 
(Gibson, 2001, Saulsbury, 1999). On rare occasions, PAN may be ANCA positive (Cohen et 
al.,  1995).  Clinical  disease  activity  in  AASV  is  determined  by  the  Birmingham  Vasculitis 
Activity  Score  (BVAS),  a  numerical  system  that weighs  organ  involvement  according  to 







dendritic  cells  (DC),  suggesting  an  immune  association  (Mueller  et  al.,  2008). 




Neutrophil  activation  and  endothelial  cell  (EC)  damage  are  hallmarks  of  AASV 
pathogenesis. ANCA‐induced EC apoptosis is evident in AASV (Yang et al., 2001). This can 
lead to EC dissociation from the basement membrane, platelet aggregation, subsequent 
thrombosis  and  vessel  occlusion  (Williams  et  al.,  2005).  Immune  involvement  is  also 
evident through the presence of TNFα, IL‐1β, IL‐6 and IL‐8 in renal biopsies and plasma of 
AASV patients (Noronha et al., 1993, Tesar et al., 1998). ANCA can bind to MPO or PR3 of 
TNFα‐primed  neutrophils  that  also  require  Fcγ  receptor  ligation  for  full  activation 
(Reumaux et al., 2003) producing pro‐inflammatory cytokines, generating reactive oxygen 
species (ROS), and degranulating to release proteolytic enzymes. Furthermore, ANCA may 
accelerate  neutrophil  apoptosis  and  phagocytosis  by MΦ which,  then  secrete  IL‐1,  IL‐8 
and TNFα adding to the  inflammatory burden  (Harper et al., 2001, Harper et al., 2000). 
ANCA  also  induce  neutrophil  adhesion,  enhancing  transmigration  thus  potentially 
contributing to lesion development (Savage, 2002).   
1.3   Cardiovascular disease in inflammatory rheumatic diseases 
Cardiovascular  disease  (CVD)  is  the  collective  term  for  a  group  of  disorders  with 




prevalence  of  CVD  such  as  atherosclerosis,  in  chronic  rheumatic  diseases  including  RA, 
PSV,  systemic  lupus erythematosous  (SLE), Behcet’s disease and psoriatic  arthritis  (PsA) 
has  been  highlighted  (Bacon  and  Kitas,  1994,  Manzi  et  al.,  1997,  Von  Feldt,  2008, 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Gladman  et  al.,  2009,  Del  Rincon,  2009,  de  Leeuw  et  al.,  2005,  Chambers  et  al.,  2001, 
Suppiah, 2011). 
1.3.1   Atherosclerosis 
Atherosclerosis  is  a  multifactorial,  inflammatory  disease  of  the  vascular  system 
characterised  by  hyperlipidemia,  endothelial  dysfunction  (ECD)  and  immune  cell 
activation at the site of  initiation (Ross, 1999, Del Rincon et al., 2003). This  leads to the 
formation  of  atherosclerotic  plaques  called  fatty  streaks  in  their  infancy,  stemmed 
through an  initial process called diffuse  intimal  thickening, an enlargement of  the  inner 
arterial  layer  lined with EC  (Nakashima et al., 2002). The  initial growth  is outwards  into 
the vessel  lumen however  lesion  size does not pre‐dispose  to plaque  rupture  (Haskard, 
2004).  
 
Atherosclerosis has been  increasingly  referred to as a disease of  the  immune system 
and  examination  of  plaques  reveals  the  presence  of  pro‐inflammatory  cytokines  (IFNγ, 






(Tabas  et  al.,  2007).  Inflammation  is  considered  to  propagate  the  development  of 




al.,  2003).  There  is  accumulating  evidence  for  accelerated  atherosclerosis  in  rheumatic 






span of 3‐18 years  in RA patients using data gathered  from 21 studies  reviewed  in Van 
Doornum et  al.,  (2002).  It  is  now established  that RA patients  have  an  excess  all‐cause 
CVD mortality (Goodson et al., 2005, Watson et al., 2003). These patients were twice as 
likely  to  suffer  myocardial  infarcts  and  developing  congestive  heart  failure  (CHF) 
(Solomon et al., 2003). The increased mortality and morbidity in RA (Wolfe and Michaud, 
2004,  Naranjo  et  al.,  2008)  could  not  be  explained  by  traditional  risk  factors  such  as 
smoking,  familial  history,  increased  BMI,  age,  dyslipidemia  and  diabetes  (Nicola  et  al., 
2005, Crowson et al., 2005).  
Systemic inflammation in RA adds to the increased risk of CV mortality in RA patients 
whose  10‐year  absolute  risk  of  developing  CVD  at  incidence  of  RA  reflects  similar 
prevalence  in  non‐RA  individuals  5‐10  years  older  (Kremers  et  al.,  2008).  This  suggests 
that  CVD  onset  may  start  in  early  RA.  Furthermore,  in  some  patients,  myocardial 
infarctions  (MI)  are  thought  to  precede  the  diagnosis  of  RA  (Maradit‐Kremers  et  al., 




thought  to  cause  diffuse  perturbation  of  vascular  function.  Small  and  large  vessel 
inflammation manifests in a high percentage of cases and RV presence has been shown to 
occur irrespective of therapy (Bacon and Kitas, 1994).  
RA  patients  also  show  a  higher  prevalence  of  atherosclerosis  (Han  et  al.,  2006, 
Gonzalez‐Gay  et  al.,  2005a) which  shares  similar  characteristics with  RA  itself  including 
raised  endothelial  cell  and  leukocyte  adhesion molecule  expression,  increased  immune 
cell  activation  and  raised  levels  of  IL‐1β,  TNFα  and  IFNγ (Pasceri  and  Yeh,  1999,  Ross, 
1999,  Van  Doornum  et  al.,  2002).  Immune  activation  is  believed  to  contribute  to 
atherogenesis  in  RA.  One  possible  cause  for  this  is  thought  to  be  a  CD4+/CD28‐  T  cell 
phenotype  found  present  in  plaques  of  patients  with  unstable  angina.  In  RA  patients, 
expansion  of  this  T  cell  subset  was  later  associated  with  increased  IMT  and  lower 
vasodilator  capacity  (Liuzzo  et  al.,  2000,  Gerli  et  al.,  2004)  suggesting  these  cells  may 
contribute to atherogenesis in RA.  
Several factors may predispose those with RA to accelerated atherosclerosis including 
the  raised  TNFα,  CRP  and homocysteine  levels,  an  altered  lipid  profile,  and  factors  not 
derived from RA pathogenesis such as prolonged inactivity and smoking status (Bacon and 
Townend,  2001,  Gonzalez‐Gay  et  al.,  2005b).  Projecting  from  this,  endothelial  injury  is 
now  also  considered  an  initiating  mechanism  in  the  development  of  atherosclerosis. 






This  figure  shows  the  presence  of  vascular  inflammation  in  two  different  diseases, 
primary systemic vasculitis (PSV) and rheumatoid arthritis (RA) with vascular damage and 
synovitis  respectively  contributing  to  the  inflammatory  burden.  Both  diseases  have 
elevated TNFα  levels, which can  lead to decreased endothelium‐dependent vasodilation 
and  endothelial  dysfunction.  Several  other  factors  may  initiate  or  contribute  to 
endothelial  dysfunction  in  these  diseases  and  examples  include  oxidative  stress,  raised 







































Sufferers  of  PSV  are  thought  to  be  at  increased  CV  risk  due  to  the  vascular 
complications  that  come  secondary  to  the  underlying  inflammation.  In  AASV  and  PAN, 
patients  showed  decreased  arterial  and  dermal  microvascular  endothelium‐dependent 




compared  to  control  individuals  (Sangle  et  al.,  2008).  Furthermore  patients  with  AASV 
also  presented  impaired  renal  function,  which  in  the  elderly  especially  was  shown  to 
predispose to CVD carrying similar CV risk to MI (Rashidi et al., 2008).  
Arterial  stiffness  is  a  determinant  for  CV  risk  and  was  shown  to  increase  in  AASV 
patients  with  active  disease  compared  to  those  in  remission  and  controls.  Recently, 
arterial  stiffness  positively  correlated  with  CRP  levels  in  AASV  suggesting  a  link  with 
inflammation (Booth et al., 2004c), which is linked to impaired vascular function, an early 
marker  for  atherosclerosis,  also  evident  in  PSV.  The  first  such  evidence  in  AASV  came 
from WG patients who had increased IMT compared to healthy controls unexplained by 
traditional  risk  factors  (de Leeuw et al., 2005). Accordingly, Chironi and colleagues  then 
showed that subclinical atherosclerosis was more frequent  in PSV patients compared to 
controls. High‐risk  status determined by CVD history,  type 2 diabetes or  a  Framingham 
risk score above 20% was more frequent  in patients with three plaques  (carotid, aortic, 
femoral) and the presence of the three combined was associated with raised CRP levels 








1.4.1   Pro‐inflammatory cytokines ‐ TNFα , IL‐1β , IFNγ , IL‐6 
Pro‐inflammatory  cytokines  aid  the  immune  response,  playing  an  important  role  in 
atherosclerosis  and  chronic  inflammation.  IFNγ  is  a  pro‐inflammatory  cytokine  with 
established anti‐viral properties, also known to have immuno‐modulatory characteristics 
increasing the expression of MHC class I and II. Although present in lesions, its role in the 
atherosclerotic  process  remains  unclear  (Hansson  and  Libby,  2006,  Haskard,  2004, 
















TNF  superfamily,  TNFα  is  a  pleiotropic  cytokine  capable  of  inducing  apoptosis  and 
regulating  cell‐mediated  immunity.  Furthermore  TNFα  has  anti‐viral  properties,  and 



















Brennan et al., 1989). A central role for TNFα  in RA was first highlighted  in mice  in vivo 
whereby  monoclonal  antibodies  (mAb)  against  TNFα  dampened  the  inflammatory 
process and halted joint damage (Keffer et al., 1991, Williams et al., 1992). Subsequently, 






most  common  of  these  are  the  nucleophile  superoxide  anion  (O2
‐)  and  the  hydroxyl 
radical  (.OH).  Oxygen  can  be  reduced  to  form  superoxide  (O2




be protonated  to  form a  hydroperoxyl  radical  or  peroxynitrite  in  the presence of  nitric 
oxide (NO). 
Intracellular  generation  of  ROS  can  arise  from  the  mitochondrial  transport  chain, 
oxidative bursts from phagocytic cells, and enzymes such as xanthine oxidase, nitric oxide 
synthase  (NOS),  cytochrome P450’s  and NADPH oxidases  (Cai  and Harrison,  2000). ROS 
can  be  toxic  to  cells  and  can  oxidise  macromolecules  such  RNA/DNA,  lipids,  proteins 
causing DNA base adducts, DNA strand breaks and oxidative protein damage (Kohen and 
Nyska,  2002,  Wiseman  and  Halliwell,  1996).  Under  inflammatory  conditions  EC  are 
exposed  to  ROS  as  a  result  of  phagocyte  activation,  enzyme  systems  (NOS,  xanthine 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the  thioredoxin  (TRX)  and  glutathione  (GSH)  systems, whilst  there  are  also  low weight 
antioxidants  such  as  vitamin  C  (ascorbic  acid),  vitamin  E,  flavonoids,  melatonin  and 
carotenoids  (Kemp  et  al.,  2008).  Thioredoxin  alongside  GSH  arguably  form  the  most 
important cellular antioxidant systems (Kemp et al., 2008, Nakamura et al., 1997). GSH is 
involved  in  xenobiotic  metabolism  (Boesterli,  2003).  GSH  is  highly  compartmentalised 
found in the ER, nucleus, cytoplasm and mitochondria (Markovic et al., 2007, Jessop and 
Bulleid, 2004, Soderdahl et al., 2003). Glutathione  is mostly  found  in a reduced state as 
GSH,  and  can  be  itself  oxidised  by  ROS  to  GSSG,  protecting  proteins  from  oxidative 
damage.  The  concentration  of  GSH  depends  on  the  rate‐limiting  enzyme  glutamate 
cysteine  ligase  (GCL)  (Meister  and  Anderson,  1983).  GCL  can  be  blocked  with  the  GCL 
inhibitor  L‐buthionine‐(S,R)‐sulfoximine  (BSO)  thus  mimicking  a  low  GSH  environment. 









arise  from  the  hypoxic  synovial  environment  and  oxidative  bursts  from  activated 
phagocytes such as neutrophils and MΦ  (Seven et al., 2008). This  is coupled with  lower 
GSH,  GSH  peroxidase,  catalase  and  vitamin  E  in  these  patients  thought  to maintain  or 
exacerbate  the  pro‐oxidant  environment  (Hassan  et  al.,  2001,  Kamanli  et  al.,  2004). 
Indeed increasing GSH levels by NAC was shown to decrease H2O2 and lipid peroxidation 
in  post‐myocardial  infarction  rats  (Adamy  et  al.,  2007).  Evidence  also  exists  for  ROS  in 
chronic  heart  failure  (CHF)  featuring  raised  serum  and  plasma  myeloperoxidase  and 
malondialdehyde,  the  latter  a  product  of  lipid  peroxidation  is  also  evident  in  RA 
(McMurray et al., 1993, Hassan et al., 2001, Tang et al., 2007).  Interestingly, decreased 
EDV  in  CHF  can  be  improved  with  vitamin  C  supplementation  suggesting  that 
maintenance of redox balance facilitates EC function (Landmesser et al., 2002)  
1.5   Endothelial cells 
Endothelial  cells  (EC)  line  the  interior  face  of  blood  vessels,  or  luminal  aspect, 
principally interacting with smooth muscle cells (SMC) in the vessel wall behind them, and 
circulating  blood‐derived  cells.  The  endothelium  controls  vascular  homeostasis  by  1. 
Regulating vascular tone and blood flow, 2. Acting as a barrier between luminal aspects of 
vessels  and  the  sub‐endothelial  matrix  (Schnittler,  1998),  3.  Maintaining  a  dormant 
coagulation  cascade  (Michiels,  2003)  and  4.  Regulating  leucokcyte  transmigration 





cytokines  including  IL‐1α,  IL‐3,  IL‐6,  IL‐7,  IL‐8,  IL‐11,  IL‐14,  IL‐15,  TNFα  and  TGFβ 









endothelial  function  and  anti‐oxidant  capacity  leading  to  lower  incidence  of  first  CV 
events  in RA patients (Jacobsson et al., 2005, Hurlimann et al., 2002, Popa et al., 2009). 
The  raised  expression  of  adhesion  molecules,  in  particular  VCAM‐1,  was  shown  to 
correlate with common carotid artery (CCA) atherosclerosis by increased IMT suggesting 
that EC activation may contribute to atherogenesis in RA (Dessein et al., 2005).  
Angiogenesis  in  RA  is  particularly  prevalent  as  it  allows  oxygenation  and  nutrient 
supplementation  in  a  hypertrophic  synovium  (Koch,  2003,  Szekanecz  et  al.,  2010). 
Endothelial  necrosis  in  AASV  can  lead  to  thrombosis  and  possible  vessel  occlusion 
(Williams  et  al.,  2005).  Mature  Endothelial  Progenitor  Cells  (EPC)  can  replenish 
dysfunctional EC and become involved in neo‐vascularisation. EPC are found raised in the 
RA synovium (Ruger et al., 2004) however, their precise role is often contradictory due to 
their  inaccurate  definition  in  RA  (Grisar  et  al.,  2005,  Jodon  de  Villeroche  et  al.,  2010, 
Chapter 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Wrigley  et  al.,  2010,  Yiu  et  al.,  2010)  and  AASV  (Zavada  et  al.,  2008,  Santana,  2009, 






of  atherosclerosis.  A  critical  characteristic  of  ECD  is  the  impaired  ability  of  a  vessel  to 
dilate  due  to  diminished  NO  production  in  response  to  physical  or  biochemical  stimuli 
(Bonetti et al.,  2003).  Several methods exist  to measure vascular  function  in  vivo. Post‐
occlusion flow mediated dilatation (FMD) is measured by induction of reactive hyperemia 
(increased  blood  flow).  This  causes  endothelial  sheer  stress,  release  of  NO  and muscle 
relaxation  thus  measuring  endothelium‐dependent  vasodilation  (EDV)  (Corretti  et  al., 
2002).  Endothelium  independent  vasodilation  (EIV)  can  be  assessed  in  response  to 
glyceryl trinitrate. In microvascular tissue (e.g. skin), Laser Doppler flowmetry records the 
flow of red blood cells and EDV responses can be measured in response to acetycholine 
(ACh),  through  iontophoresis, while  sodium nitroprusside  (direct NO donor)  records EIV 
(Khan et al., 2010). In vitro, ECD can be assessed by measuring several EC markers such as 






RA  features  vascular  inflammation  (vasculitis)  secondary  to  the  disease  and  coupled 
with  PSV  has  been  shown  to  be  at  risk  of  ECD.  In  PSV,  ECD was  first  demonstrated  in 
Kawasaki’s  disease  (KD)  (Dhillon  et  al.,  1996)  while  recent  studies  showed  decreased 




following  induction  of  remission  (Raza  et  al.,  2000).  This  was  later  independently 
confirmed  in  AASV  (WG,  CCS)  and  PAN  patients.  The  same  study  showed  evidence  of 
diffuse ECD  in different vascular beds supported by  the  fact  that  these patients did not 
have  brachial  artery  pathology  but  exhibited  decreased microvascular  EDV  (Filer  et  al., 
2003). The role of TNFα  in ECD in PSV was highlighted in two subsequent studies where 
following  anti‐TNFα  (Infliximab)  treatment  patients  exhibited  marked  improvement  in 
forearm and microvascular EDV responses compared to EIV (Booth et al., 2004b, Raza et 
al.,  2006).  Thus,  anti‐TNFα  was  able  to  improve  endothelium‐dependent  vascular 
responses  suggesting  that  PSV might  be  a  potential  archetypal model  for  the  study  of 
vascular inflammation (Booth et al., 2004b, Booth et al., 2004c). 
ECD  is  also  considered  a  contributing  factor  for  accelerated  atherosclerosis  in  RA 
(Gonzalez‐Gay et  al.,  2008).  Young  to middle aged RA patients with no CV  involvement 
were  shown  to  have  decreased  brachial  artery  FMD  compared  to  controls,  which 
inversely correlated with CRP and LDL‐cholesterol levels (Vaudo et al., 2004).  Even newly 




established  RA  (Foster  et  al.,  2010).  In  established  RA  patients,  TNFα  blockade  also 
caused a  transient  improvement  in  FMD over 14 weeks but  led  to a  steady  increase  in 
mean arterial diameter  (Bosello et al., 2008), however  in a  study by Sidiropoulos et al., 
anti‐TNFα was shown to induce sustained increases in FMD over 18 months (Sidiropoulos 









Although  effective  blockade  of  TNFα  alleviates  ECD  suggests  an  active  role  for  the 
cytokine,  there  is  yet  to  be  a  convincing  direct  causal  effect.  Perhaps  bridging  this  gap 
comes a recent study that showed TNFα was able to decrease eNOS protein expression 
(Anderson  et  al.,  2004).  TNFα was  first  shown  to  inhibit  EDV  responses  in  vivo  in mice 
(Wang  et  al.,  1994)  and  similarly  in  human  volunteers  decreasing  venous  responses 
(Bhagat  and Vallance,  1997).  This was  later  also  confirmed  in  arterial  beds  (Chia  et  al., 
2003).  Induction  of  ECD  was  shown  ex  vivo  in  rat  mesenteric  arteries  where  TNFα 
inhibited NO‐dependent EDV but was abolished in the presence of superoxide dismutase 
(SOD).  This  suggested  a  role  for  O2
‐  and  peroxynitrite  formation,  which  inhibit  eNOS 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by  impairing Ca2+  influx across  the plasma membrane  (PM). This was attributable  to an 
effect  on  store‐operated  Ca2+  channels  (SOCs),  and  exogenous  Cer  itself  was  found  to 
reduce  Ca2+  influx  through  SOC within  one minute  of  application  (Church  et  al.,  2005). 
Agonist‐evoked  generation of NO by  eNOS  is  also  tightly  regulated by Ca2+  and  release 









Guanine  nucleotide‐binding  protein  (G‐protein)  coupled  receptors  (GPCR)  receive  a 
wide  range  of  Ca2+‐mobilising  ligands  including  bradykinin,  acetylcholine  and  thrombin 
(Dudzinski  and  Michel,  2007).  Following  receptor  stimulation,  phospholipase  C  (PLC) 
located  on  the  intracellular  leaflet  of  the  PM  is  activated  and  hydrolyses 
phosphotidylinositol  4,5  biphosphate  (PIP2)  to  inositol  1,4,5  triphosphate  (IP3)  and 
diacylglycerol  (DAG).  IP3  then  translocates  through  the  cytosol  and  binds  to  the  IP3 
receptor (IP3R) on the ER causing the release of intracellular ER store Ca
2+. This resulting 
depletion  of  luminal  ER  store  Ca2+  is  detected  from  Ca2+‐sensitive  proteins  in  the  ER 
membrane  which  cross‐talk  with  plasmalemmal  partners  inducing  the  influx  of 
extracellular Ca2+ (Lewis, 2007). These processes are discussed below.  
1.6.1.1   Ca2+ entry channels in EC 
Ca2+  signalling  in  EC  can  occur  in  various  ways  by  means  of  a  broad  range  of 
multifunctional,  selective  and  non‐selective  ion  channels.  Several  Ca2+  entry  channels 
exist  including purinergic  ligand‐gated  receptor  channels  (P2x4), which are non‐selective 
cation  channels  (NSC),  the  transient  receptor  potential  channels  (TRPC)  and 
Na2+/Ca2+exchange  (NCX)  transporters  (Nilius  and  Droogmans,  2001).  In  1986,  Putney 
proposed  the  concept  of  ‘capacitative  Ca2+  influx’  or  capacitative  Ca2+  entry  (CCE)  in 
excitable  cells,  the  process  now  referred  to  as  store  operated  calcium  entry  (SOCE) 
(Putney,  1986).  Store  operated  calcium  (SOC)  channels  are  regulated  by  the 
concentration of  intracellular Ca2+  ions and  in EC  represent  the major pathway  for Ca2+ 




2+)  stores  (ER/SER)  by  A)  using  Ca2+  chelators,  B)  blocking  Ca2+ 
reuptake  through  sarco/endoplasmic  reticulum  Ca2+‐ATPase  (SERCA)  pumps  or  C) 
stimulating  Ca2+  release  from  intracellular  stores  (Parekh,  2008b).  Physiologically, 
stimulation of agonist‐sensitive  iCa
2+ stores by agonists such as bradykinin leads to store 
emptying  of  Ca2+  and  the  opening  of  PM  SOC  channels.  The  most  widely  studied 
prototype  SOC  channels  are  the  Ca2+‐released‐activated  Ca2+  channels  (ICRAC)  identified 
due  to  a  calcium‐specific  current  directly  evident  following  intracellular  Ca2+  store 
emptying. ICRAC have a single channel conductance which is highly Ca
2+‐selective and could 




to  involve  two  key  components,  the  stromal  interaction  molecule  (STIM),  an  ER/SER 
membrane  embedded Ca2+  sensor  and Orai,  component  of  CRAC  channel  pores  on  the 
PM  (Putney and Bird,  2008).  In  vitro,  ER Ca2+  stores  can be pharmacologically depleted 
using  the SERCA  re‐uptake pump blocker  thapsigargin or  the Ca2+  ionophore  ionomycin 


















luman  of  the  endoplasmic  reticulum  (ER).  IP3  signals  endoplasmic  reticulum  Ca
2+  store 
release  which  triggers  Ca2+  influx  through  store‐operated  Ca2+  (SOC)  channels  in  the 
plasma  membrane.  This  is  mediated  through  direct  cross‐talk  of  stromal  interacting 

































Of two splice variants,  it  is STIM‐1 that  is associated with Ca2+ entry, while STIM‐2  is 
believed to regulate Orai‐1 activation and have limited activation itself (Zhou et al., 2009). 
STIM translocation to the puncta leads to Orai‐3 recruit at the PM close to the ICRAC locus. 
This  been  shown  to  parallel  Ca2+  spikes  suggesting  these  observations  reflect  SOCE 
through  ICRAC  as  a  result  of  intracellular  Ca








Production  of  nitric  oxide NO  in  EC  is mediated  by  endothelial  nitric  oxide  synthase 
(eNOS). Regulation of NO  is a  complex process and can  result  from various  stimuli  that 





One  of  the  remarkable  features  of  Ca2+  signalling  is  its  temporal  and  spatial 
orientation,  which  ensures  that  Ca2+  activates  only  pathways  related  to  the  upstream 
stimulus.  This  means  that  influx  of  Ca2+  occurs  close  to  or  itself  creates  Ca2+ 
microdomains,  cytoplasmic  areas  of  high‐Ca2+  concentration  that  are  activated  only  by 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specific  targets;  eNOS  is one of  these,  shown  to  co‐localise with  caveolae  (Feron et al., 
1996). In support of these observations, NO production was greater in PM‐targeted eNOS 
than  its  cytosolic  homologue,  which  was  less  sensitive  to  SOCE  (Lin  et  al.,  2000).  This 
suggests that SOCE‐derived Ca2+ microdomains, in close proximity to eNOS and caveolae, 




NOS  (iNOS,  NOS  II)  and  endothelial  NOS  (eNOS,  NOS  III)  found  in  vascular  EC,  cardiac 
myocytes and blood platelets. eNOS is composed of a C‐terminal end reductase domain 
and  an  N‐terminal  end  oxygenase  domain  whilst  between  the  two  exists  an  allosteric 
small  sequence  binding  site  for  Calmodulin  (CaM), which  is  essential  for  the  enzymatic 
functioning of eNOS (Figure 1.3) (Dudzinski et al., 2006). 
1.6.2.1   Stimulants of eNOS activation 
The  Ca2+‐dependence  of  eNOS  activation  varies  according  to  the  type  of  stimulant 
which  may  be  a  physical  (liquid  flow,  shear  stress),  pharmacological  (statins),  energy 






eNOS  activation  is  dependent  of  the  presence  of  a  number  of  cofactors  including 
substrate L‐arginine. The requirement for Ca2+ was considered essential for all or nothing 
activation  however,  fluid  shear  stress  can  cause  Ca2+  transients  (series  of  momentary 
cytoplasmic  Ca2+  oscillations)  leading  to  eNOS  activation  in  a  Ca2+‐independent manner 
(Dimmeler et al., 1999, Fleming, 2010). In most other examples however, eNOS activation 
is  tightly  Ca2+‐dependent  (Park  et  al.,  2009b)  and  sustained  activation  of  membrane‐
bound eNOS has been shown to require CCE or SOCE discussed above (Lin et al., 2000). 
Therefore  the  Ca2+  requirement  varies  depending  on  the  stimulus.  CaM  is  an  essential 




The  importance of  eNOS  is  highlighted by  the  great  level  of  control  exerted over  its 
activity  at  a  number  of  levels.  Binding  of  tetrahydrobiopterin  (BH4)  to  the  eNOS  N‐
terminal  oxygenase domain  facilitates  eNOS dimerisation  (Berka  et  al.,  2004a,  Berka  et 
al., 2004b). This allows binding of L‐arginine to the oxygenase domain close to heme and 
BH4 and molecular oxygen to the ferrous iron (Crane et al., 1998, Raman et al., 1998). In a 







When  EC  are  stimulated  with  agonist,  eNOS  becomes  rapidly  depalmitoylated,  binds 
Ca2+/CaM  and  dissociates  from  the  PM  (Michiels,  2003).  Similarly,  eNOS  is  tonically            






residues  is  mostly  associated  with  increased  activation  whereas  phosphorylation  of  a 
threonine  residue  at  Thr495  inhibits  eNOS  activation  and  dephosphorylation  of  this  site 
accordingly  increases enzyme activity  (Fleming et al., 2001). Phosphorylation of eNOS  is 
mediated through various kinases discussed below (David‐Dufilho et al., 2005, Stahmann 
et al., 2006, Thors et al., 2008, Thors et al., 2004, Fleming et al., 2001). The specificity of 
kinase  depends  on  the  stimulus  target  amino  acid.  The  increasing  number  of  eNOS 
phosphorylation sites being identified includes Tyr81 (Fulton et al., 2008), Ser633 (Michell et 






















(A)  Schematic  representation  of  endothelial  nitric  oxide  synthase  (eNOS)  showing  the 
different  binding  motifs  including  the  calmodulin  (CaM)  binding  region  (inside)  and 
various  phosphorylation  sites  (outside).  Figure  adapted  from Mount  et  al.,  (2007)  and 
Fleming et al., (2010). (B) eNOS dimer showing electron flow from NADPH (Nicotinamide 
adenine dinucleotide phosphate) through FAD (Flavin adenine dinucleotide), FMN (flavin 
mononucleotide)  and  BH4  (tetrahydrobiopterin)  to  the  tetrahedral  haem  enabling  the 
formation  of  L‐arginine  (L‐Arg)  from  L‐citrulline  (L‐Cit).  Coupled  eNOS  describes  the 
dimerised  protein  with  normal  electron  flow  through  the  flavins  to  BH4  and  haem 
resulting  in  L‐arginine  formation  and NO  formation  rather  than  superoxide  generation. 
Figure adapted from Schmidt and Alp (2007). 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eNOS  activation  to  date.  Thr495  dephosphorylation  leads  to  eNOS  activation,  regulating 
CaM binding (Harris et al., 2001, Chen et al., 1999, Greif et al., 2002, Fleming et al., 2001). 






Ca2+/CaM  and  Ca2+/CaM‐dependent  protein  kinase  II  (CaMKII)  have  been  tightly 
associated  with  rapid  eNOS  activation  (Cai  et  al.,  2008).  Bradykinin  (Bk)  and  thrombin 
relay their stimulatory signal through G‐protein coupled receptors (GPCR) and have both 




Bradykinin  signals  through  the  β2  adrenergic  receptor,  a  GPCR  which  houses  the 
pertussis‐toxin‐insensitive  Gaq  protein  subtype  (Vanhoutte  et  al.,  2009).  Bradykinin 
induces  phosphorylation  of  Ser1177  in  a  Ca2+‐dependent  manner  even  at  low 
concentrations  of  the  agonist  (100  nmol/L),  through  rapid  CaMKII  activation. 






et  al.,  2002,  Fleming  et  al.,  2001,  Chen  et  al.,  1999,  Boo  et  al.,  2002a).  Akt  has  been 




of  CaMKII  inhibitor  KN‐93  was  able  to  block  Bk‐induced  Ser1177  phosphorylation 
suggesting  that  CaMKII  is  a  key  kinase  involved  in  this  process  (Fleming  et  al.,  2001) 
(Figure  1.4).  Bk  also  leads  to  a  rapid  dephosphorylation  of  Thr495  probably  through 
protein  phosphatase  1  (PP1).  Although  evidence  for  PP1  involvement  remains 
circumstantial,  it  is  believed  that  pharmacological  inhibition  of  PP1  abrogates  the  Bk‐




Thrombin  signals  through  the protease‐activated  receptor  (PAR),  a GPCR,  specifically 
the PAR‐1 subtype on the PM (Coughlin, 2000, Hirano et al., 2007) although recently PAR‐
2 was also suggested to be a target (Watts and Motley, 2009).   This  is thought to occur 
through  the  pertussis‐toxin‐sensitive  GaI  or  Gaq
  subunits  (Coughlin,  2000,  Michel  and 
Vanhoutte, 2010). The thrombin signalling pathway  is complex and the kinases  involved 
are still under debate (Figure 1.4).  It was  initially shown that thrombin tightly regulated 
CaMKII  activation  (Borbiev  et  al.,  2001,  David‐Dufilho  et  al.,  2005).  Furthermore,  like 
Chapter 1                                                                                                         General introduction 
  [34] 
histamine  thrombin  has  been  shown  to  phosphorylate  Ser1177  via  an AMPK‐dependent, 
Akt/PKB‐independent manner. This process is considered to be Ca2+‐dependent, however 
without  the  involvement of CaMKII or protein kinase C  (PKC)  (Thors et al., 2004). More 
recently AMPK was shown not to be a downstream target of thrombin stimulation since 
inhibition of the upstream AMPK kinase (CaMKII) using the CaMKII‐specific inhibitor STO‐
609 or by  inhibition AMPK  itself had no effect on Ser1177 phosphorylation  (Stahmann et 
al.,  2006).  Thrombin  phosphorylation  of  Ser1177  was  completely  dependent  on  Ca2+, 
suggesting a role for CaMKII but a different downstream kinase to AMPK (Stahmann et al., 
2006).  This  contradicts  the  findings  by  Thors  et  al.  (2004)  above  who  used  a  generic 
protein  kinase  inhibitor  (H89)  to  inhibit  AMPK  activation  rather  than  one  specific  to 
CaMKII.  This may  highlight  a  role  for  two  independent  pathways  involving  CaMKII  and 
AMPK both requiring the presence of Ca2+. 
Thrombin  has  been  linked  to  Ca2+  store  release  and  SOCE  (Sandoval  et  al.,  2001) 
working  independently of Akt/PKB and PI3K,  increasing Ser1177 phosphorylation and  the 
NO  surrogate  marker  cGMP  levels  in  the  presence  of  Ca2+  (Motley  et  al.,  2007).  This 
process was suggested to be regulated by PKCδ (Motley et al., 2007). Thrombin, like Bk, is 
believed to have an auto‐inhibitory function on eNOS activation. It was recently shown to 
phosphorylate  the  inhibitory  eNOS  residue  Thr495,  which  is  associated  with  decreased 
eNOS  activation  (Watts  and  Motley,  2009).  Here  it  was  able  to  induce  a  rapid,  but 
transient PAR‐2 mediated phosphorylation of Ser1177 and upon  its cessation was met by 



























The  figure  outlines  the  pathways  involved  in  bradykinin  and  thrombin‐induced 
phosphorylation of eNOS, leading to eNOS activation. The blue filled panels represent the 
bradykinin  pathway  and  the  green  filled  panels  show  the  thrombin  pathway.  Both 
pathways  lead  to  phosphorylation  of  eNOS  (pSer1177).  The  clear  panels  (blue  outline) 
represent the regulation of eNOS phosphorylation by adenosine triphosphate levels. PM, 
















































heme  located  in  the N‐terminal end oxygenase domain.   Generation of NO sees a  two‐










Endothelium‐dependent vasodilation  (EDV)  is mediated through smooth muscle  (SM) 
relaxation,  which  dilates  the  vessel  itself  (Figure  1.5).  Nitric  oxide  exerts  its  effects 
through  guanosine  3’,  5’‐cyclic  monophosphate  (cGMP)  generation  and  cyclic  GMP‐
dependent protein kinase  (PKG) activation,  leading  to SM relaxation  through decreased 
iCa
2+  signalling  in  SMC.  Nitric  oxide  release  from  EC  diffuses  through  to  the  proximal 
Chapter 1                                                                                                         General introduction 
  [37] 
underlying  smooth muscle  layer  and  binds  to  its  only  known  receptor  to  date,  soluble 
guanylate cyclase. Soluble guanylate cyclase is a homodimeric protein with an N‐terminal 




the  cGMP‐dependent  protein  kinase  or  protein  kinase  G  (PKG),  which  is  thought  to 
decrease  contractility  by  inhibiting  store‐operated  Ca2+  entry  and  sarco/endoplasmic 








One  of  the  main  mechanisms  of  nitric  oxide  (NO)‐dependent  vasodilation  occurs  by 
decreasing  smooth  muscle  cell  (SMC)  intracellular  calcium  (iCa
2+).  Endothelial  cell  (EC) 
Ca2+  leads to activation of endothelial nitric oxide synthase (eNOS). This generates nitric 
oxide  (NO)  that  diffuses  to  the  underlying  smooth muscle  binding  to  soluble  guanylate 
cyclase  (sGC) which mediates  the  conversion of GTP  (guanosine  triphosphate)  to  cGMP 
(cyclic guanosine monophosphate). cGMP targets cGMP‐dependent protein kinase (PKG) 
decreasing  iCa
2+, essential  for muscular  contraction  in SMC. Endothelial  cell dysfunction 
(ECD) in this context describes the loss of NO and impaired vasodilation. In the presence 
of endothelial  cell  (EC) Ca2+ but during  increased oxidative  stress, eNOS uncoupling can 
take place, which favours peroxynitrite (ONOO‐) formation as opposed to NO generation 
and  vasodilation.  In  the  absence  of  EC  Ca2+,  there  is  an  inhibition  of  upstream  NO 












































Sphingolipids  have  become  increasingly  recognised  as  important mediators  of  signal 
transduction  mechanisms,  facilitating  intracellular  messages  through  their  lipid  by‐
products.  Serine  palmitoyl  CoA  transferase  is  the  rate‐limiting  enzyme  in  sphingolipid 
biosynthesis (Merrill and Jones, 1990). Plasma membranes consist mainly of cholesterol, 
phospholipids  and  sphingolipids,  (Dumitru  et  al.,  2007)  of which  sphingomyelin  (SM)  is 




and  3,  and  an  amine  group  at  C2.  This  is  coupled with  a  ceramide moiety, which  is  an 
acylated  sphingosine  at  the  2‐amino  position  (Huwiler  et  al.,  2000).  Sphingolipids  are 
thought to have atherogenic potential and plasma SM is considered an independent risk 
factor  for  coronary  heart  disease  (Nelson  et  al.,  2006).  Accordingly  myriocin,  an  SM 




Sphingomyelin  phosphodiesterase  (EC  3.1.4.12),  otherwise  known  as 
sphingomyelinase  (SMase)  catalyses  the  hydrolysis  of  sphingomyelin  (SM)  to  ceramide 





SMases exist  in  various  splice  variants  that  generally differ  in  terms of  their  primary 
structure,  cation  dependence  and  sub‐cellular  localisation  (Pavoine  and  Pecker,  2009). 
Broadly speaking SMases were divided into three general categories according to their pH 
optima and called acid, neutral or alkaline SMase (Goni and Alonso, 2002). These enzymes 
derive  from  distinct  genes  termed  sphingomyelin  phosphodiesterase  (SMPD).  The  acid 
SMase  (ASM) gene SMPD1, was  the  first  to be cloned  from human urine  in 1989 giving 
two  splice  variants  (Quintern  et  al.,  1989a,  Schuchman  et  al.,  1991,  Schuchman  et  al., 
1992, Quintern et al., 1989b). It was later confirmed that SMPD1 gave rise to a lysosomal 
and  secretory  fraction of  the enzyme  termed accordingly  and now known as  lysosomal 
SMase  (L‐SMase) and secretory SMase  (S‐SMase). Neutral  sphingomyelinases  (nSMases) 
arise from three distinct genes termed SMPD2‐4  following SMPD1 described above. The 
neutral SMase genes give rise to a protein product each termed nSMase1 (from SMPD2) 
(Hofmann et  al.,  2000), nSMase2  (SPMD3)  (Tomiuk et  al.,  1998)  and nSMase3  (SMPD4) 
(Krut  et  al.,  2006).  The  nSMases  are  Mg2+‐dependent  enzymes  with  an  optimum 
hydrolytic  capacity  of  pH  7.4  (Goni  and  Alonso,  2002).  They  are  sub‐cellular  enzymes 
localising  to  the  ER,  golgi  apparatus  and  inner  plasmalemmal  face  (Krut  et  al.,  2006, 
Hofmann  et  al.,  2000,  Tomiuk  et  al.,  1998,  Tani  et  al.,  2007).  Alkaline  SMase  is  a Mg2+ 






































































































































































































































































































































































































































































































































































































and  have  been  associated  with  cell  growth,  proliferation,  apoptosis  and  senescence 
(Hannun  and Obeid,  2008).  nSMases  are  ubiquitously  expressed  and  all  three  enzymes 
share similar biochemical characteristics (Stoffel et al., 2007, Levade et al., 1991, Krut et 
al., 2006). nSMase1 and nSMase2 are present in significant amounts in the brain, have a 
high  affinity  for  Mg2+  and  are  activated  by  fatty  acids  and  phosphatidylserine  (PS) 
(Hofmann et al., 2000). nSMase3 is a member of the C‐tail‐anchored integral membrane 
proteins  and  forms  part  of  the  TNFR1 membrane  receptor  and  ‘factor‐associated with 
nSMase activation’  (FAN) signalling which  is essential  for nSMase activation  (Krut et al., 
2006).  nSMase3  (SMPD4)  was  shown  to  be  abundant  in  striated  smooth  muscle 





et  al.,  1996,  Kolmakova  et  al.,  2004,  Tellier  et  al.,  2007).  Much  of  our  current 
understanding of nSMases in cell signalling has come from work on cardiomyocytes and 
vascular  smooth muscle  cells  (VSMC).  Indeed  nSMase  has  been  closely  associated with 
pro‐inflammatory markers  such  as  TNFα  and  apolipoprotein  A‐1  suggesting  a  link with 
atherosclerosis  (Oral et al., 1997, Tellier et al., 2007, De Palma et al., 2006, Auge et al., 
1996, Kolmakova et al., 2004). Interestingly, nSMase has shown a sensitivity to changes in 
oxidative  stress  induced by TNFα  following a decrease  in GSH  (Liu  et  al.,  1998,  Liu  and 
Chapter 1                                                                                                         General introduction 
  [43] 






shown  to work  at  neutral  pH  by  hydrolysing  lesional  LDL‐associated  SM,  suggesting  its 
lipase  activity  it  is  not  limited  to  acidic  microenvironments  thus  may  be  applicable  in 
disease (Schissel et al., 1996b). As mentioned above, the two products of the SMPD1 gene 
were termed lysosomal SMase (L‐SMase) and secretory SMase (S‐SMase) on the basis of 
their  topology.  Pulse‐chase  radiolabelling  of  the  protein  precursor  in  normal  and  I‐cell 
fibroblasts (cells lacking the capability to traffic proteins to lysosomes), revealed ASM to 
be subject to proteolytic processing from an initial 75 kDa protein to a 70‐72 kDa mature 
enzyme which  can be digested  to  a  57  kDa protein  (Ferlinz  et  al.,  1994, Hurwitz  et  al., 
1994b,  Marathe  et  al.,  1998,  Hurwitz  et  al.,  1994a).  Assessed  by  matrix‐assisted  laser 
desorption/ionization (MALDI) mass spectrometry, the placental ASM showed eight intra‐
molecular  disulfide bridges  spanning  the  length of  the protein  (Lansmann et  al.,  2003). 
The importance of the cysteine residues in ASM was highlighted in a study by Qiu et al., 
(2003), who showed that deletion or mutation of the carboxy terminal Cys629 significantly 










(A) The primary polypeptide  form of acid sphingomyelinase  (ASM) showing  its different 
structural domains prior to signal peptide digestion. The saposin domain is thought to be 
involved in substrate presentation to the phosphodiesterase domain. (B) Conformational 
structure  of  the mature  ASM  protein  showing  the  C‐carboxyl  terminal  end  involved  in 
activation  of  ASM  and  the  location  of  the  catalytic  phosphodiesterase  domain.  Figure 

























































The  SMPD1  product  is  subject  to  post‐translational  modification  and  mannose‐6‐
phosphate  (M6P)  trafficking  (Ferlinz  et  al.,  1994).  Lysosomes  are  acidic  intracellular 
vesicles  that  contain  hydrolytic  enzymes  taking  part  in  phagocytosed  bacterial  killing, 
autophagy and transport of proteins (Kornfeld, 1987). It has been suggested that L‐SMase 






ASM  precursor  to  the  default  secretory  pathway.  The  precise  targeting  of  lysosomal 
hydrolases  depends  on  M6P  binding  residues  recognised  by  M6P  receptors  and  pre‐
lysosomal shuttling. The key enzyme catalysing this M6P tagging is N‐acetyl glucosamine 





2005).  An  alternative  trafficking  pathway  has  been  proposed  whereby  sortilin,  a 








protein  is  trafficked  to  the  golgi  where  if  mannose‐6‐phosphate  (M6P)  tagged,  it  is 
targeted  to  lysosomes where  it  is  activated  by  Zn2+  binding.  Alternatively,  the  proASM 
takes the default golgi secretory pathway where it is released from the cell and requires 

























Lysosomal  acid  sphingomyelinase  (L‐SMase)  is  best  known  for  its  involvement  in 
Niemann‐Pick disease  (NPD) a  lysosomal storage disorder that  features abnormally high 
levels of SM due to SMPD1 deficiency (Schneider and Kennedy, 1967). Localisation of L‐
SMase however  is  not  only  limited  to  lysosomes but  can be  PM‐associated,  possibly  in 





the  protection  gained  in  its  absence  in  ASM  knockout  (ASM‐/‐)  cells.  Defective  TNFα‐
induced apoptosis has been witnessed in ASM‐/‐ EC and hepatocytes (Haimovitz‐Friedman 
et  al.,  1997,  Garcia‐Ruiz  et  al.,  2003).  Similarly,  apoptosis  was  also  averted  following 
radiation  treatment  in  ASM‐/‐  human  lymphoblasts  (Santana  et  al.,  1996),  after 




reducing  agent  DTT  but  was  not  directly  affected  by  GSH  (Liu  and  Hannun,  1997). 
Accordingly, observations by Qiu et al.,  (2003)  support a  role  for oxidative  stress  in  the 
activation  of  L‐SMase.  A  recent  account  described  ROS  involvement  in  ASM‐mediated, 




recently  reported  that  sensitization  of  glioma  cells  to  chemotherapy  was  due  to 
expression  of  ASM  and  increased  Cer  levels,  which  could  be  prevented  by  neutralizing 
ROS  (Grammatikos  et  al.,  2007).  Other  activators  of  L‐SMase  include  Fas/Fas  ligand 
(Zhang  et  al.,  2007,  Jin  et  al.,  2008)  and  endostatin  (Zhang  et  al.,  2005a).  Intriguingly, 
TNFα  has  been  shown  to  cause  rapid  activation  of  L‐SMase  in  bovine  coronary  artery 
endothelial  cells  (BCAEC)  raising  Cer  levels within  2 minutes  leading  to  decreased  EDV. 
This was  suggested  to  occur  through  Cer‐induced O2
‐  production  and  eNOS  uncoupling 
with no direct causal effect of Cer (Zhang et al., 2002).  
1.7.2.2.2.3   L‐SMase and disease  






lipid  rafts  (LR)  and membrane  platform  formation  (Gulbins,  2003,  Jin  et  al.,  2008).  Fas 
ligand  (FasL)‐induced  inhibition  of  EDV  could  be  prevented  by  disrupting  L‐SMase 
transport to the plasma membrane in coronary artery EC (CAEC) (Jin et al., 2008).  Zhang 
et  al.,  demonstrated  that  these  events may  be  regulated  through  a  redox mechanism. 
Accordingly, superoxide production was able to increase L‐SMase activity and lead to the 



































The  figure  shows  the  chemical  structures  of  sphingomyelin,  ceramide  and 
phosphorylcholine.  Acid  sphingomyelinase  (Acid  SMase)  hydrolyses  sphingomyelin, 





























al.,  2000). Macrophages  and  fibroblasts  can  release  active  S‐SMase  however  the most 
abundant  source  are  EC  (Marathe  et  al.,  1998,  Schissel  et  al.,  1996a),  while  Chinese 
Hamster  Ovary  (CHO)  cells  are  often  used  for  recombinant  human  ASM  transfections 
(Schissel et al., 1996a, Qiu et al., 2003).  
1.7.2.2.3.1   Regulation of S‐SMase 
Most  notably,  pro‐inflammatory  cytokines  have  been  shown  to  induce  S‐SMase 
release. In particular, IL1β, IFN‐γ and to a lesser extent IFN−β caused active S‐SMase to be 
detected in HUVEC medium by 18 hours (Marathe et al., 1998). Lipopolysaccharide (LPS) 
and  TNFα  have  been  linked with  S‐SMase  release  (Wong  et  al.,  2000)  and  though  this 
evidence  suggests  a  role  for  TNFα  in  L‐SMase  activation  in  EC  in  vitro,  its  effect  on  S‐





by  pro‐inflammatory  mediators,  possibly  increasing  systemic  levels  of  the  enzyme.  S‐
SMase activity from human serum was shown to  increase following the addition of pro‐
oxidant 2,2'‐azobis‐2‐amidinopropane (AAPH) and could be halted using the anti‐oxidant 
ascorbic  acid  (Claus  et  al.,  2005).  In  the  study described  above by McCollister  et  al.,  S‐
SMase  was  found  to  increase  by  4  hours  in  MΦ  medium  after  being  challenged  with 
Salmonella or E. coli. In support for the role of ROS in S‐SMase activation, ASM‐mediated 
bacterial  killing was ROS‐dependent,  however  it was not  clear whether  this  involved  S‐
SMase (McCollister et al., 2007).  
1.7.2.2.3.2   S‐SMase in vascular pathophysiology  
As with  L‐SMase,  S‐SMase has  also been  linked with  atherosclerosis  (Marathe et  al., 
1999, Marathe  et  al.,  2000)  and  proposed  to  regulate  subendothelial  LDL  retention  in 
early  atherogenesis  (Tabas  et  al.,  2007).  Several  lines  of  evidence  support  its  role  in 
atherogenesis.  Increased  SMC  proliferation  is  evident  in  atheromatous  lesions  (Ross, 
1999)  and  early  studies  showed  that  the  mitogenic  effects  of  oxidised  LDL  on  SMC 
proliferation could be reproduced using exogenous bacterial SMase  (nSMase) and short 
chain  ceramides  (Auge  et  al.,  1996). Work  from  the  Tabas  group  later  showed  that  S‐
SMase  can  hydrolyse  lesional  (not  plasma)  LDL  bound  SM  at  neutral  pH  outside  its  pH 












haemophagocytic  lymphohistiocytosis  (HLH)  (Takahashi  et  al.,  2002),  type  2  diabetes 
(Gorska  et  al.,  2003)  and  following  ionizing  radiation  treatment  in  cancer  patients 
(Sathishkumar et al., 2005). ASM is known to be sensitive to ROS‐mediated activation as 
shown in sepsis patients while raised pro‐inflammatory cytokine profiles may underlie the 
increased  S‐SMase  levels  in  HLH.  In  chronic  heart  failure  (CHF),  correlation  analysis 
revealed  a  negative  association  between  S‐SMase  activity  and  peripheral  vasodilator 







ways  including de  novo  in  the  ER,  recycling  of  exogenous  Cer  (short  chain  C6‐Cer),  SM 

















sphingomyelinase  (FAN)‐mediated  apoptosis  through  nSMase  activation  (Segui  et  al., 
1999).  Conversely,  Cer  involvement  has  been  described  in  cell  proliferation  and 
associated  with  MAPK‐dependent  mitogenic  effects  in  response  to  TNFα,  bacterial 
nSMase and oxidised LDL (Auge et al., 1996, Raines et al., 1993, Sasaki et al., 1995). 
1.7.3.1   Topology of Cer generation by ASM 
One  of  the  leading  questions  surrounding  the mechanism  of  S‐SMase‐mediated  Cer 
generation is its access to SM. SM is highly abundant in the outer leaflet of the PM giving 
S‐SMase  likely access to  large pools  (Merrill and Jones, 1990). Generation of Cer on the 
outer plasmalemmal  face has been  shown  to  lead  to alteration of PM architecture and 









et  al.,  2000)  and  also  to  stimulate  the  release  of  oxygen  radicals  in  EC  itself  (Li  et  al., 








ASM  (Qiu et  al.,  2003),  it  is possible  that  increased ROS generation  could activate ASM 
generating Cer‐enriched LR, clustering of NADPH subunits propagating ROS formation and 
amplifying  redox  signalling  in  EC  (Zhang et  al.,  2008).  The above highlight  the potential 




et  al.,  2006).  Due  to  its  biophysical  nature,  Cer  indeed  favours  the  formation  of  Cer‐





In  similar  fashion,  these  microdomains  may  also  fuse  creating  larger  Cer‐enriched 
macrodomains  (platforms)  (Grassme  et  al.,  2001).  Membrane  platforms  are  known  to 
cluster and aggregate surface receptors which are thought to create a highly dense area 
of receptor signalling units, facilitating efficient signal transduction (Grassme et al., 2001, 
Gulbins  and Grassme,  2002, Grassme et  al.,  2003).  Accordingly  evidence  exists  for  Cer‐
mediated clustering of CD95 and CD40 at the PM surface, an event thought to be crucial 
for  CD95  signalling  (Grassme  et  al.,  2001,  Grassme  et  al.,  2002).  Similarly,  lateral 
association of Cer in the PM can lead to its aggregation which may potentiate cell signals 
by  oligomerising  receptor  sub‐units  and  causing  protein  dimerisation  (Deaglio  et  al., 
2007).  To  this  end,  ASM  translocation  to  the  cell  surface  can  lead  to  Cer‐dependent 
formation of LR redox signalling platforms (Jin et al., 2008).  
Although Cer was also reported to prevent caveolin‐1 inhibition of eNOS, proximal to 
to  LR,  planar  lateral  association  of  Cer  molecules  is  thought  to  affect  ion  channel 
formation such as ICRAC (Figure 1.10) (Der et al., 2006). Accordingly Cer has been shown to 
interfere with Ca2+  signalling  in  various  cell  types  including  rat pinealocytes,  rat  thyroid 
FRTL‐5  cells  and  cardiac  myocytes  (Negishi  et  al.,  1998,  Condrescu  and  Reeves,  2001, 
Tornquist  et  al.,  1999).  Similarly,  In  T  lymphocytes,  nSMase  and  Cer  led  to  decreased 
SOCE, which was abrogated in ASM‐/‐ cells (Church et al., 2005). Therefore Cer generation 
at  the  PM by  S‐SMase  could  induce  Cer‐enriched  platform  formation,  thus  altering  ion 












































Both  RA  and  PSV  have  been  linked  with  enhanced  CVD  in  particular  accelerated 
atherosclerosis.  What  both  these  diseases  have  in  common  with  atherosclerosis  is 
endothelial dysfunction supported by observations in clinical disease. ECD in this setting is 
best described as impaired EDV brought about by decreased NO production. The process 
of NO production  is  carried out by eNOS activation,  an enzyme  tightly Ca2+‐dependent. 
Previous work from our  laboratory has found that Cer can regulate the major source of 
cell  Ca2+  by  blocking  SOCE.  Cer  is  a  ubiquitous  downstream  lipid  messenger  produced 
following SM catabolism by SMases. A particular fraction of SMase is soluble and readily 
secreted by EC  (S‐SMase)  in  response to pro‐inflammatory cytokines  found raised  in RA 
and  PSV.  S‐SMase  therefore  could  access  multi‐site  endothelia  and  alter  EC  signalling, 








and  ROS  activate  sphingomyelinase,  which  may  be  a  key  mediator  of  endothelial  cell 
dysfunction  through  ceramide  generation  causing  a  decrease  in  iCa
2+  signalling  and 





2. To  establish  a  model  for  the  exploration  of  S‐SMase‐induced  endothelial 
dysfunction 
3. To  determine  whether  TNFα and  oxidative  stress  induce  the  secretion  and 
modulate the activity of native endothelial‐derived S‐SMase 


















ASM specific Peptide‐CPG beads      Alta Bioscience 
Benchtop microcentrifuge        Eppendorf 5415R 
ECL solution            GE Healthcare 
E.L.I.S.A. 96 well plates        Maxisorp, Nunc Technologies 
Exposure Film  (X‐ray)         Kodak 
Fluorometric Nitric Oxide Assay kit       Calbiochem, Molecular Probes 
Foetal calf serum           Biosera 
FURA‐2 AM            Invitrogen, Paisley, UK 
Hanks Buffered Salt Solution        Gibco Scientific 
Heparin             Multiparin   
Human Serum           HD Supplies 
Hydrochloric Acid           Fisher Scientific 
Microplate Fluorescence reader ‐      Fluoroskan Ascent, Labsystems 
Microplate photometer        Anthos ht II  
Medium 199             Gibco (Invitrogen) 
NBD‐SM             Molecular Probes 
Parafilm             Pechiley Plastic Pack’g, Menasha, US. 
PVDF Membrane           Geneflow 
Sodium Nitrate           Fisher Scientific 
Solvents (Methanol, ethanol, Chloroform)    Fisher Scientific 
Tris/Glysine/SDS (10x)          Geneflow 
Tris/Glycine (10x)          Geneflow 
TLC plates             Alugram® Macherey‐Nagel, Germany 
Trypsin‐EDTA            Gibco (Invitrogen) 
Vacuum Pump (Speed Vac SC100 Savant)    Divac, 2.4 L, Leybold 
Vivaspin‐30 concentrators         GE Healthcare 























































Molten  LaminAir  Model  1.2  Class  II  biological  safety  cabinets  were  used  for  sterile 
conditions  and maintaining  sterile  solutions  and  equipment. Non‐sterile  solutions were 




  Material  PEX  Source  Storage 
AASV cohort 1(4)  Plasma  Yes  Renal Immunobiology group (1)  ‐800C 
AASV cohort 2(4,5)  Serum  No  Wellcome clnical trials unit (3)  ‐800C 
AASV cohort 3(4)  Plasma  Yes  Renal Immunobiology group (1)  ‐800C 
AASV cohort 4(4,7)  Plasma  Yes  Renal Immunobiology group (1)  ‐800C 
AASV cohort 5(3,5)  Serum  No  Renal Immunobiology group (1)  ‐800C 
RA(6)     Serum  No  Russell’s Hall Hospital (2)  ‐800C 
 
Table 2. 3 Clinical patient sample cohorts 


































Blood  was  taken  from  consented  human  healthy  control  individuals  with  no  known 
chronic  ailment.  Peripheral whole  blood  (10 mL) was  extracted  and  placed  into  50 mL 
centrifuge tubes. For plasma preparations, 100 µL of 25,000 U heparin (Multiparin) was 
added to the tube prior to the blood. The heparin was mixed by gentle inversion. Blood 
was  centrifuged  895  x g  (2500  rpm)  for  10 minutes  at  room  temperature.  Plasma was 
aspirated and aliquoted in working aliquots of 25 µL and stored at ‐200C whilst in use or 













the  Birmingham  Women’s  Hospital  delivery  suite  department,  Birmingham.  This 
procedure  followed  an  ethically  approved  protocol  (Sth.  B’ham;  2002/277)  and 
anonymity was ensured. Prior  to HUVEC extraction, 25  cm2 vented  tissue  culture  flasks 
were  coated  with  a  film  of  0.2%  gelatin.  Umbilical  cords  were  kept  within  containers, 
sterilised by 70% alcohol swabbing prior to entry into culture hoods. Umbilical cords still 
attached  to  the  placenta  were  selected  wherever  possible  for  maximum  sterility. 
Umbilical cords were wiped with ethanol and initially cannulated unilaterally using a glass 
cannula  into  the umbilical  vein  available.  Sterile  PBS  (20 mL) was  syringed  through  the 
umbilical vein to wash out any blood and blood clots. The cord was bilaterally cannulated 
and 10 mL of  1.0 mg/mL  collagenase  in HBSS‐Ca2+ was  syringed  in  and  the  cords were 
incubated  for 15 minutes at 370C, 5% CO2. During  this  time,  the excess gelatin  solution 
was  apirated  from  the  tissue  culture  flasks.  Following  incubation,  the  umbilical  cords 
were lightly massaged to ensure the detachment of HUVECs. Syringing approximately 25 




of  fresh  growth  M199  to  ensure  comprehensive  dispersion  of  cells.  A  further  1.0  mL 
M199 per allocated flask was added and the cell suspension was loaded into each gelatin‐





medium was  then  removed and cells were washed up  to  three  times with pre‐warmed 
sterile  PBS.  Fresh  growth M199  (5 mL) was  added  to  each  25  cm2  flask  and  cells were 
incubated for 24 hours at 370C, 5% CO2. M199 was once again aspirated, the cells washed 







All media were  used within  than  4 weeks  of making  up.  HUVEC medium was  changed 
every 48 hours during normal culture conditions. Primary cultures of HUVEC seeded from 
an umbilical cord underwent medium the first medium change within 3 hours of seeding 
and  1 mL  of  centrifuged  (322  x  g,  1200  rpm)  original medium was  replaced.  A  second 
medium  change  followed  24  hours  after  seeding  and  repeated  every  48  hours.  HUVEC 
were cultured using 0.2 mL/cm2 of medium. For a two‐fold cell subculture, plastic culture 
flasks were  pre‐coated with  0.2%  gelatin:dH2O  solution.  Cultured  HUVEC were washed 
three  times with  sterile pre‐warmed PBS  (2 mL/25 cm2). PBS was  removed and 1x pre‐
warmed 0.05%  trypsin/EDTA  (Gibco)  (0.5 mL/25  cm2) was added and  incubated  for 1‐2 
minutes.  The  cells  were  dislodged  by  gentle  tapping  of  the  culture  flask.  The  trypsin 
solution was neutralised with 5 mL growth M199. The cell suspension was aspirated and 
centrifuged  at  322  x  g  (1200  rpm)  for  8  minutes  at  20‐230C.    The  supernatant  was 
















chloroform:methanol  solution,  4  mL  ammonium  hydroxide  (2  N)  was  added  using  a 
volumetric  pipette  ensuring  a  slow  dispensing  rate  without  mixing  the  solution  in  the 
bottle. Upon addition of all the ammonium hydroxide, the whole solution was mixed by 




nmol)  substrate  (NBD‐SM),  20  mL  ZnSO4  (2  mmol/L)  followed  by  20.0  µL  of  sample. 
Samples were  either  clinical material  (serum/plasma)  or media  supernatants  produced 








carefully  aspirated  and  loaded  into  a  new microcentrifuge  tube.  The  organic  layer was 
evaporated  under  vacuum  (Divac,  Leybold) whilst  being  centrifuged  (SpeedEvac  SC100, 
Savant)  for  15 minutes.  A  solid  pellet  resulted which  contained  cleaved  NBD‐ceramide 
(NBD‐Cer)  and  non‐cleaved  NBD‐sphingomyelin  (NBD‐SM).  The  total  pellet  was 
reconstituted  in  10  µL  chloroform  (100%)  and  to  ensure  uniform  loading  amongst 
samples, 9 µL was pipetted onto a glass silica TLC plate 2 cm from the origin. TLC solvent 
(25.0 mL) chloroform/methanol/ammonium hydroxide [2.0 N] (65:25:4 v/v/v) was added 
to  a  glass  tank  2  minutes  prior  to  extraction  to  allow  for  the  saturation  of  the  tank 
atmosphere. A solvent saturated piece of cardboard covering the height of the tank was 
also added standing against  the side of  the  tank  to ensure atmospheric  saturation. The 
tank  lid  was  carefully  removed  and  the  TLC  plate  was  inserted  in  vertically  in  a  plate 
holder.  A  layer  of  Vaseline  was  applied  onto  the  rim.  Solvent  was  allowed  to migrate 
sufficiently to allow separation of NBD‐SM and NBD‐Cer. When the front reached a few 
millimetres  below  the  plate  top  edge,  the  plate  was  removed  and  dried  in  a  fume 
cupboard. The plate was  immediately wrapped  in  foil  to protect  from  light. Analyses of 











Upper panel,  samples were  spotted onto TLC plates.  Following TLC  separation,  the TLC 
plates were loaded onto a lid of a 96‐well tissue culture microplates (A) and placed in the 
reading  tray  of  a  fluorescence  microplate  reader  for  analysis  (B).  Spots  on  each  plate 
resulting  in  a  fluorescence matrix  (C).  Following  analysis  of  fluorescence  from  the  TLC 
plates  was  exported  from  the  Ascent  Software  onto  an  Microsoft  Excel  spreadsheet 




























sulphate  for  2  hours  at  370C.  The  reaction  was  stopped  upon  the  addition  of 
chloroform/methanol (2:1). The solution was centrifuged and the lower organic layer was 
aspirated and freeze‐dried to evaporate and yield a substrate (NBD‐SM) pellet. The pellet 
was  re‐suspended  in chloroform, spotted onto a TLC plate and allowed  to migrate. The 
percentage  hydrolysis  of NBD‐SM  to NBD‐ceramide was  calculated  through  fluorescent 













NBD‐Cer was calculated as a percentage of  the  total NBD  fluorescence of both Cer and 
SM fractions. Intra and inter‐assay statistics were performed.  
2.2.4   Measuring ASM activity by high‐performance liquid chromatography (HPLC) 
The  in vitro  reaction was performed as  in section  (2.2.3)  (TLC method). A pelleted solid 
phase of NBD‐SM and NBD‐Cer was achieved. The pellet was reconstituted  in 100 µL of 
ethanol (100%) and transferred to a glass sampling vial (Chromacol, UK) and 5 µL of the 
reaction  mixture  was  auto‐sampled  WPS‐3000‐RS  (Dionex,  UK)  onto  a  HPLC  system 
(Dionex, UK) equipped with a reverse‐phase C18 column (Phenomex, UK) and the sample 
was  eluted  at  a  flow  rate  of  1.0  mL/min  using  an  isocratic  buffer  consisting  of 
methanol:Tris‐HCl (96:4, 0.5 mol/L Tris‐HCl, pH 9.0). NBD fluorescence was detected using 
a  fluorescence  detector  RF‐2000  (Dionex,  UK)  set  at  excitation  (485  nm)  and  emission 
(530 nm). The peak products were identified by retention time, which was compared to a 
known  standard.  The  amount  of  product  was  calculated  using  a  regression  equation 
established  by  an  ASM  treated  NBD‐SM  standard  curve.  Sample  peak  analysis  was 
performed using Chromeleon  softaware  (v6.8)  (Dionex, UK) establishing area under  the 





This  assay  indirectly  measures  SMase  activity  monitored  by  10‐acetyl‐3,7‐





served  as  an  independent  method  to  confirm  findings  recorded  by  TLC  within  this 







using human serum or plasma  in  this method was  the presence of  confounding  factors 
such  as  phosphorylcholine  and  choline  (Figure  2.3b)  (Ilcol  et  al.,  2004,  Hidaka  et  al., 
2008).  The  interference  of  choline  in  the  assay  sample may  act  as  a  false  positive  and 




























assay  kit  reaction  pathway  following  sphingomyelin  hydrolysis  by  SMase.  (B)  Assay 
confounders present in blood (orange). Reaction solution provided in the assay kit (blue 



























































and  incubated  for  180 minutes  at  370C.  Fluorescence  intensity  of  the  heat‐inactivated 













enzyme  activity  in  acidic  conditions.  Initial  experiments  indicated  that  early  resolution 
incubation  time with  the Amplex  red  reagent was not  sufficient  to distinguish between 
enzyme  activity  and  background  fluorescence  (Figure  2.5a).  In  an  attempt  to  enhance 
sensitivity, we increased the enzyme:substrate reaction time (from 1 hour to 2 hours) and 
substrate  incubation  time with  the amplex  red working  reagent  for up  to 3 hours.  This 
enhanced the assay sensitivity 2‐fold (Figure 2.5b).  
 
The pH of plasma/serum tends  to vary around pH 7.3.  Increasing volumes of plasma  in 
acid buffer  (pH 5.0)  shifted  towards a more basic pH, not suitable  for  the assay  (Figure 
2.6a). To determine the suitable volume of plasma/serum, two PSV patients with differing 
ASM  activity  were  used;  one  with  low  S‐SMase  activity  and  one  with  high  activity, 
previously  determined  by  the  TLC  activity  assay.  Using  duplicate  samples  from  each 
patient, one HI and one normal, the plasma was added to acid buffer as 10, 20 and 30% 
mixtures (v/v) (Figure 2.6b‐d). The greatest resolution was provided from samples using 
10%  (v/v)  plasma  and  to  a  lesser  extent  with  20%  plasma  (Figure  2.6b‐c).  The  initial 
fluorescence  is  thought arise  from the background  fluorescence of Amplex Red reagent 





























(A)  Differing  volumes  of  pooled  human  plasma were  added  to  acid  buffer  (62 mmol/L 
sodium acetate, 0.1%  Igepal NP‐40  type, pH 5.0)  to  represent  the percentage  indicated 
above and the pH was measured. Samples are added to acid buffer (62 mmol/L sodium 
acetate, 0.1% Igepal NP‐40 type, 5% v/v 2mmol/L zinc sulphate, pH 5.0) in the presence of 
0.5  mmol/L  sphingomyelin  and  incubated  for  2  hours  at  370C.  Amplex  Red  reaction 
cocktail  is  added  and  incubated  for  180  minutes  at  370C.  (B)  10%,  (C)  20%,  (D)  30% 
plasma:buffer (v/v). High S‐SMase activity patient (black/red lines) was compared against 
a  low S‐SMase activity patient  (blue/green  lines)  (determined by  the TLC SMase assay). 
Fluorescence  intensity  measure  at  550  nm  (excit.)  and  615  nm  (emm.)  from  heat‐
inactivated plasma  (red, High SMase activity patient; green,  low SMase activity patient) 








These  assays  demonstrated  the  need  to  use  small  volumes  of  plasma/serum  in  this 
method,  which  are  in  line with  the  amount  of  sample  used  for  the  TLC  activity  assay. 
Optimisation of the sample volumes led to the need to examine the effect of different HI 
times  assay  sensitivity.  A  PSV  patient  with  high  ASM  activity  was  used  and  Figure  2.7 
suggested that different HI times (> 30 min.) did not enhance assay sensitivity. To confirm 




samples were HI  and one was  spiked with  purified ASM  (pASM,  Sigma).  The  data  here 
confirmed  that  not  denaturing  the  enzyme  led  to  a  significantly  higher  fluorescence 
intensity  (FI) compared to HI samples whilst spiked pASM substituted the  lack of native 
ASM in HI samples in the presence of choline oxidase (lines with squares). Furthermore, 
in samples  incubated without choline oxidase, all  fluorescence was omitted  (Figure 2.8, 
lines with  inverted  triangles)  suggesting  that  the  change  (Δ) observed between HI  and 
non‐HI  samples  was  attributed  to  ASM  activity.  Thus,  we  concluded  from  these 
observations  that  by  heat  inactivating  a  plasma/serum  sample  and  comparing  its 
fluorescence  against  a  non‐HI  counterpart  we  could  determine  specific  ASM‐derived 
enzymatic  activity.  Intra  and  inter‐assay  variability  was  estimated  to  be  between  3‐6% 
examined using HIFCS and FCS (data not shown). Having established this altered method 
for measuring ASM in patient plasma/serum,  it was utilised to assay S‐SMase activity  in 








Patient  plasma  was  heat  inactivated  for  30,  45  and  60  minutes  at  570C.  Samples  are 
added  to  acid  buffer  (62  mmol/L  sodium  acetate,  0.1%  Igepal  NP‐40  type,  5%  v/v 
2mmol/L  zinc  sulphate,  pH  5.0)  in  the  presence  of  0.5  mmol/L  sphingomyelin  and 
incubated for 2 hours at 370C. Amplex Red reaction cocktail  is added and  incubated for 
180 minutes at 370C. Activity was compared against non‐heat‐inactivated plasma  (‘non‐
HI’)  and  non‐heat‐inactivated  plasma  spiked  with  purified  ASM  (Sigma)  (‘pASM’). 

















30  minutes  at  570C  and  compared  against  non‐heat‐inactivated  plasma  (‘non‐HI’)  and 
heat‐inactivated  plasma  spiked  with  purified  ASM  (Sigma)  (‘HI  &  pASM’).  Samples  are 
added  to  acid  buffer  (62  mmol/L  sodium  acetate,  0.1%  Igepal  NP‐40  type,  5%  v/v 


















Healthy  control  plasma  samples were  heat‐inactivated  for  30 minutes  at  570C.  Healthy 
control plasma (10 µL) was added to acid buffer (62 mmol/L sodium acetate, 0.1% Igepal 
NP‐40  type,  5%  v/v  2mmol/L  zinc  sulphate,  pH  5.0)  in  the  presence  of  0.5  mmol/L 
sphingomyelin and incubated for 2 hours at 370C. Amplex Red reaction cocktail is added 
and  incubated  for 180 minutes at 370C.  (A) healthy control 4,  (B) healthy control 6 etc. 












2mmol/L  zinc  sulphate,  pH  5.0)  in  the  presence  of  0.5  mmol/L  sphingomyelin  and 
incubated for 2 hours at 370C. Amplex Red reaction cocktail  is added and  incubated for 
180 minutes at 370C. Patients with low activity (A‐B) and patients with high activity (C‐F). 








(Figure  2.10c‐f)  S‐SMase  activity.  For  patients  with  high  activity  this  is  evident  by  the 
increased Δ  between HI  and  non‐HI  samples  at  180 minutes, which  differs  from  those 
with  low  activity.  To  accurately  compare  independent  data  between  the  Amplex  red 
assay  and  the  established  TLC  activity  assay,  enzyme  activity  was  standardised  and 
expressed in international units of activity (1 unit of pASM hydrolyses 1 nmol of SM/hour, 
















550  nm  (excit.)  and  615  nm  (emm.)  using  a  Fluoroskan  Ascent microplate  reader  (Lab 

























The  assay  is  sensitive  enough  to  be  performed  in  a  96  well  plate  and  the  amount  of 
formazan  detected  is  directly  proportional  to  the  number  of  viable  cells.  HUVEC  were 




slow  growing  lines.  At  confluence, medium was  replaced with  ASM  (Sigma)  containing 
fresh  growth M199  and HUVEC were  incubated  for  1  hour  at  370C.  For  TNFα, medium 








Mitochondrial  transmembrane  potential  (ΔΨm)  can  be  studied  by  observing  the 
incorporation  of  3,3’‐dihexyloxacarbocyanine  iodide  (DiOC6)  (Sigma‐Aldrich).  Disruption 




were  sub‐cultured  and  6x104  cells  re‐seeded  in  gelatin  coated  (0.2%)  24‐well  tissue 
culture  plates.  HUVEC  were  cultured  until  confluence  (48‐72  hours).  For  TNFα 
treatments, growth M199 was removed and HUVEC were washed once with pre‐warmed 
HBBS‐Ca2+  (0.2 mL/well)  to  remove  serum. Control or  conditioned HESFM  (1.0 mL) was 
added  to  each  well.  HUVEC were  incubated  for  18  hours,  370C.    For  ASM  treatments, 
growth M199 was removed and replaced with fresh control or conditioned growth M199 
for  1  hour,  370C.  For  both  treatments  the  method  is  the  same  following  treatment. 
Control  and  conditioned  media  were  removed  and  placed  into  plastic  flow  cytometry 
tubes  (Falcon)  in order  to  retain any dead HUVEC. Adherent HUVEC were washed once 
with HBSS‐Ca2+  (0.2 mL/well) and washing buffer was also added to corresponding  flow 
cytometry  tubes  (Falcon). Pre‐warmed 1x  trypsin‐EDTA  (0.05%, 0.2 mL/well) was added 
and HUVEC were  incubated  for  1 minute  at  370C.  Fully  supplemented  growth M199  (2 
mL/well) was quickly added to each well to neutralise the trypsin. The HUVEC suspension 
was  aspirated  and  added  to  the  corresponding  FACS  tube.  HUVEC were  centrifuged  at 
322 x g (1200 rpm) for 10 minutes at room temperature. Supernatants were removed and 
HUVEC were washed with HBSS‐Ca2+  (0.5 mL/tube),  re‐suspended and centrifuged once 




recorded  and  analysed.  The  percentage  of  DiOC6






Media  from  cells  treated  with  TNFα  were  harvested  for  S‐SMase  content.  The  ultra‐
filtrates were collected  following media concentration  (2.2.8.4)  to  increase the S‐SMase 







48‐72 hours. Upon confluence  the medium was  removed,  cells were washed once with 







Immediately upon  removal of  the wash buffer, 5 mL/25 cm2 HESFM  (Gibco;  Invitrogen; 
see 2.2.1.1) with solvent control or loaded with 10 ng/mL TNFα, both supplemented BSA 
(0.2%) was  added  and HUVEC were  incubated  at  370C  for  30 minutes,  3,  6,  12  and  24 












Growth M199  (Sigma‐Aldrich) was  removed  and HUVEC were washed once with HBSS‐
Ca2+ (4 mL) and supplemented with 10.5 mL control unconditioned, BSO (100 µmol/L) or 
NAC 1 mmol/L)  loaded M199 for 16 hours at 370C (Table 2.6). After 16 hours, all media 
were  removed,  cells  were washed  once  as  above  and  10.5 mL  of  HESFM with  solvent 
control,  IL‐1β  (5  ng/mL)  or  TNFα (10 ng/mL) was  added  to  appropriate  flasks.  BSO and 
NAC pre‐treated cells were  further  treated with TNFα  (10 ng/mL) and  incubated  for 18 
hours.  TNFα (10  ng/mL)  alone  and  IL‐1β (5  ng/mL)  controls  were  performed.  After  18 
hours, media were collected (2.2.8.3.1), concentrated (2.2.8.4) and cells lysed for protein 
content  as  described  below  (2.2.8.5).  The  same  concentrations  were  used  for  all 
treatments.  For  co‐treatment  of  BSO  and  NAC with  TNFα,  HUVEC were  cultured  as  in 
2.2.8.3.1, the growth M199 replaced with 10.5 mL HESFM containing solvent control, BSO  









(40C)  centrifuge  twice  for  20  minutes  checking  the  volumes  in  between.  Media  was 





mL/75  cm2) was  added  to  each  flask.  Cells were  incubated  for  1 minute  and dislodged 
following  gentle  agitation.  M199  (15  mL)  was  added  to  each  flask  to  neutralise  the 
trypsin. The cell suspension was aspirated, placed into a 50 mL universal centrifuge tube 
and  centrifuged  at  322  x  g  (1200  rpm)  for  8  minutes.  All  medium  was  removed  by 
aspiration  with  a  5  mL  serological  pipette  (Corning)  and  a  200  µL  pipette  (Gilson)  for 
residual  volumes.  Ice‐cold  RIPA  lysis  buffer  (50 µL)  supplemented  with  protease  and 





































HUVEC  calcium  (Ca2+)  responses  were  measured  using  the  fluorescent  Ca2+‐sensitive 










added  to  each  well  (200  µL/well),  and  foil‐wrapped  coverslides  incubated  at  room 
temperature  for  30  minutes.  Room  temperature  was  used  to  help  prevent  leakage  of 
FURA‐2 AM  into  intracellular organelles.  FURA‐2 AM‐loaded medium was  removed and 
cells were washed once with HBSS‐Ca2+ (100 µL/well) at room temperature to remove un‐
incorporated dye. Cells were  incubated  in 200 µL HBSS‐Ca2+  for a  further 15 minutes to 




µL) was  added  to  each well  and  the  coverslide was  taken  to  a  dark microscope  room. 
Coverslides  were  loaded  onto  the  stage  of  a  fluorescence  microscope,  the  lens  was 
focused  and  baseline  fluorescence  was  recorded  for  30  seconds.  Cells  were  then 
stimulated one well at a time with 100 µL 2x concentrated (2.0 µmol/L) bradykinin or 2 
U/mL thrombin in HBSS‐Ca2+, diluted to 1x with the 100 µL HBSS‐Ca2+ already in each well. 
Video  montage  using  SimplePCI  (v5.3.1.091305,  Compix  Inc.  USA)  was  recorded  for  5 









high  ASM  activity  patient  for  1  hour.  FURA‐2  AM  loading  and  Ca2+  mobilisation  was 
performed as above  (2.2.10.2).  For  supernatant  transfer, HUVEC were  seeded as above 
for 24 hours (2.2.10.2). Cells were treated with M199 containing S‐SMase or HI S‐SMase. 
To  obtain  this, media  from  18  hour  TNFα  (10  ng/mL)  treated  cells  were  collected  and 
concentrated  (2.2.8.5).  Concentrated media  were  assayed  for  ASM  activity  by  the  TLC 
assay (2.2.3) to show a specific activity of 150 mU calculated from an ASM standard curve 
(Figure 2.14). For Ca2+ flux studies, cells were treated with an equivalent of 750 mU/mL 
ASM  for  1  hour  at  370C.  Media  were  then  removed  and  FURA‐2  AM  loading  was 
Chapter 2                                                                                                     Materials and Methods 
  [92] 















Ca2+  dependent‐phosphorylation  of  eNOS  at  Ser1177  and  de‐phosphorylation  at  Thr495. 
HUVEC at low passage were re‐seeded onto 6 well plates at a density of 2.5x105/well and 
cultured for 48 hours in growth M199. Medium was replaced with fresh growth M199 at 
48  hours  and  cells  were  cultured  for  a  further  24‐48  hours.  On  the  day  of 




(P/S  only),  whilst  control  well  were  incubated  with  solvent  control  in  fresh M199‐P/S. 
Chapter 2                                                                                                     Materials and Methods 
  [93] 
Cells  were  incubated  for  either  30  or  60  minutes.  Following  treatment  with  ASM,  2x 
concentrated  bradykinin  (2 µmol/L)  or  thrombin  (2 U/mL) were  added  to  reach  a  final 
concentration  of  1 µmol/L  and  1 U/mL  respectively.  To  ASM  loaded  and  control wells, 






a  small  Dounce  homogeniser  (30  strokes).  Cell  lysates  were  incubated  on  ice  for  15 
minutes  and  centrifuged  at  9300 x  g  (10000  rpm) using  an  Eppendorf  5415R benchtop 
centrifuge  at  40C  for  2  minutes.  The  supernatant  was  placed  into  a  new  0.5  mL 
microcentrigufe centrigued tube and the pellet discarded. Of the cell lysates prepared, 5 
µL  was  aliquoted  for  protein  estimation  (2.2.14),  stored  at  ‐200C  and  used  within  1 
month. Electrophoresis and immunoblotting of eNOS is described below (2.2.12.2).  
2.2.12   Immunoprecipitation & immunoblotting 








Antibody  Species  Source  Dilution  Conc./Weight 
Primary antibodies 
anti‐ASM  Rabbit  Santa‐Cruz Biotech.  1:200 (IB*)  1 mg/mL 
anti‐ASM  Rabbit  Santa‐Cruz Biotech.  IP**  2mg 
anti‐eNOS  Mouse  BD Biosciences  1:1000  0.55 mg/mL 
anti‐peNOS  Rabbit  Cell Signalling  1:500  ‐ 
anti‐b‐actin  Mouse  Sigma‐Aldrich  1:5000  ‐ 
Secondary HRP‐conjugated antibodies   
anti‐rabbit (ASM)  Donkey  GE Healthcare  1:5000   
anti‐mouse (eNOS)  Sheep  GE Healthcare  1:5000   
anti‐rabbit (peNOS)  Donkey  GE Healthcare  1:3000   








































proteins  to  the  IgG  fraction were  removed  by  centrifugation  at  600  x  g  (2600  rpm)  30 
seconds  in a pre‐chilled bench‐top microcentrifuge  (Eppendorf) at 40C. The supernatant 
was incubated for 2 hours at 40C with 1 µg anti‐ASM antibody (Santa‐Cruz Biotech. UK). 




















8.0 mL  14.5 mL  7.5 mL  300 μL  150 μL  30 μL 
10% 
(120‐40 kDa) 
10 mL  12.5 mL  7.5 mL  300 μL  150 μL  30 μL 
12% 
(40‐15 kDa) 
12 mL  10.5 mL  7.5 mL  300 μL  150 μL  30 μL 
20% 
(< 20 kDa) 





















SDS‐PAGE was performed  in 8%  (eNOS) or 10% (ASM)  resolving gels  (Table 2.8) using a 
running buffer (above) prepared from a 10x concentrate (GeneFlow, National diagnostics, 
UK) as 10% (v/v/v)  in distilled H2O. Gels were prepared  in casting cassettes  (Invitrogen) 
creating wells using plastic combs (Invitrogen). For eNOS, lysates were thawed and kept 
on  ice  while  the  protein  content  was  calculated  using  a  BSA  standard  curve  from 
absorbance  estimates  obtained  previously  in  a  BCA  assay  (2.2.14).  Protein  antigen was 
loaded onto each  lane of  a 5%  stacking gel  (Table 2.8),  alongside 5 µL protein markers 
(SeeBlue,  Invitrogen)  in an independent lane. For eNOS, protein loading was normalised 
across  samples  and  an  equal  amount  of  protein  was  loaded  per  lane  (10‐50  mg)  in 
concentrated  loading  buffer  (5x)  to  prevent  excessive  protein  dilution.  An  appropriate 
amount of 5x loading buffer was added to each sample alongside DTT (40 mmol/L, final). 
For ASM, immunoprecipitated protein was resuspended in 20 µL of 1x loading buffer. The 
proteins  were  allowed  to  migrate  for  approximately  90  –  100  minutes  with  a  current 
ranging between 95‐105 V. A blotting sandwich was assembled (Figure 2.12) using PVDF 
membrane (Geneflow, UK), which had been previously activated by soaking in methanol 














5%  BSA  solution  on  a  rocker  for  1  hour  at  room  temperature.  For  eNOS  blots,  each 











Filter pares  















The  blocking  solution  (above)  was  removed  and  primary  antibody  (anti‐ASM  or  anti‐
eNOS, anti‐β‐actin, eNOS  loading  control)  at  the  concentrations  indicated  (Table 2.6)  in 
antibody loading solution (above) was added. The membrane was incubated overnight at 
40C  on  a  rocker.  Membranes  were  then  washed  three  times  with  1x  TBS/Tween‐20 
(0.1%).  Secondary  HRP‐conjugated  secondary  antibody  (Table  2.6)  in  TBS/Tween‐20 
(0.1%) 2% BSA was added and the membranes incubated for 1 hour at room temperature. 
Membranes  were  washed  3  times  with  1x  TBS/Tween‐20  (0.1%)  at  room  temperature 
enhanced chemiluminescence detection solution (ECL, GE Healthcare) was prepared and 
washed over the membranes for 2 minutes lifting the membrane and touching against a 




by  GeneSnap  and  the  GeneGenius  gel  imaging  system  (Syngene,  UK).  X‐ray  film 






























Analysis  of  nitric  oxide  (NO)  can  be  performed  using  a  Sievers  Chemiluminescence NO 
Analyser  (GE  Power  and Water,  UK).  This  is  a  very  sensitive  technique  that  measures 
nitrites  in  solution  as  low  as  10‐12  mol/L.  Briefly,  the  reaction  formed  depends  on  the 




in  the  solution  sampled.  The generated NO  is purged by nitrogen under  vacuum  into a 






in  the  far  red  to  infrared  spectra  and  releases  a  single  photon  for  every NO2 molecule 
produced. The number of photons detected is directly proportional to the total amount of 
NO  present  in  the  sample.  Light  is  detected  by  a  photomultiplier  and  recorded  as  a 





confluence.  On  the  day  of  experimentation,  growth M199  was  removed  and  replaced 
with HESFM for 1 hour to ensure serum starvation. Cells were stimulated with agonists 1 
µmol/L  bradykinin  or  1 U/mL  thrombin  for  30 minutes,  370C,  5% CO2.  The  conditioned 
medium was collected in 1.5 mL microcentrifuge tubes and centrifuged for 8 min at 322xg 
(1200  rpm)  to  pellet  any  dead  cells.  Supernatants were  removed  and  frozen  alongside 
fresh  medium  for  background  control  at  ‐800C  until  analysis.  Conditioned media  were 
slowly thawed on  ice. Nitrite analysis was performed by  injecting 100 µL of conditioned 
culture medium into a glass purge vessel containing 1% Sodium Iodide/glacial acetic acid 











at  a  density  of  2.5x105  cells/well  and  cultured  in  growth M199  for  72‐96  hours  until  a 




background  was  established  by  placing  the  ISO‐NOP  electrode  (WPI,  UK)  a  few 
millimetres above the cell monolayer distal to the magnetic stirrer. Cells were stimulated 
with  agonist  and  immediate  responses were  recorded.  Recording  is  performed with  an 






of whole cell  lysates and human plasma samples. Copper  (Cu2+)  reduction by protein to 
cuprous ions (Cu1+) in an alkaline environment can be observed by colorimetric detection. 
Briefly,  bicinchoninic  acid  (BCA)  reacts  with  the  reduced  cuprous  cations  to  produce  a 






absorbance  was  performed  using  StingRay  software  v1.5  (DazDaq,  UK).  Protein 
concentration  was  estimated  by  calculation  against  a  BSA  calibration  curve  (2000‐7.8 







expressed  as  standard deviation  (S.D.)  or  standard  error  of  the mean wherever  stated. 
The minimum confidence level at which data were considered significantly different was 
indicated as p   0.05. Normality tests for Gaussian distribution of data populations were 
determined by assessing  the kurtosis  and  skewness of  the data and by  the D’Agostino‐
Pearson normality test. For parametric analyses the Student’s unpaired t‐test was used, 
and  Student’s  paired  t‐test  for  parametric  paired  data.  Non‐parametric  data  from  un‐
paired  populations  were  analysed  with  Mann‐Whitney  U  test.  Non‐parametric  data 
expressed  in  paired  observations were  analysed using  the Wilcoxon  signed  ranked  test 






















(CVD)  development  and  decreased  life  expectancy  (section  1.3;  p8).  Primary  Systemic 
Vasculitis  (PSV)  and  Rheumatoid  Arthritis  (RA)  are  examples  of  these  diseases with  CV 
involvement  (Jacobsson  et  al.,  1993,  Filer  et  al.,  2003)  (1.3.2‐3;  p11‐13).  Controlling 
systemic  inflammation  leads  to  improved outcome, decreased  risk of developing a  first 
cardiovascular event and thus decreased mortality in RA (Jacobsson et al., 2005, Listing et 
al.,  2008,  Popa  et  al.,  2009).  Atherosclerosis  is  an  inflammatory  disease  and  likely 
underlying pathology behind the CVD in PSV and RA (Chironi et al., 2007, Pasceri and Yeh, 
1999, Van Doornum et al., 2002). The initiating factors are believed to involve endothelial 
cell  dysfunction  (ECD),  which  leads  to  decreased  endothelium‐dependent  vasodilation 














2004,  Sidiropoulos  et  al.,  2009,  Raza  et  al.,  2000).  TNFα  has  contrasting  effects  on 
endothelial  function  by  a)  inducing  eNOS  activation  (De  Palma  et  al.,  2006),  and  b) 
causing ECD by decreasing endothelial NO availability (Kim et al., 2001) and impaired NO‐
dependent  vasodilatation  (Bhagat  and  Vallance,  1997,  Zhang  et  al.,  2002,  Chia  et  al., 
2003). This dysregulation of vascular homeostasis has detrimental effects on endothelial 
signalling  in  inflammatory  conditions  and  the  details  of  its  role  on  subsequent 
atherosclerotic development remains unclear.  
 
One  signaling  pathway  that  has  started  to  receive  more  attention  over  the  past 
decade is the sphingomyelin‐ceramide (SM‐Cer) pathway. Pro‐inflammatory cytokines (IL‐
1β,  IFNγ)  induce  the  secretion  of  ASM  (S‐SMase)  generating  Cer  and  TNFα  has  been 
reported  to  promote  rapid  but  transient  activation  of  intracellular  ASM  (L‐SMase) 
(1.7.2.2.2‐3;  p47‐51)  (Marathe  et  al.,  1998,  Zhang  et  al.,  2002,  Wong  et  al.,  2000).  
Elevated  S‐SMase  has  been  documented  in  clinical  diseases  (p52)  in  particular  chronic 
heart  failure  (CHF)  (Doehner  et  al.,  2007).  In  CHF  it  was  associated  with  decreased 
peripheral blood flow, positively correlating with TNFα and disease severity (NYHA class) 
however,  the  precise  role  of  S‐SMase  in  pathophysiological  processes  remains  unclear. 
One  mechanism  involves  reorganisation  of  plasma  membrane  (PM)  architecture.  Cer‐






SOC  channels  is  completely  abrogated  in  ASM‐/‐  T‐lymphocytes  (Church  et  al.,  2005) 
suggesting a role for Cer in ion channel regulation.  
EDV  featuring eNOS‐generated NO  is a process  tightly  regulated by  iCa
2+  signaling 
(Fleming  et  al.,  2001)  from  the  ER  stores  and  influx  across  the  PM  through  SOCE. 
Deregulation of this signalling pathway by S‐SMase and Cer may lead to inhibition of Ca2+‐
dependent EDV and ECD. The progress of atherosclerosis in PSV (Chironi et al., 2007) and 
RA  (Gonzalez‐Gay  et  al.,  2005a,  Shoenfeld  et  al.,  2005)  is  likely  to  be  a multi‐factorial 
process. Diffuse ECD is evident in PSV occurring distally to the primary inflammatory site 
(Raza  et  al.,  2000)  suggesting  a  role  for  inflammatory  mediators  driven  by  systemic 
extraarticular disease featuring TNFα.   
We propose a mechanism whereby  vascular  inflammation  leads  to activation and 
secretion  of  S‐SMase  generating  Cer  and  inhibiting  SOCE. Decreased  iCa
2+  signaling  can 
lead  to  dysregulation  of  NO  production  through  impairment  of  Ca2+‐dependent  eNOS 
activation viewed as an early step  in ECD, a mechanism for accelerated atherosclerosis. 
This  hypothesis  regarding  the  role  of  S‐SMase  in  vascular  dysfunction  in  chronic 
inflammatory autoimmune diseases predicts that the active enzyme should be present in 
blood of  patients.  The objectives of  this  study were  to  investigate  S‐SMase  in diseased 
patients against healthy controls and to correlate S‐SMase activity with anthropometric, 









from which  the  percentage NBD‐SM  substrate  catabolised  reflected  enzymatic  activity. 
For analytical methodology see 2.2.3. 
3.2.2   Active S‐SMase is raised in plasma of patients with primary systemic vasculitis 
S‐SMase was  found  elevated  in  patients with  primary  systemic  vasculitis.  A  small 
pilot  cohort  of  11  non‐clinically  phenotyped  patients  with  ANCA  associated  primary 
systemic  vasculitis  (AASV)  (cohort  1,  Table  2.3)  was  initially  used.  These were  patients 
that  all  underwent  therapeutic  plasmapheresis  (plasma  exchange,  PEX)  during  their 
management.  In  total,  11  PEX  AASV  patient  samples  were  compared  against  healthy 
control plasma that was not age or sex‐matched (n = 9) for S‐SMase activity (Figure 3.1a). 
S‐SMase  levels  in  PEX  AASV  patients  were  increased  more  than  3‐fold  (29.40  ±  24.04 


































A  third  cohort  of  clinically  phenotyped  patients  undergoing  PEX  was  used  to  further 
characterise  levels  of  S‐SMase  in  AASV,  (Figure  3.2).  This  cohort  also  included  a  small 
inflammatory  disease  control  group,  which  included  ANCA  negative  disease  control 
patients associated with impaired kidney function (See 2.2.1.5). This provided an insight 
as to whether active S‐SMase is present in diseases with overt vascular inflammation or if 
higher  S‐SMase  activity  is  associated  more  closely  with  ANCA  positive  small  vessel 
vasculitides. Plasmapheresis may dilute patient plasma with  similar effects on S‐SMase. 
To account  for  this, plasma  from disease patients and controls was assayed  for protein 
content  and  S‐SMase  activity  normalized  accordingly.  In  total,  18  AASV  patients  were 




S‐SMase  levels  in  patients  with  active  AASV  (1.4    0.98  pmol/mg/h‐1)  compared  to 
healthy  controls  (0.15  ±  0.14  pmol/mg/h‐1)  (p  <  0.0005)    (Figure  3.2a)  while  ANCA 
negative  inflammatory  disease  control  patients  also  showed  raised  enzyme  activity 
suggesting a dissociation of S‐SMase activity with ANCA status (1.47 ± 0.90 pmol/mg/h‐1) 
(p  <  0.0005).  Plasma  S‐SMase  activity  was  similar  between  ANCA  positive  and  ANCA 








increased  activity  of  the  enzyme  or  whether  it  could  be  secreted  in  an  inactive  form. 






relate  to  accumulated  vascular  damage  through  chronic  ECD  (Figure  3.3d).  Disease 
activity  was  assessed  according  to  the  Birmingham  Vasculitis  Activity  Score  (BVAS) 
(Luqmani  et  al.,  1994).  In  univariant  regression  analysis  S‐SMase did not  correlate with 
the BVAS of patients at the time of plasma exchange (r2 = 0.087) (Figure 3.3a). Induction 
of clinical remission is largely described as a BVAS of below 1 (Booth et al., 2004a). None 
of  the patients  in  this  cohort exhibited a BVAS < 9  (Figure 3.4a), whilst all patients had 
highly  active  disease  with  a median  BVAS  of  17.5  (IQR  14  –  20; mean  16.6)  (data  not 
shown). Since a BVAS above 5 is regarded as active disease and given the patients’ high 
scores here, the lack of a significant S‐SMase/BVAS relationship it is not surprising, rather 




0.0001)  (Figure  3.3b,c,f).  S‐SMase  activity  also  did  not  relate  to  the  number  of  organs 













determined  in  vitro  by  the  TLC  activity  assay.  IDC  patients  exhibited  various  stages  of 
renal  failure and were ANCA negative. Plasma S‐SMase activity was normalised  to  total 



















S‐SMase  activity  in  plasma  of  AASV  (n=18  total)  patients  undergoing  plasma‐exchange 
(PEX)  positively  correlates with  (D)  accumulated  vascular  damage  (VDI)  (p  < 0.003)  but 
not  with  (A‐C,  E‐F)  BVAS,  age,  creatinine  levels,  duration  of  follow  up  and  number  of 
organs  involved  clinically.  Plasma  S‐SMase  activity  was  determined  in  vitro  by  the  TLC 











Plasmapheresis  is  mentally  and  physiologically  stressful  for  the  patient  and  may 
affect  S‐SMase  levels,  thus  serum  from  a  small  pilot  cohort  of  AASV  patients  was 
examined (Figure 3.4). Data confirmed the presence of S‐SMase in PSV separate from the 
effects of  plasmapheresis.  This  cohort  included  its  own healthy  control  individuals,  and 
patients with active or inactive disease and remission patients according to BVAS. These 
included  patients  with  Wegener’s  granulomatosis  (n=8)  and  microscopic  polyangiitis 
(n=8).  Healthy  controls  (n=4)  exhibited  lower  active  S‐SMase  levels  (3.56  ±  7.16 
pmol/mL/h‐1)  than  patients with  active  disease  (n=5)  (23.69  ±  15.30  pmol/mL/h‐1)  (p  < 
0.04)  (Figure  3.4).  There  was  no  significant  increase  between  healthy  controls  (3.56  ± 
7.16)  and  patients with  inactive  disease  (n=9)  (10.62  ±  12.71  pmol/mL/h‐1)  or  those  in 
remission (n=2) (4.79 ± 1.90 pmol/mL/h‐1). The small numbers did not allow for accurate 
conclusions between subgroups.  
To  confirm  the  findings  above,  a  second,  larger  cohort  of  AASV  patient  sera was 
compiled.  Serum  from  these patients was  collected prior  to  and  following  14 weeks of 
active  treatment.  Pro‐inflammatory  cytokines  are  known  to  induce  S‐SMase  secretion 
thus our secondary question was to ask whether decreasing the  inflammatory response 
affected S‐SMase levels  in these patients. The cohort was composed of 20 patients, WG 
(n=14), MPA  (n=4)  and  renal  limited  vasculitis  (n=2). Of  the  total,  45%  (9) were  female 
and the cohort had a median age of 64.7 years (mean 60.9 ± 15.3). These patients were 
compared against a group (n=7) of early remission AASV patients (6‐12 months), (median 





TNFα  blockade  leads  to  decreased  CV  mortality  in  RA  (Popa  et  al.,  2009)  and 
suppression of  inflammation restores endothelial  function, at  least  temporarily  (Raza et 






Importantly,  S‐SMase  levels  were  significantly  lower  in  6/12  month  remission 





patients,  S‐SMase  activity  fell  in  16  patients  (80%),  increased  in  3  patients  (15%)  and 
remained  the  same  in 1 patient  (5%). Patients  responded differently  to  treatment with 
regards to S‐SMase. Specifically, S‐SMase activity decreased more than 40% in 2 patients 
(n=2), more than > 30% (n=3), >20% (n=3), >10% (n=3) and less than 10% (n=3). S‐SMase 
activity  increased  in  3  patients  while  in  1  patient  it  remained  the  same.  These  data 

































matched  serum  and  early  remission  patient  serum.  Serum  from  AASV  patients  was 
extracted prior  to commencement of  resolving  treatment  (Week 0) and 14 weeks after 
resolving  treatment  (Week  14).  AASV  patients  (n=20  total)  included  Microscopic 
polyangiitis  (n=4),  Wegener’s  granulomatosis  (n=14),  renal  limited  vasculitis  (n=2). 
Healthy  controls  (n=13).  AASV  Remission  patients  (6/12 months)  (n=7).  HC  vs Week  0; 
***p < 0.0001, Week 0 vs Remission; **p < 0.0002, Week 14 vs Remission; * p < 0.0004. 
Data  represent  means  of  three  independent  measurement  of  each  sample  (n=3). 
Statistical analysis was performed using the Mann‐Whitney U‐test. (B) S‐Smase activity in 
AASV  serum  (serum  cohort  2)  falls  following  resolving  treatment.  Serum  from  AASV 
patients was extracted prior to commencement of resolving treatment (Week 0) and 14 
weeks  after  treatment  (Week  14).  AASV  patients  as  in  (A). Week  0  vs Week  14;  *p  < 
0.0008. Data represent means of three independent measurements of each sample (n=3). 







established  clinical  laboratory  markers  of  PSV  summarised  in  table  3.1.  In  univariate 
regression analysis S‐SMase activity levels at week zero (0) did not relate to immune cell 
counts  including  total  white  cell  counts,  lymphocyte  and  neutrophil  levels  (Table  3.1). 
There was also no relation with haemoglobin, VEGF and renal function such as glomerular 
filtration  rate  (MDRD  eGFR)  (Table  3.1).  Univariate  analysis  also  indicated  a  negative 
relationship  between  cytokines  and  S‐SMase  in  most  cases.  There  was  no  correlation 
between S‐SMase activity IL‐6, IL‐8 and IL‐10. TNFα, IL‐1β and IFNγ are known to induce 
S‐SMase  secretion  from  EC  (Marathe  et  al.,  1998,  Wong  et  al.,  2000)  and  therefore 





expected  TNFα to  therefore  correlate  with  S‐SMase  levels  in  these  patients.  We  also 
found a negative correlation between S‐SMase levels and IL‐1ra (p < 0.03) however, this 
lone  association  comes  with  certain  caveats.  Given  the  number  of  parameters  tested 







as  CRP,  ESR  or  creatinine  levels  (Figure  3.6,  Table  3.1).  Interestingly  S‐SMase  did  not 
relate  to  accumulated damage  (VDI)  (Figure  3.6b), which  contrasts  previous  findings  in 
AASV  PEX  patients  (3.2.3)  (Figure  3.3d).  This  may  have  been  due  to  inconsistent  VDI 
scoring for these patients and missing data points which was also the case with age and 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then,  relapse  is  common unless active  treatment  is  longer maintained  (De Groot et  al., 
2005). This assumption of continuing sub‐clinical vascular inflammation was supported by 
the  continued  high  cytokine  levels  (Figure  3.7).  The  VDI  increased  significantly  from  a 
median of 1 (mean 1.47 ± 1.74) at week zero (0) to median of 2 (mean 2.34 ± 1.94) (p < 
0.004) by week 14 suggesting continuous cumulative damage. Inflammatory markers CRP 
and  ESR  fell  following  treatment  by  week  14.  Median  patient  CRP  levels  prior  to 
treatment were 61 mg/L  (mean 97.9 ± 123 mg/L) and fell  to a median of zero  (0) mg/L 
(mean 4.2 ± 8.24 mg/L) by week 14 (p = 0.0002) (Figure 3.7d). Although analysis of ESR 






Despite  the  induction  of  clinical  response  and  decrease  in  CRP  and  ESR  levels  in 
most  of  these  patients,  TNFα,  IFNγ and  IL‐1β  levels  were  not  significantly  altered 
following treatment (Figure 3.7e‐i). This was expected for TNFα as not all patients from 
this cohort received anti‐TNF (infliximab). Of the total (20), 12 patients received infliximab 
while  there  was  no  data  for  one  of  these  patients.  TNFα  levels  were  not  significantly 
altered  in  those  receiving  infliximab,  nor  those  not  receiving  treatment  (Figure  3.7g‐i). 
Patients  receiving  infliximab  showed  a  non‐significant  decrease  in  median  levels  of 
TNFα by  week  14 (median  123.9  pg/mL,  range  50.16‐224.3;  mean  121.6  ±  49.93) 
compared to week zero (0) (median 140.8 pg/mL, range 47.96‐440.2; mean 169.7 ± 116) 
(Figure  3.7g‐i).  This  could  be  because  the  reversibility  of  TNFα  levels  may  require 
prolonged treatment beyond 14 weeks. Cytokine production can be transient and so can 
be  the  effect  of  infliximab.  For  example,  infliximab  can  rapidly  improve  EC  function 
however,  this  effect  is  short‐lived  and  endothelial  responses  return  to  baseline  by  2 
weeks, following a single‐only infusion of the antibody (Raza et al., 2006). Importantly in a 














associate  with  raised  plasma  S‐SMase  activity.  Furthermore,  serum  S‐SMase  fell 
significantly  14 weeks  through  to  6 months  following  the  commencement  of  resolving 
treatment. To further examine the role of S‐SMase as a mediator of vascular dysfunction 

































Figure  3.7  Disease  activity  and  inflammatory  marker  status  following  resolving 
treatment In AASV serum used for S‐SMase assays  
Scoring  before  and  after  treatment  for  disease  activity  was  assessed  by  Birmingham 
Vasculitis  Activity  Score  (BVAS)  (A),  accumulated  vascular  damage  assessed  using  the 
vasculitis damage index (VDI), (B) erythrocyte sedimentation rate and C‐reactive protein 
(CRP)  levels  (C‐D)  in  patients  with  AASV.  BVAS  and  CRP  are  significantly  lower  by  14 
weeks. Pro‐inflammatory cytokines showed no difference by 14 weeks (E‐I). IFNγ and IL‐
1β  levels (E‐F). TNFα  levels in all patients (G), TNFα  levels in patients not receiving anti‐
TNFα  (Infliximab) treatment (H), TNFα  levels  in patients receiving anti‐TNFα  (Infliximab) 












ECD  in  vasculitis  is  a  strong  candidate  mechanism  believed  to  mediate  accelerated 
atherosclerosis  in  secondary  vasculitis  such  as  seen  in  RA  and  SLE  (Raza  et  al.,  2000). 
Patients  with  early  RA  have  dysfunctional  endothelia  and  exhibit  decreased  EDV 
consistent with  other  evidence  for widespread  vascular  inflammation  in  these  patients 
(Bergholm et al., 2002). We wanted to see if the increased S‐SMase activity seen in AASV 
was  also mirrored  in  RA.  To  do  this,  serum  from  35  patients  with  established  RA was 
compared to that of healthy controls (n = 13) due to limited availability of samples from 
patients  and  healthy  individuals  (Figure  3.8).  Our  data  revealed  that  RA  patients  also 
exhibited  elevated  S‐SMase  levels  (84.10  ±  34.50  pmol/mL/h‐1),  more  than  1.5‐fold 
greater than age‐matched healthy controls (52.30 ± 34.85 pmol/mL/h‐1) (p < 0.02) (Figure 
3.8).  This  finding  confirms  that  S‐SMase  is  not  only  raised  in  inflammatory  primary 
vasculitis  but  is  also  evident  in  other  chronic  inflammatory  diseases  that  feature 
secondary vasculitis. Since EC are the only major source of S‐SMase this suggests that  it 
may  be  another  hallmark  of  the  activated  endothelium,  linked  to  its  dysfunction  as 













S‐SMase  activity  is  raised  in  serum  of  rheumatoid  arthritis  (RA)  patients  (n=35  total) 
compared  to  age‐matched  healthy  control  (HC)  individuals  (n=13  total)  serum  as 






Data  in  this  chapter  show  that  S‐SMase was  raised  in AASV but did not  correlate 




et  al.,  1999)  and  figure  3.9a  confirms  that  S‐SMase  correlates well with  the  increasing 
levels of LDL in RA serum (p < 0.0007). Furthermore, there was a strong relationship with 
the  LDL:HDL  ratio  (Figure  3.9b)  but  not  with  HDL  itself  (Figure  3.9c).  Interestingly,  S‐
SMase  did  relate  to  ApoB  (Figure  3.9d),  which  makes  sense  given  the  relationship 
between  LDL  and  S‐SMase  as  ApoB  is  a  component  of  LDL.  There  was  no  correlation 
between  the  HDL  component  ApoA  and  S‐SMase  (Figure  3.9e)  supporting  the  lack  of 
association between S‐SMase and HDL (Figure 3.9c). There was also no correlation with 
total cholesterol  levels  (Table 3.3). Furthermore, S‐SMase showed a positive correlation 
with  triglyceride  levels  but  patients  with  a  history  of  hypercholesterolemia  had  lower 
levels than those who did not (Figure 3.9g‐h). These data suggest that the association of 










(HR)  is  considered a positive  indicator of  cardiovascular mortality  in healthy  individuals 
(Thomas et al., 2001). Accordingly, S‐SMase levels were compared against PP and the PP x 
HR index, which is a measure of pulsatile stress. We found a positive correlation with PP 











































disease duration  (C)  or  pulse pressure  (D).  There was no difference  in  S‐SMase activity 
between patients with extraarticular disease and those with not (B). Homocysteine levels 
negatively  correlated  with  S‐SMase  activity  (F).  Statistical  significance  was  determined 









S‐SMase did not  correlate with  systolic and diastolic blood pressure  (Figure 3.11a‐b) 
whilst hypertensive patients  showed no difference  in  their  S‐SMase  levels  compared  to 
non‐hypertensive RA patients  (Table 3.5). We therefore  looked  for other  traditional CV 
risk  factors.  Smoking  is  a  strong  independent  CV  risk  factor  and  contributor  to  the 
pathogenesis of RA. Patients that were active smokers showed higher S‐SMase levels than 
those  who  had  never  smoked  (p  <  0.05)  and  they  also  had  higher  but  insignificant  S‐
SMase levels compared to ex‐smokers (Figure 3.11c). Smoking described as pack‐years, is 
the  cumulative  smoking  burden  and  defined  as  the  number  of  years  one  pack  (20)  of 




whose primary  cause of death was CV‐related was assessed.  S‐SMase  levels  in patients 
with  all‐cause  CVD  were  mildly  elevated  compared  to  those  without  CVD  and  similar 
results were obtained for RA patients that died of CVD (Figure 3.11e‐f).  
RA  patients  with  elevated  S‐SMase  were  at  higher  risk  of  coronary  heart  disease 
(Figure 3.12a), which is in agreement with the finding of increased S‐SMase levels in CHF 















independent  risk analyses above make  it unlikely  that  these associations have occurred 
by chance.  In support of  this, other parameters such as  lipid profiles and smoking have 
shown a  relationship with S‐SMase and are  independent  risk  factors  for CVD. However, 
not  all  the  clinical  parameters  showed  a  correlation  with  S‐SMase,  strengthening  the 
concept  that  the  positives  were  not  a  chance  finding  related  to  the  large  number  of 
correlations performed.  SCORE  risk  analysis did not  show any  correlation with  S‐SMase 
levels and neither did the health assessment questionnaire scores (Table 3.4). Levels of S‐





S‐SMase  with  CRP,  ESR,  Hb  and  creatinine  nor  with  markers  of  endothelial  activation 








RA  cohort,  it  may  be  appropriate  to  take  into  consideration  post‐hoc  analysis  by 
performing corrections to some of the data sets. This could prevent over‐interpretation of 
the  significance  of  these  tests.  Although  S‐SMase  correlated  highly  with  several 
parameters  here  including  lipids  and  CV  risk  algorithms,  increasing  statistical  tests  also 
increases the chances of generating type I errors, or false positive statistical significance, 
when in fact this was not true in the first place. Applying Bonferroni’s corrections in this 
instance  would  provide  control  over  the  generation  of  type  I  errors  however,  this 
application  is  also  prone  to  type  II  errors  (over‐looking  true  statistical  significance). 
Although such adjustments should not be used hastily, the chances of gaining statistical 


























S‐SMase  activity  did  not  correlate  with  diastolic  or  systolic  blood  pressure  (A‐B)  but 
positively  correlated with  (D)  smoking  (pack‐years).  (C) Current  smokers have higher  S‐














































Our  data  on  the  levels  of  S‐SMase  in  inflammatory  conditions  suggest  it might  be  a 




from  standard  curves  (Figures 2.2,  2.11)  and  compared  (Figure 3.13a‐c). The TLC assay 
appeared  to  be more  sensitive  at  detecting  higher  S‐SMase  levels  (Figure  3.13a).  This 
purposefully  composed  cohort  included  healthy  individuals  and  diseased  patients  with 
varying  degrees  of  S‐SMase  activity.  Both  methods  detected  similarities  in  S‐SMase 
activity in these patients. Figure 3.13b clearly shows the same trend of S‐SMase activity in 
both  assays  used.  Non‐parametric  correlation  analysis  using  the  Spearman  rank 




their  sensitivity.  This  may  not  be  surprising  since  the  simpler  1‐step  TLC method  only 
relies on interaction of the enzyme with its substrate whereas the multi‐step Amplex Red 
method  depends  on  multiple  enzymes  and  does  not  measure  the  cleaved  substrate 







Detecting  ASM  activity  by  high‐performance  liquid  chromatography  (HPLC)  using 
radiolabelled  SM  substrates  is  established  (He et  al.,  2003). We utilised  this method  to 
detect ASM activity using  the NBD‐SM previously utilised  for  the TLC method.  Selected 
plasma  from  healthy  controls,  ANCA  positive  and  ANCA  negative  inflammatory  disease 
patients was used here. HPLC analysis was the third independent assay used to determine 
S‐SMase activity in these selected patients (Figure 3.13). As with the Amplex Red method, 
analyses  of  the  same  patient  samples  by  HPLC  produced  the  same  trend  of  S‐Smase 
activity similar to the previous two methodologies employed (TLC & Amplex Red) (Figure 
3.13d) with healthy controls exhibiting low activity whilst diseased patients had raised S‐
SMase  plasma  levels.  Both  TLC  and  HPLC  methods  incorporate  a  fluorescent  NBD‐SM 
substrate and followed the same reaction procedure but the two assays differ in terms of 
the  detection  method  used.  The  data  here  suggest  that  the  HPLC  method  lacks  the 
sensitivity of its TLC counterpart (Figure 3.13e) in similar fashion to the Amplex Red assay. 
The TLC assay was able to detect higher S‐SMase  levels  in almost all  (13 of 14) patients 
and  in  some  cases  this  was  >  2‐fold  higher  (Figure  3.13e). Non‐parametric  correlation 
analysis revealed a positive relationship (r2 = 0.87, p < 0.002) between the TLC and HPLC 
methods  (Figure  3.13f)  however;  low  activity  samples  may  be  prone  to  inadequate 
separation during this assay at least in comparison to the TLC method. In conclusion, the 
HPLC based assay is a fast and accurate method for the detection of S‐SMase activity  in 









S‐SMase  activity  in  ANCA  negative  and  positive  patients,  and  healthy  controls  was 
assessed  using  the  Amplex  Red  SMase  activity  assay  (Left  panel).  Confirmation  of  S‐
SMase activity using NBD‐SM substrate and fluorescence detected by HPLC (Right panel). 
Both  were  compared  against  values  estimated  by  the  TLC  activity  assay  for  the  same 
patients.  The TLC assay is more sensitive than the Amplex Red assay and HPLC detection 
(A+D). Both assays indicate the same trend of activity amongst the same panel of patient 













healthy  individuals  (Doehner  et  al.,  2007,  Takahashi  et  al.,  2002). However, we are  the 
first  to  observe  that  increased  S‐SMase  levels  are  present  in  chronic  inflammatory 
immune  diseases.  This  was  first  shown  in  plasma  from  renal  vasculitis  patients 
undergoing  plasmapheresis  (3.2.1‐2)  and  then  validated  by  assessing  serum  from  two 
further independent AASV cohorts (3.2.3‐5).  
We also found that treatment in AASV led to a concurrent decrease in S‐SMase activity 





















Chronic  inflammatory  diseases  such  as  PSV  and RA  are  associated with  increased 
CVD, which drives higher mortality rates and decreased life expectancy compared to the 
healthy  population  (Gonzalez‐Gay  and  Garcia‐Porrua,  2002,  Jacobsson  et  al.,  1993, 
Jacobsson  et  al.,  2005,  Kremers  et  al.,  2008).  These  diseases  have  been  conclusively 
demonstrated  to  show a  long‐standing association with accelerated atherosclerosis and 
the initiating mechanisms that drive this process are not fully understood (Gonzalez‐Gay 
et al., 2005a, Gonzalez‐Gay et al., 2008, Mukhtyar et al., 2009, Ross, 1999, Shoenfeld et 
al.,  2005,  van  Leuven  et  al.,  2006).  In  this  retrospective  study,  we  investigated  the 
presence and activity of  S‐SMase  in  two different diseases  that  feature primary  (AASV) 
and  secondary  vascular  inflammation  (RA).  The patient  cohorts  used here were  from a 
hospital setting, the majority reflecting highly active clinical disease.  
 
In  recent years S‐SMase has been  linked with clinical disease  (Gorska et al., 2003, 
Tilg and Moschen, 2008, Claus et al., 2005, Doehner et al., 2007, Takahashi et al., 2002, 
Sathishkumar et  al.,  2005),  however,  data herein provides  a novel  insight  into  S‐SMase 
presence  in  autoimmune  inflammatory  diseases.  It  has  been  suggested  that  increasing 
age  is  associated with  raised  S‐SMase  activity  levels  (Doehner  et  al.,  2007). Due  to  the 









may  respond  differently  to  endothelial  stress.  The  patients  used  in  our  study  were 
collected  retrospectively  not  allowing  sex‐matching.  The  healthy  controls  in  our  study 
were all of white ethnic background and the patients were of a demographic unknown to 
us,  thus  ethnic  bias  was  not  accounted  for.  Ethnic  sub‐grouping  is  also  important  in 




The  AASV  cohorts  were  composed  of  patients  with  WG,  MPA  and  renal‐limited 
vasculitis, however due to sample size we were not able to subgroup our analyses as was 
the case with the early RA patient cohort. To control for this using the AASV patients, a 
small  longitudinal  study  using  the  same population  of  patients would  allow more  clear 
conclusions to be drawn on the involvement between disease subtypes. In addition to the 
above, several traditional risk factors predispose to CVD development including smoking 
status,  diabetes  mellitus,  dyslipidemia  and  hypertension  (Gonzalez‐Gay  et  al.,  2005a) 
while diabetes has already been  linked with raised S‐SMase  levels  (Gorska et al., 2003). 
We  did  not  account  for  these  backgrounds  above  nor were  obesity  and  cardiac  health 
considered.  
Our  data  confirmed  previous  reports  (Doehner  et  al.,  2007,  He  et  al.,  2003, 




undergoing  PEX  exhibited  raised  S‐SMase  levels  compared  to  healthy  controls  (Figure 
3.1).  It  therefore may be the case that PEX patients have higher  levels of S‐SMase than 
those stated in this study due to diluted plasma (Figure 3.1). Plasmapheresis is a stressful 
procedure  that  may  lead  to  psychological  and  physiological  stress.  Accordingly,  we 
examined  serum  from  AASV  patients.  Patients  with  inactive  disease  and  those  in 
remission  appeared  to  have  lower  S‐SMase  activity  than  those  with  active  disease 
confirmed following induction of treatment (Week 14) and in early remission patients (>6 
months)  (Figure  3.5).  This  data  suggests  that  the  ongoing  inflammatory  process  may 
indeed drive S‐SMase activity levels. 





shown to alleviate the  inflammatory process  improving vascular  function  in PSV and RA 
(Booth et al., 2004b, Raza et al., 2006, Hurlimann et al., 2002).  
ECD in PSV can be seen in stable disease and during acute flares indicating a process 
not  directly  related  to  overt  disease  activity  (Raza  et  al.,  2000).  Filer  et  al.  (2003) 
demonstrated  that  EDV  lacked  any  correlation  with  BVAS,  CRP,  VWf,  VDI  and  disease 
duration in AASV, whilst there was no difference between active and remission patients’ 
EDV ability according to BVAS. The lack of relationship between ECD and ANCA status may 
suggest  that  diffuse  ECD  is  a  transient  process,  not  governed  directly  by  inflammatory 




therefore not without  reason. BVAS,  ESR and CRP were decreased  in  these patients by 
week 14 indicating successful improvement of clinical disease and early remission (Figure 
3.7).  However,  neither  IL‐1β,  IFNγ  or  TNFα,  all  of  which  induce  S‐SMase  release,  fell 






closely  linked  with  TNFα  levels  (Wang  et  al.,  1994)  and  may  explain  the  lack  of 
relationship between CRP and S‐SMase in our AASV cohort (Figure 3.6). As expected, anti‐
inflammatory cytokine IL‐10 showed no relationship with S‐SMase supporting the role of 
S‐SMase  as  a  possible  specific  inflammatory  biomarker.  Interestingly  pro‐inflammatory 
cytokines  IL‐6  and  IL‐8  also  did  not  relate  to  S‐SMase  suggesting  that  only  certain 
cytokines mediate its secretion. However, S‐SMase related to IL‐1ra levels in AASV which 



















presentation.  Increased  S‐SMase  activity  may  therefore  relate  to  sub‐clinical 




cohort with documented vascular and CV parameters. Age  is a CV  risk  factor  in RA and 
non‐RA  individuals  (Kremers  et  al.,  2008).  Despite  a  recent  observation  that  S‐SMase 
correlates with age, weight and BMI in CHF patients, this was not evident in our AASV or 
RA  patient  cohorts  (Doehner  et  al.,  2007).  S‐SMase  is  considered  to  play  a  role  in 
atherogenesis  through  increased  sub‐endothelial  LDL  retention  and  MΦ  foam  cell 
formation and therefore may be an important CV risk factor (Tabas et al., 2007, Devlin et 
al.,  2008). We  found  a  strong  correlation  of  S‐SMase  activity with  plasma  LDL  in  these 




are  carried  in  LDL  (Figure  3.9).  To  reduce  this  occurring  by  chance,  there  was  no 
association found between S‐SMase and HDL and ApoA (Figure 3.9). Homocysteine is an 
independent CV risk factor known to propagate LDL oxidation (Clarke et al., 1991) whilst 
raised  levels of homocysteine are  found  in patients with RA  (Hernanz et  al.,  1999). We 




of  patient  IL‐6  data  (8  of  31)  also  did  not  allow  us  to  accurately  comment  on  the 
significance of its relationship with S‐SMase (p < 0.03). Interestingly there was a positive 
correlation between S‐SMase and Wcc in RA patients (Figure 3.10), which have long been 





AASV  and  RA  as  the  secretion  of  S‐SMase  may  be  transient  not  reflecting  clinical 
observations.  








extraarticular  disease  may  not  be  surprising  as  it  uses  a  variety  of  vascular‐specific 






an  increased  absolute  10‐year  risk  of  developing  CVD  (Kremers  et  al.,  2008). The 
Framingham  risk  score  takes  into  account  the  age,  sex,  total  cholesterol  level,  HDL, 
diabetes,  systemic  BP  and  smoking  status  of  an  individual  and  predicts  a  variety  of  CV 
endpoints  including  generalised  10‐year  CVD  risk  predicted  here.  We  also  found  a 
significant association of S‐SMase with 10‐year CVD risk (p < 0.004) (Figure 3.12), which 
was  calculated  using  the  Framingham  risk  score  and  the  Joint  British  Societies  criteria 
from the guidelines on prevention of CVD. This was also confirmed using the Framingham 









These  data  generated  significant  S‐SMase  correlations  with  four  different  CV 
parameters  and  a  number  of  methods  used  in  cardiology  to  calculate  risk  of  cardiac 
events,  which  further  decreases  the  chances  of  the  above  correlation  occurring  by 
chance.  This  study  has  revealed  a  possible  link  of  S‐SMase with  increased  CV  risk  and 
other  traditional  risk  factors  including  blood  lipids,  smoking  status,  Wcc  and  aortic 






of  significance of p < 0.05, we should expect  to gain at  least 1 significant outcome. Put 
simply  the  more  tests  one  performs,  the  greater  the  chance  of  generating  statistical 
significance  in  one  of  these  tests  by  chance.  This  observation  is  a  type  I  error  and 
Bonferroni’s correction (BC) aims to help prevent this occurring; it provides stringent and 
just  control over  the generation of  false positives  thus avoiding misinterpreting data as 
significant  when  in  fact  it  is  not.  BC  however,  is  a  fairly  conservative  and  contentious 
method and there are no criteria for its use even among statisticians (Perneger, 1998). In 
BC, adjustment of the p value depends on the total number of parameters or statistical 
tests  performed.  For  example,  where  the  level  of  significance  (α)  is  p  <  0.05  and  10 
univariate analyses are performed, the adjusted level of significance becomes α 0.05/10 = 
0.005. When performed post‐hoc, the level of significance is multiplied by the number of 
tests  i.e. where  the  resulting α  is  0.03,  then  0.03  x  10  =  0.3  after  BC  (non‐significant). 
Chapter 3                                                                            ASM in clinical inflammatory disease 
  [150] 




stringent  handling  of α, whereas  this  may  not  actually  the  case.  In  fact  in  reality  it  is 
thought to lead to publication bias with researchers not revealing non‐significant results 
(Perneger,  1998,  Nakagawa,  2004).    Indeed  BC  is  a  good method  of  preventing  type  I 
errors  but  it  also  leaves  a  study  open  to  type  II  errors  (over‐looking  a  statistical 
significance when it is true). Researchers may often appear to test as many parameters as 





(false  positive)  can  be  theoretically  generated  by  virtue  of  probability.  Table  3.3, 
composed  largely  of  independent  variables  shows  correlations  in  7  out  of  22  tests 
performed which suggests that BC is potentially inappropriate. Undoubtedly, corrections 
performed  on  this  data  set  would  lead  to  more  of  the  correlations  becoming  non‐
significant.  However,  it  then  would  not  be  possible  to  know  which  tests  were  truly 
significant in the first place. In this table (3.3), S‐SMase strongly associates with LDL and 
the LDL:HDL ratio even after post‐hoc BC (p < 0.02; p < 0.05 respectively; data not shown 




(e.g.  Framingham  &  Reynolds  scores),  others  are  independent  from  each  other.  In  14 




any  true  association  of  S‐SMase  with  these  algorithms.  A  particular  example  is  the 
relationship of S‐SMase with the CVD 10‐year risk and CHD risk algorithms (p = 0.056 after 
BC,  significant  with  15%  variation).  Thus,  although  S‐SMase  appeared  to  significantly 





of  clinical  backgrounds  and  a  causative  link  of  S‐SMase  as  a marker  in  ECD.  Additional 
considerations  for  appropriate  disease  controls  include  the  use  of  osteoarthritis  (OA) 
patients and Behcet’s disease patients,  the  latter exhibiting  impaired vascular  functions 
(Schmitz‐Huebner and Knop, 1984, Chambers et al., 2001). Furthermore, given that ECD is 
considered  an  early  event  in  atherosclerosis  (Gonzalez‐Gay  et  al.,  2008)  it  would  be 










Understanding  the  role  of  SMases  in  disease  offers  considerable  advantages  in 
many pathophysiological  conditions. Currently  there  is no  routine  test  for measuring S‐
SMase  activity  from  human  blood.  In  the  quest  to  develop  a  robust,  easy‐to‐handle 
method to measure S‐SMase in plasma or serum we altered a commercially available kit 
from Molecular Probes  that  relies on Amplex  red oxidation. Data  from patients used  in 
the development of  this  assay was  confirmed  in  another  two  independent  assays  (TLC, 
HPLC). Due to its multistep methodology it may lack the sensitivity of other assays while it 





In  summary,  chronic  ECD  in  PSV  and  RA  may  share  similar  characteristics  with  the 
vascular  endothelium  becoming  more  susceptible  to  CV  risk  factors.  We  envisage  a 
mechanism  where  the  prevalent  systemic  inflammation  in  RA  independently  drives 






















TNFα plays  a  critical  role  in  the  inflammatory  response  and  has  been  shown  to 
contribute to disease progression and severity in a wide range of conditions including RA, 
AASV  and  heart  failure  (Listing  et  al.,  2008,  Booth  et  al.,  2004a,  Booth  et  al.,  2004b, 
Feldmann and Pusey, 2006).  Inflammation has profound effects on  the vascular  system 
and  is  thought  to  be  a  major  contributor  to  vascular  damage  in  processes  such  as 
atherosclerosis (Hansson and Libby, 2006). Pro‐inflammatory cytokines such as IL‐1β and 
IFNγ  have  been  shown  to  promote  S‐SMase  release  from  isolated  EC  (Marathe  et  al., 
1998). Whether  TNFα  induces  the  secretion  of  S‐SMase  remains  unclear  but  evidence 
suggested a link  in vivo (Wong et al., 2000). TNFα  is thought to play a prominent role in 
regulating  the  production  of  other  pro‐inflammatory  cytokines  in  clinical  disease 
(Brennan  et  al.,  1989).  Given  this  primary  role  for  TNFα  we  therefore  wanted  to  ask 





The  regulation  of  SMase  activation  is  complex.  The  SMase/Cer  pathway  is  a 
complex web enzymatically governed by 4 genes (SMPD1‐4) and 5 distinct phenotypes all 
of  which  have  different  localizations  from  the  PM  (Tani  et  al.,  2007),  ER  and  Golgi 
(nSMase) (Stoffel et al., 2007, Krut et al., 2006, Hofmann et al., 2000), endo‐lysosomes (L‐
SMase) (Marathe et al., 1998) and a secretory fraction (S‐SMase) (Schissel et al., 1996a, 
Tabas,  1999).  All  SMases  are  ubiquitously  expressed  at  cellular  level,  however,  much 
more S‐SMase is found in MΦ and stromal cells with EC being by far the most abundant 
source  (Marathe  et  al.,  1998).  SMase  activity  is  differentially  regulated  between  cell 
types. nSMase can be inhibited by GSH (Hofmann et al., 2000, Liu and Hannun, 1997, Krut 
et al., 2006) while several biological activators have been described in cardiac myocytes 
(CM),  vascular  smooth  muscle  cells  (VSMC)  and  EC  reviewed  in  Pavoine  and  Pecker 









































TNFα  could  directly  induce  S‐SMase  release  from  human  EC.  The  standard  culture 
medium used for routine HUVEC growth is medium 199 (M199) (+FCS, 15% v/v) (2.2.1.1). 
Early  experiments  revealed  high  background  levels  of  S‐SMase  in  the  culture  medium 
(data not  shown)  and no  significant difference between TNFα‐treated  (100 ng/mL)  and 
un‐treated  control  cells,  confirmed by  immunoblotting  (Appendices;  Figure A1.1). Thus 
components  of  M199  culture  medium  were  examined  for  possible  S‐SMase  activity. 
Human pooled serum did not demonstrate significant  levels of S‐SMase and neither did 
standard  M199  alone  and  thus  were  not  considered  major  sources  of  contamination 
(data not shown). However, FCS was found to be a rich source of the enzyme, in line with 
previous literature (Spence et al., 1989). Fully supplemented M199 showed high S‐SMase 





the  HIFCS  to  the  volume  found  in  our  culture  medium  (15%  v/v)  did  not  reveal  any 












Despite  inactivating  the  S‐SMase  in  FCS,  no effect  on HUVEC S‐SMase  secretion was 
observed  following  TNFα treatment  (Figure  4.1c).  This  contradicts  earlier  findings 
showing that pure HIFCS (100% v/v) had minimal activity and complete absence in diluted 
HIFCS (15% v/v) (Figure 4.1b), however the presence of this serum may induce S‐SMase 
secretion.  A  high  dose  of  TNFα  (100  ng/mL)  did  not  seem  to  induce  greater  S‐SMase 
secretion from HUVEC compared to untreated cells while S‐SMase in the medium appears 
to increase with time regardless of TNFα presence. This suggested that HUVEC secreted 











SMase  activity  in  FCS  and  HIFCS  and  serum‐free  M199.  FCS  and  HIFCS  (15%  v/v) 
represents  culture medium  volume.  (C) HUVEC were  brought  to  confluence  in  24‐well 















able  to maintain  HUVEC  viability  beyond  6  hours  compared  to  that  of  18  to  48  hours 
reported above. In our laboratory, the majority of HUVEC were not adherent by 6 hours, 
and  so media  were  harvested  between  0‐6  hours  in  the  first  instance. We  found  that 
TNFα  (100 ng/mL) here did not  induce significant S‐SMase release from HUVEC into the 
medium  compared  to  untreated  cells  (Figure  4.2a). However,  the  excess  cell  death  or 
stress  due  to  starvation may  have  led  to  non‐specific  S‐SMase  release.  Since  IL‐1β  has 








with  apoptosis.  The  experiments were  not  continued  due  to  a  change  in  experimental 










DMEM  containing  0.2%  BSA.  Data  represent  mean  values  of  two  independent 
experiments ± SD. HUVEC were treated with (B) TNFα (10 ng/mL) and (C) IL‐1β (5 ng/mL) 







As mentioned above, DMEM alongside Roswell  Park Memorial  Institute  (RPMI)  have 
been the media of choice for the study of S‐SMase secretion in vitro to date (Marathe et 
al., 1998, Schissel et al., 1998a, Schissel et al., 1996a, McCollister et al., 2007). We found 





Cell  viability was  therefore assessed by  the MTS assay  (Promega)  (abbreviations  list) 
over 18 hours. HUVEC were incubated with different media formulations for 18 hours in 
96‐well plates. DMEM with 0.2% BSA led to higher dead cell numbers while the addition 
of  heat‐inactivated  foetal  calf  serum  (HIFCS),  endothelial  cell  growth  factor  (EGF)  and 
heparin  ameliorated  this  effect.  HESFM,  which  included  basal  fibroblast  growth  factor 
(bFGF), was  the best performing medium with  the  least dead cells  (Figure 4.3).  Serum‐
free  conditions  generally  led  to  some  decrease  in  HUVEC  viability,  however,  the  cells 
retained their natural morphology and hallmark cobblestone appearance. Although more 
than  3  experiments  would  allow  for  safer  conclusions,  the  experiments  in  figure  4.3 
clarified that using DMEM used in these conditions led to increased cell death. Figure 4.3 
also confirmed that HESFM was suitable for use in this model due to the increased HUVEC 









HUVEC  were  brought  to  confluence  in  96‐well  tissue  culture  plates  using  fully 
supplemented M199. M199 was removed and replaced with the combinations above for 







et  al.,  2001,  Zoellner  et  al.,  1996).  Thus  HUVEC  cytotoxic  responses  to  TNFα  were 
measured by the MTS assay.  
4.2.1.4.1   HUVEC morphology and viability is not affected by TNFα   
Healthy  viable  HUVEC  exhibit  a  smooth  spindle‐shaped  outline  under  rigorous 
proliferation and a  cobblestone appearance with  larger nuclei upon confluence. HUVEC 
under  distress  or  committed  to  apoptosis,  however,  are  characterised  as  highly 
vesiculating cells, that undergo fragmentation and begin to shrink while at the same time 
lose  physical  contact  with  neighboring  cells  and  underlying  matrices.  We  found  that 
HUVEC  could  usually  remain  adhered  for  up  to  6  hours with M199 whilst  this was  not 
possible  in  DMEM,  both without  serum.  Since  loss  of  adhesion  is  an  early  event  in  EC 




We  found  that  increasing  concentrations  of  TNFα  (0‐100  ng/mL)  did  not  induce  any 
morphological  changes  in  HUVEC  incubated  in  serum‐free  HESFM  for  24  hours  whilst 
H2O2  confirmed  overall  necrosis  (Figure  4.4,  lower  panel  1‐6).  Although  serum‐free 







Upper  panel, HUVEC  in  24‐well  tissue  culture  plates were  grown  to  confluence  in  fully 
supplemented M199.  Medium  was  replaced  with  serum‐free M199  (A).  Cells  begin  to 
detach by 3 hours (B) and continue by 12 hours (C). Lower panel, HUVEC were cultured in 
M199  until  confluent,  the  medium  replaced  with  serum‐free  HESFM  for  24  hours 













HUVEC  were  brought  to  confluence  in  96‐well  tissue  culture  plates  using  fully 
supplemented M199. M199 was removed and replaced serum‐free HESFM supplemented 
with either DMSO (10% v/v), H2O2 (1 mmol/L) or varying concentrations of TNFα  for 18 










to  morphological  changes  or  decrease  cell  viability.  A  hallmark  of  apoptosis  is 
mitochondrial  membrane  depolarization.  To  ensure  there  was  no  effect  of  TNFα  in 
prolonged culture, we observed the mitochondrial membrane potential of HUVEC treated 
with  TNFα.  Viable  cells  uptake  3,3’‐dihexyloxacarbocyanine  iodide  (DiOC6)  dye  and  are 
able  to  retain  it  in  intact  mitochondria  called  DiOC6
high.  In  apoptotic  cells  the  dye  is 
bleached from the mitochondria and are thus called DiOC6
low. This is a method positively 




low)  thus  harvesting  the  cells  prior  to  DiOC6  loading  ensured  greater  dye 
retention (95%) (Appendix Figure A2a). HUVEC were therefore treated as  in 2.2.7, page 
84. Approximately  13.6% of  untreated  cells were DiOC6
low while both DMSO  (10%)  and 
CHX/TNFα (10 µM/100  ng/mL)  led  to  a  2‐fold  increase  in  apoptosis  compared  to 
untreated/solvent  control.  Furthermore,  cycloheximide  (CHX)  and  TNFα  co‐treatment 
showed  a  1.7‐2.1‐fold  increase  in  apoptosis  compared  to  TNFα  alone  treated  HUVEC 
(Figure 4.6; (Appendix Figure A2b). CHX pre‐treatment may have enhanced apoptosis in 
CHX/TNFα treatments. The percentage of TNFα−alone treated HUVEC apoptosis did not 







HUVEC were brought to confluence  in 24‐well  tissue culture plates  in M199. The media 
were  removed,  the  cells  washed  twice  with  HBSS‐Ca2+  and  incubated  with  untreated 
serum‐free  HESFM  (0  ng/mL  TNFα),  HESFM  containing  DMSO  (10%  v/v),  HESFM 































the media  supernates  and  thus  the  S‐SMase.  Rather  than  using  24‐well  plates  with  1‐
1.5x105 HUVEC when confluent, 75cm2 tissue culture flasks were used (6‐8x106 HUVEC). 
The  supernates  were  then  concentrated  20‐fold  from  a  10  mL/sample  to  a  final  0.5 
mL/sample; an overall 25‐fold concentration factor between samples from 75cm2 culture 
flasks  compared  to  those  from 24‐well plates  (2.2.8.4; Tables 2.4‐5). This enhanced  the 
sensitivity  of  the  assay  and  allowed  greater  differentiation  between  samples  (Figure 
4.8a).  Comparatively,  concentrating  the  supernates  increased  S‐SMase  activity  in 




variation  ratio  due  to  the  improved  sampling  (Figure  4.8c).  Each  sample  was  then 




may be  a more potent  inducer of  S‐SMase  than  IL‐1β  in HUVEC,  although  this was not 








M199.  The medium was  removed  and  the  cells washed  twice with HBSS‐Ca2+. Medium 
was replaced with fresh serum‐free HESFM supplemented with TNFα (10 ng/mL) or IL‐1β 







Concentrated  serum‐free  HESFM  from  18  hour  TNFα  (10  ng/mL)  or  IL‐1β  (5  ng/mL) 
treated HUVEC in 75 cm2 tissue culture flasks. S‐SMase activity was assessed by the TLC 
assay.  (A)  S‐SMase  activity  from  concentrated HUVEC media  not  normalised  to  protein 
and compared to S‐SMase activity from un‐concentrated media (B). (A) represents values 
from 3 independent experiments, (B) represents values from 4 independent experiments. 











The  SMPD1  products  L‐SMase  and  S‐SMase  can  be  differentiated  according  to  their 
cellular  trafficking.  L‐SMase  is  mannose‐6‐phosphorylated  (M6P)  and  shuttled  within 
lysosomes whereas conversely S‐SMase is believed to follow the Golgi secretory pathway. 
Interestingly  the  two  products  appear  to  be  simultaneously  regulated  by  pro‐





25 cm2  rather  than 75 cm2 culture  flasks and  treated as described previously  in HESFM 














HUVEC were grown  to  confluence  in 25  cm2  tissue  culture  flasks  in M199,  the medium 
removed,  the  cells  washed  with  HBSS‐Ca2+  and  replaced  with  serum‐free  HESFM 
supplemented with  TNFα  (10 ng/mL)  for  the 0.5,  3,  6,  12,  and 24 hours.  TNFα  treated 
HUVEC medium  (Blue  bars)  was  compared  to  control  (black  bars).  HUVEC media were 
concentrated and S‐SMase activity was assessed by the TLC assay. Data in (A) represents 









we  examined  the  effect  of  TNFα‐blockade  using  the  chimeric  monoclonal  anti‐TNFα 
antibody  infliximab (Remicade).  Infliximab is now an established treatment regime for a 
variety of diseases including RA (Feldmann and Pusey, 2006) and a promising avenue for 





HUVEC  S‐SMase  release.  Furthermore,  infliximab appears  to decrease basal  levels  of  S‐
SMase  secretion  however,  the mechanism  by which  this might  occur  is  unknown.  This 















HUVEC were grown  to  confluence  in 75  cm2  tissue  culture  flasks  in M199,  the medium 
removed,  the  cells  washed  with  HBSS‐Ca2+  and  replaced  with  serum‐free  HESFM 


















vitro  and  in  vivo  (Marathe  et  al.,  1998, Wong  et  al.,  2000).  IL‐6  is  a  pro‐inflammatory 
cytokine with an  important  role  in RA pathogenesis propagating acute phase  responses 
and  T  and  B  cell  proliferation.  Recently  the  IL‐6  receptor  antagonist,  Tocilizumab,  a 
humanised monoclonal  antibody was  licensed  for  use  in  the  treatment  of  RA.  LPS  has 
been shown to increase TNFα levels while LPS‐induced S‐SMase secretion is suggested to 
be  mediated  by  IL‐1  production  in  vivo  (Wong  et  al.,  2000).  This  underlines  the 
importance of cytokine involvement in S‐SMase secretion. Figure 4.11 clearly shows that 




















HUVEC were grown  to  confluence  in 75  cm2  tissue  culture  flasks  in M199,  the medium 
removed,  the  cells  washed  with  HBSS‐Ca2+  and  replaced  with  serum‐free  HESFM 
supplemented  with  TNFα  (10  ng/mL),  IL‐1β  (5  ng/mL)  or  IL‐6  (5  ng/mL)  for  18  hours. 












ROS  were  first  proposed  to  alter  ASM  activity  by  oxidative  switching  of  C‐terminal 
cysteine  residues,  specifically  Cys629  (Qiu  et  al.,  2003)  later  shown  using  UV‐C  light‐
induced  ROS  in  U937  cells  (Charruyer  et  al.,  2005)  and  TNF‐related  apoptosis‐inducing 
ligand  (TRAIL)  stimulation  which  could  be  inhibited  by  GSH  precursor N‐acetylcysteine 
(NAC)  (Dumitru  and  Gulbins,  2006).  Oxidative  stress  is  evident  during  inflammation  in 
diseases such as CHF and RA (Kamanli et al., 2004, Sarban et al., 2005, Anker et al., 1998, 
Castro et al., 2002). Previous research from our laboratory found glutathione (GSH) to be 
decreased  in RA  synovial  fluid,  serum and peripheral  CD4+  T  cells  compared  to healthy 
controls. Thus elevated ROS due to depleted antioxidant capacity may affect the redox‐




We  have  obtained  the most  physiologically  relevant  S‐SMase  and  placed  it  under  a 
redox environment to examine  its susceptibility  to chemical changes  in vitro  (4.2.3.1‐2). 
Stock  S‐SMase  activity  was  confirmed  using  the  TLC‐based  assay.  A  10‐fold  lower 
concentration of dithiothreitol (DTT) than previously published (Qiu et al., 2003) was used 
to  study  the  reduction  potential  S‐SMase.  As  shown  with  recombinant  human  ASM 
(rhASM),  treatment  of  isolated  EC‐derived  S‐SMase  with  DTT  (10  mmol/L)  completely 




concept  experiment  was  carried  out  once  and  was  designed  to  see  whether  S‐SMase 
activity  could  be  suppressed  by  chemical  reduction.  More  experiments  were 




and H2O2  (1 mmol/L) was  used  to  re‐oxidise  the  enzyme  (Figure  4.13a). We  confirmed 
that DTT  could decrease  S‐SMase activity  in  a dose‐dependent manner while H2O2 was 
able to re‐oxidise S‐SMase increasing its activity, albeit modestly (Figure 4.13a). This data 
suggests  that  S‐SMase  could  be  partially  rescued  following  excess  chemical  reduction 
(DTT, >1 mmol/L) despite using a strong free radical generator. Catalase, added to each 
reaction to neutralise the H2O2 was itself not found to affect S‐SMase activity.  
To  induce  a  partial  reduction  of  S‐SMase,  a  constant  concentration  of  DTT  (0.5 
mmol/L) was added to a reaction, allowing scope for re‐oxidation with reasonable levels 
of  H2O2  (0.1,  1  mmol/L),  preventing  enzyme  damage  (Figure  4.13b).  We  found  that 
increasing  concentrations  of  H2O2  may  partially  re‐oxidise  the  previously  reduced  S‐
SMase. These data suggest the enzyme is secreted in an activated form, can be chemically 
reduced using DTT and may regain its activity through re‐oxidation using H2O2. Due to the 
lack  of  protein  availability  (S‐SMase  from  media  culture  supernates)  for  further 
experiments,  more  work  would  be  required  to  supplement  this  data  and  better 































HUVEC  in  HESFM  were  treated  with  TNFα  (10  ng/mL)  for  18  hours,  the  medium  was 
removed  and  concentrated.  (A)  The  S‐SMasehigh  medium  was  subjected  to  varying 
concentrations  of  DTT  for  15  minutes  at  370C  followed  by  incubation  with  H2O2  (1 
mmol/L) for 15 minutes at 370C. All aliquots were exposed to catalase (10 U/mL) for 30 
minutes at 370C. Values are representative of one experiment (n=1).  (B) The S‐SMasehigh 



















these  compounds  with  TNFα  (10  ng/mL).  This  allowed  minimal  exposure  of  GSH 
regulating  agents.  Accordingly,  figure  4.14a demonstrated  that  co‐treatment  of  BSO or 
NAC with  TNFα  for  18 hours did not  alter  S‐SMase activity.  This may  suggest  that GSH 
levels have not been adequately depleted despite previous indications (Jornot and Junod, 
1993, Toborek et al., 1995). With this in mind, HUVEC were pre‐treated with BSO and NAC 
for  16  hours,  and  then  treated with  TNFα  alone  for  a  further  18  hours  (Figure  4.14b). 
Interestingly,  this  lead  to  slightly  depressed  S‐SMase  activity  from HUVEC  treated with 
BSO compared to those treated with TNFα alone. NAC was able to cause a non‐significant 
decrease in S‐SMase activity as predicted. This surprising finding using BSO led to us to try 
and  augment  these  observations  by  increasing  HUVEC  exposure  to  BSO  and  NAC. 
Accordingly,  HUVEC  were  pre‐treated  with  BSO  or  NAC  for  16  hours  followed  by  co‐
treatment with TNFα for a further 18 hours increasing the total exposure time with BSO 
or NAC 34 to hours. This timeframe is similar to a published method where however a 32‐
fold higher  concentration of BSO  (3.2 mmol/L;  48 hours) had minimal effect on HUVEC 
Chapter 4                                                         The regulation of ASM activation and secretion 
  [184] 
death (Tsou et al., 2007).  In  line with data from  figure 4.14b,  these treatments  led to a 
significant  decrease  in  S‐SMase  activity  from medium  of  HUVEC  treated with  BSO  and 




Accordingly,  the  above  would  benefit  from  the  observation  of  cell  death  in  these 
cultures, albeit not evident by light microscopy at the time. To support the effect of BSO 




















TNFα  (10  ng/mL)  for  18  hours.  (B) HUVEC  in  serum‐free HESFM were pre‐treated with 
BSO (100 µmol/L) or NAC (1 mmol/L)  for 16 hours. The media were then replaced with 





















have  been  shown  to  directly  regulate  S‐SMase  secretion  in  vitro  including  IL‐1β,  IFNγ, 
IFNβ (Marathe et al., 1998) and TNFα  indirectly  in vivo (Wong et al., 2000). Accordingly, 
TNFα  can  reach  a  maximal  plasma  concentration  before  IL‐1β  and  IL‐6.  Anti‐TNFα 
infusions  were  shown  to  significantly  decrease  IL‐1β  and  IL‐6  in  lethal  bacteraemia 
(Tracey  et  al.,  1987,  Fong  et  al.,  1989). We  found  that  TNFα  directly  induces  S‐SMase 
from  human  EC  in  vitro  and  that  this  could  be  blocked  with  the  anti‐TNFα  antibody 
(Infliximab). However, there appears to be specificity to S‐SMase regulation by cytokines. 
IL‐4,  a pro‐inflammatory  cytokine notably  involved  in Th0  to Th2 differentiation, did not 
affect  S‐SMase  levels  and  neither  did  IL‐6  (Fig.  4.17)  (Marathe  et  al.,  1998).  This  is 
supported by IL‐4‐induced inhibition of ASM mRNA upregulated by TNFα  (Hatano et al., 
2005,  Hatano  et  al.,  2007).  This  is  not  surprising  since  IL‐4  can  itself  inhibit  IL‐1β  and 
TNFα production  (Miossec  et  al.,  1992).  This  highlights  the  importance  of  TNFα  in  the 










Rapid  activation  of  ASM  by  TNFα   (2 min.  and  3  hr.)  has  been  previously  described 
(Wong et al., 2000, Zhang et al., 2002). We found that un‐stimulated human EC secrete 
basal  levels  of  S‐SMase.  However,  significant  activation  and  secretion  of  S‐SMase 
occurred  between  12‐18  hours  and  remained  high  up  to  24  hours  later  confirming  a 
recent  report  in MCF7  cells  (Jenkins  et  al.,  2010a). Our  data  suggest  that  EC may have 
pools of S‐SMase that when depleted upon stimulation require transcriptional activation 
to ensure continued enzyme secretion. Like SMase, soluble  inflammatory mediators are 
trafficked  and  secreted  in  different  spatial  and  temporal  patterns  (Manderson  et  al., 
2007). Constitutive secretion of S‐SMase occurs through the Golgi secretory pathway as 
blockade  of  ER‐Golgi  transport  abolished  release  of  V5‐tagged  S‐SMase  (Jenkins  et  al., 
2010a). 
 
Proteins  are  transported  from  the  ER  and  trans‐Golgi  network  (TGN)  to  the  PM  for 
secretion  generally  via  the  constitutive  or  regulated  secretory  pathways  (CSP;  RSP). 
Constitutive  secretion  occurs  in  small  secretory Golgi‐vesicles  from  the  TGN  to  the  PM 




Stanley  and  Lacy,  2010).  In  EC,  Weibel‐Palade  bodies  (WPB)  are  specialised  storage 
granules that can be activated by IL‐4, TNFα, SMase and exogenous Cer (Inomata et al., 
2009,  Bhatia  et  al.,  2004).  Secretion  pathways  vary  between  molecules  and  cell  type 
(Reefman et al., 2010, Huse et al., 2006, Murray et al., 2005a). A specific example  is  IL‐






Mannose‐6‐phosphate  (M6P)  or  sortilin  tagged  ASM  pre‐cursors  are  trafficked  to 
lysosomes.  Thus  ASM  pre‐cursors  not M6P  tagged  are  shuttled  to  the  Golgi  secretory 
pathway (Schissel et al., 1998a, Jenkins et al., 2010b, Schissel et al., 1998b, Marathe et al., 
1998,  Ni  and  Morales,  2006).  Evidence  for  this  lies  in  I‐cell  fibroblasts  which  have 
mutations of M6P machinery proteins such as NAGTP, where most of ASM precursor  is 
secreted (Takahashi et al., 2005). While the M6P theory remains under debate (Quintern 









factors  Sp1,  TATA  and  AP‐1  (Schuchman  et  al.,  1992).  It  was  suggested  that 
phosphatidylcholine  phospholipase  C  (PC‐PLC)  could  lead  to  sequential  diacyglycerol 
(DAG)  and  NF‐κB  translocation  via  TNFR1  using  ASM  activation  (Schutze  et  al.,  1992, 
Kolesnick, 1987, Wiegmann et al., 1994). However, this involvement of ASM in TNFα/NF‐





endosomes  (Schneider‐Brachert  et  al.,  2004,  Schutze  et  al.,  1999).  These  processes 
however  were  observed  during  apoptosis  involving  lysosomal  L‐SMase  rather  than  S‐
SMase. 
 
TNFα  leads  to  the  secretion  of  cytokines  (IL‐1,  IL‐6,  IL‐8,  GM‐CSF),  matrix 
metalloproteinases  (MMP), prostaglandins,  chemokines,  complement  factors,  lysosomal 
enzymes and protease inhibitors (Brennan et al., 1989, Haworth et al., 1991, Butler et al., 
1995, Dayer et al., 1985, Brennan and McInnes, 2008, Lee et al., 2010). TNFR1 stimulation 








al.,  1992,  Zerimech  et  al.,  1993,  Lemaire  et  al.,  1997).  Importantly,  the mechanisms  of 
cytokine‐induced cathepsin secretion are not yet  fully understood  (Krueger et al., 2009, 
Lemaire et al., 1997). In addition to ASM, TNFα and IL‐1β can also activate other lipases 
such  as  pro‐inflammatory  type  IIA  secreted  phospholipase  A2  (sPLA2)  and  endothelial 
lipase  (EL)  (Andreani et al., 2000).  In HUVEC, EL  secretion was also  shown within 12‐24 
hours using similar TNFα concentrations (10 ng/mL; Fig. 4.9) (Jin et al., 2003, Hirata et al., 
2000).  This was  at  least  partially  due  to  regulation  at mRNA  level  in HUVEC  (Jin  et  al., 
2003) similar to the effect of IL‐1β on ASM in breast carcinoma cells MCF7 (Jenkins et al., 
2010a).  
Recently, TNFα,  IL‐1β and phorbol myristate acetate  (PMA)  (PKC activator,  structural 
homologue of DAG) were shown to  increase S‐SMase  release  from MCF7 cells while  IL‐
1β was  able  to  increase  SMPD1  transcripts  in  contrast  to  PMA.  This  suggested  an 
alternative  mechanism  to  account  for  the  enhanced  protein  secreted.  As  such,  it  was 
shown  that  S‐SMase  could  retain  its  activity  following  CHX  treatment  implying  little 
protein  turnover  (Jenkins  et  al.,  2010a),  thus  supporting  a  role  for  S‐SMase  in  chronic 
inflammatory disease.  The above observations  suggest  that  S‐SMase  release may occur 
through  the CSP, however  the precise mechanisms of  TNFα‐induced S‐SMase  secretion 
remain unclear.  Ser508 on ASM,  situated  in  the C‐terminal end of  the protein, has been 
associated  with  its  release  as  secretion‐incompetent  Ser508  mutants  failed  to  generate 
PM‐specific C16‐Cer and  retained  their  lysosomal  targeting  (Jenkins et al.,  2010a,  Lee et 





SMase  activation  (Jenkins  et  al.,  2010a).  In  contrast  to  L‐SMase,  which  undergoes 
complete  carboxy‐terminal  removal,  S‐SMase  retains  the  entire  C‐terminal  and  is  a 
regulator  of  its  activity  by  terminal  cysteine  (Cys629)  switching of  rhASM  (Jenkins  et  al., 
2010b, Qiu et al., 2003).  
TNFα−mediated  ROS  production  has  been  linked  with  ASM  activation  (Gao  et  al., 
2007, Dumitru  and Gulbins,  2006).  This  redox  sensitivity  of ASM was  also  confirmed  in 
neutrophils,  glioma  and  U937  cells  (Scheel‐Toellner  et  al.,  2004,  Grammatikos  et  al., 
2007). We  investigated  the  redox  regulation  of  human  endothelial‐derived  S‐SMase  by 
applying  non‐specific  oxidative  stress  using  H2O2.  Our  data  showing  that  DTT  could 
abrogate S‐SMase activity (figure 4.12‐13) confirmed previous observations that S‐SMase 
is  secreted  in  an  activated  state  (Claus  et  al.,  2005, Wong  et  al.,  2000, Marathe  et  al., 







Thus  inflammatory  conditions  in  vivo  might  also  regulate  S‐SMase  activation. 







Inflammatory  conditions  and  increased  reactive  oxygen  species  (ROS)  lead  to  oxidative 
activation of S‐SMase by terminal Cys629 switching. Increased levels of ROS diminish anti‐
oxidant  systems  such  as  glutathione  (GSH).  In  vitro  this  is  described  using  buthionine 
sulfoximine  (BSO)  and  N‐acetylcysteine  (NAC)  which  decrease  and  augment  GSH 















































by  maintaining  an  intracellular  redox  balance  (Charruyer  et  al.,  2005,  Dumitru  and 
Gulbins, 2006). To  further clarify  the  role of oxidative switching on S‐SMase activity we 
decided  to  manipulate  intracellular  (GSH)  EC  redox  environments.  Even  modest 
concentrations of BSO (2 to 200 µmol/L) can deplete HUVEC of GSH up to 95% even after 
27  hours  (Jornot  and  Junod,  1993,  Heng‐Long Hu  et  al.,  2000,  Toborek  et  al.,  1995).  A 
decrease  in  GSH  renders  cells  in  a  pro‐oxidant  state  and  since  ASM  is  activated  by 
oxidation  of  Cys629,  this  should  lead  to  increased  S‐SMase  activity.  S‐SMase  activity  in 
medium  from NAC & TNFα  treated  cells  appeared  to  be decreased  compared  to  TNFα 
alone treated cells suggesting that raised GSH, due to NAC, maintained physiological ROS 
levels preventing ASM cysteine switching. However, this was also the case for S‐SMase in 
medium  from  BSO  &  TNFα  treated  cells.  Interestingly,  TNFα  itself  has  been  shown  to 
increase GSH levels in EC and hepatocytes by 24 hours (Toborek et al., 1995, Morales et 
al.,  1997).  This  supports  our  observations  that  showed  both  BSO  and  NAC  treatments 
independently  decreasing  S‐SMase  activation.  It  remains  unclear whether  the  effect  of 
BSO/TNFα was an in vitro artefact since the effect was consistent.  
In  summary,  IL‐1β  and  TNFα directly  induced  the  secretion  of  a  redox‐sensitive 
enzyme from human EC  in vitro. This was not seen with IL‐6 suggesting specificity in the 
regulation  of  S‐SMase  by  inflammatory  cytokines.  Our  model  is  arguably  the  most 
physiologically  relevant  for  characterising  native  S‐SMase  as  a  redox‐sensitive  enzyme. 





















Although many  studies  have  investigated  the  regulation  and  cellular  effects  of  ASM 
and nSMase following stimulation of cell surface receptors, none have looked directly at 
the  effect  of  exogenous  ASM  on  the  outer  PM  leaflet  and  the  consequences  on 





lipid  messengers  of  SM  catabolism  have  contrasting  effects.  ASM  has  been  linked  to 
apoptosis and the strongest link came from the protection offered to cells in its absence 
(Santana et al.,  1996,  Separovic et  al.,  1999,  Llacuna et al.,  2006).  There are  conflicting 
reports concerning the roles of SMase and Cer in eNOS regulation. Cer has been shown to 
mediate  EDV  in  rat  aorta,  a  process  blocked  in  eNOS‐inactivated  tissue  (Johns  et  al., 
1998).  TNFα was  reported  to  increase  eNOS  activation  in  EC  through  Cer  generation 
independent  of  Ca2+  (Bulotta  et  al.,  2001).  However,  in  bovine  coronary  artery  EC,  Cer 
could activate eNOS in a Ca2+‐dependent manner (Igarashi et al., 1999). These events are 
likely to be mediated through the Cer messenger, sphingosine‐1‐phosphate (S1P) that has 










However,  S1P  formation  is  a  downstream  event  of  Cer  catabolism.  Closer  to  the  cell 
surface,  formation  of  Cer  in  lipid  rafts  (LR)  at  the  PM  is  believed  to  have  detrimental 
effects on membrane dynamics  (van Blitterswijk et al., 2003). Cer  is highly hydrophobic 
and tends to associate in lipid rich compartments, such as the PM itself. Previous work in 
our  laboratory  showed  that TNFα can decrease Ca2+  signals  in T cells and  that  this was 
mediated by ASM blocking Ca2+  through  ICRAC  (Church et al., 2005). Capacitative calcium 
entry (CCE) describes the influx of Ca2+ through membrane SOC in response and parallel 
to,  depletion  of  ER  Ca2+  stores  (Putney,  1986).  Ca2+  influx  in  response  to  ER  store 
emptying  occurs  through  Ca2+  release‐activated  Ca2+  channels  (ICRAC)  (Parekh,  2008b), 
found  in  close  vicinity  to  caveolae,  which  are  rich  in  SM  and  considered  a  target  for 
exogenous, secreted SMase (Isshiki et al., 1998, Isshiki et al., 2002). SMases were indeed 
first  suggested as modulators of  iCa
2+ mobilisation  in T  lymphocytes  (Breittmayer et al., 
1994).  Furthermore,  TNFα was  shown  to  inhibit  store‐operated  Ca2+  entry  (SOCE)  into 









CV  complications  (Vanhoutte  et  al.,  2009).  Store  operated  Ca2+  influx  leads  to  eNOS 
activation, found to co‐localise in a PM domain probably within caveolae (Lin et al., 2000), 
specifically caveolin‐1, which blocks eNOS activation through protein‐protein  interaction 
(Feron  et  al.,  1998).  Influx  of  Ca2+  breaks  the  caveolin‐1/eNOS  association  while 
calmodulin (CaM) binding to eNOS, necessary for its activation, facilitates the transfer of 
electrons  from  the eNOS  reductase domain  to  the oxidase domain  (Ghosh et  al.,  1998, 
Dudzinski and Michel, 2007, Michel and Vanhoutte, 2010). 
 
Impaired  EDV  is  depicted  as  ECD,  considered  an  early  step  in  atherosclerosis.  ECD 
features  decreased  NO  production  that  can  come  as  a  result  of  decreased  eNOS 
expression,  depleted  substrate  (L‐arginine)  or  co‐factors,  altered  eNOS  signalling  and 
inactivation  (Shimokawa  et  al.,  1991,  Schmidt  and  Alp,  2007).  eNOS  dysregulation  can 
manifest  as  dysfunctional  phosphorylation  status  on  multiple  residues.  The  two  most 





of  exogenous  ASM  on  iCa
2+  mobilisation  and  eNOS  activation  in  EC.  Thus  we  asked 
whether  ASM  could  cause  ECD  through  decreasing  iCa
















TNFα and FAS  (Haimovitz‐Friedman et  al.,  1997,  Sawada et  al.,  2002, Garcia‐Ruiz et  al., 
2003).  This  work  involved  activation  of  intracellular  ASM.  We  therefore  wanted  to 











HUVEC  were  brought  to  confluence  in  96‐well  tissue  culture  plates  and  treated  with 
exogenous ASM (Sigma‐Aldrich) in fully supplemented M199 for 60 minutes. HUVEC were 
also treated with DMSO (10% v/v) and H2O2 (1 mmol/L) for 60 minutes. Cell viability was 
determined  by  the  MTS  assay.  Data  are  expressed  as  a  percentage  of  control  fully 







HUVEC were brought to confluence  in 24‐well  tissue culture plates  in M199. The media 
were  removed,  the  cells  washed  twice  with  HBSS‐Ca2+  and  incubated  with  fully 
supplemented M199 containing solvent control, DMSO (10% v/v), CHX/TNFα (10 µM/100 









The  assays  featuring  iCa
2+  signalling  in  EC  in  vitro  were  carried  out  at  neutral  pH  to 
mimic the near‐vascular microenvironment. Thus, Hank’s Buffered Saline Solution (HBSS) 
(Table 2.2, p61) was used  to  visualise EC under  fluorescence microscopy because of  its 
neutral pH and suitability for sustained HUVEC viability. ASM can hydrolyse SM on LDL at 
neutral  pH  (Schissel  et  al.,  1998a).  Furthermore,  we  found  that  ASM,  if  anything,  was 
more potent at neutral pH  in HBSS  compared  to  its  activity  in a buffered aqueous acid 
solution (Appendix figure A3).  
Given  the  previous  work  showing  that  SMase  could  depress  iCa
2+  signals  in 
lymphocytes  and  the  importance of  the Ca2+  signal  in  EC  function, we next went  on  to 
study  the  effects  of  ASM  on  iCa






2+  responses  in  HUVEC  evoked  by  vasoactive  agonists  was 
performed using the  iCa
2+ specific chelator type dye Fura‐2 AM (Invitrogen, UK). HUVEC 
were  stimulated  with  bradykinin  (Bk)  and  thrombin  (Thr)  to  elicit  a  Ca2+  flux.  Typical 
responses to Bk and Thr are shown in figure 5.3. A baseline was measured for 30 seconds 
prior  to  addition  of  agonist.  In  this  false  colour  representation  of  the  ratiometric  Fura 
images, cells with low cytoplasmic Ca2+ appear green (Fura emission, 340) while those in 
which  the  Ca2+  is  raised  appear  red/orange  (Fura  emission,  380).  Mean  values  of  the 































Application  of  exogenous  ASM  onto  HUVEC  reduces  iCa
2+  responses  to  Bk.  Previous 




concentration  range  for  ASM  we  calculated  the  activity  of  S‐SMase  in  plasma  from 












2+  signals  in  response  to  1 µmol/L  Bk  compared  to 
control  un‐treated  HUVEC  (Figure  5.4).  Incubation  of  HUVEC with  ASM  for  30 minutes 
inhibited Bk‐induced  iCa
2+  responses with  the most profound effect observed  in HUVEC 
treated  with  250  mU/mL  (p  <  0.05)  whereas  500  mU/mL  ASM  induced  a  significantly 
depressed (p < 0.05 vs control) but slightly elevated response compared to 250 mU/mL 





To  understand  whether  the  effects  of  ASM  are  transient,  occurring  only  in  the 
presence of ASM in the medium, we decided to examine the persistence of the effect of 
ASM  on  iCa
2+  responses.  Here,  HUVEC were  pre‐treated with  ASM  for  30 minutes,  the 
ASM was  removed and  the cells  incubated  for a  further 60 minutes with  fresh medium 
199 (recovered cells, R). In parallel, separate cultures were latently pre‐treated with ASM 
for  30 minutes  but  not  allowed  to  rest  in  fresh medium  (unrecovered  cells, UR).  ASM 
inhibited Bk‐induced iCa
2+ responses in a dose‐dependent manner (Figure 5.5).  
In  recovered  (R)  HUVEC,  intra‐group  comparison  (e.g.  control  Vs  ASM‐treated 
recovered HUVEC) confirmed that ASM caused decreased iCa
2+ responses to Bk compared 
to  control  HUVEC.  In  recovered  HUVEC,  iCa




responses  in  recovered HUVEC  appear  to  initially  respond  to ASM quenching  however, 
did not  return  to baseline  levels  in  cells  treated with 250 and 500 mU/mL of ASM and 
were significantly lower than control untreated HUVEC (p < 0.05, p < 0.01) (Figure 5.5).  





all  ASM  concentrations  (25‐500  mU/mL).  In  conclusion,  the  effects  of  ASM  persist 
following its removal from culture medium suggesting that a second messenger, such as 
Cer,  may  indeed  mediate  the  inhibition  of  iCa








































HUVEC were  seeded  in  8‐well  glass  coverslides  for  24‐48  hours  in M199.  HUVEC were 
incubated  with  solvent  control  or  ASM  (25‐500  mU/mL)  for  (A)  30  minutes,  (B)  60 
minutes.  In  ASM  treated  HUVEC,  intracellular  Ca2+  responses  evoked  by  bradykinin  (1 
µmol/L) were compared to control, untreated HUVEC (CTRL). Intracellular Ca2+ signalling 
is expressed as the peak rise ratio of 340:380 nm. Statistical significance was determined 






















HUVEC were  seeded  in  8‐well  glass  coverslides  for  24‐48  hours  in M199.  HUVEC were 




were  stimulated  with  bradykinin  (1  µmol/L)  to  evoke  intracellular  Ca2+  responses.  For 
intra‐group  comparisons,  intracellular  Ca2+  responses  to  bradykinin  were  compared 
between untreated and ASM‐treated HUVEC in both recovered and unrecovered groups. 
For  example,  comparisons  were made  in  unrecovered  cells  (untreated  vs  ASM)  and  in 
recovered  cells  (untreated  vs  ASM).  ASM‐treated  recovered  (R)  HUVEC  were  also 
compared  to  ASM‐treated  unrecovered  (UR)  HUVEC.  Statistical  significance  was 










Given  the  high  in  vivo  levels  of  S‐SMase, we  examined  the  effect  of  a  high  dose  of 
exogenous ASM on HUVEC  iCa






plasma  and  examined  its  effects  on HUVEC  iCa
2+  signalling.  Plasma  from a  patient who 
had  undergone  PEX  was  diluted  in  M199  for  HUVEC  incubation  and  termed  ‘Vasc’.  In 














































either M199  (medium)  or human plasma  for 30 minutes. HUVEC were  then  stimulated 
with bradykinin (1 µmol/L) and iCa
2+ responses were recorded. (Medium) unconditioned 
culture  medium,  (PP)  healthy  control  pooled  plasma,  (PP‐HI)  heat‐inactivated  healthy 






















were  loaded  with  medium  conditioned  with  10%  (v/v)  concentrated  supernate  from 
previously  un‐stimulated HUVEC.  These were  compared  to  heat‐inactivated‐S‐SMasehigh 
























HUVEC were  seeded  in  8‐well  glass  coverslides  for  24‐48  hours  in M199.  HUVEC were 
incubated  with  either  M199  or  S‐SMasehigh  media  supernate.  HUVEC  concentrated 
medium was  derived  from  HUVEC  treated  with  TNFα  (10  ng/mL)  for  18  hours.  (CTRL) 
untreated HUVEC in M199; (heat‐inactivated) heat‐inactivated S‐SMasehigh concentrated 






In  a  quiescent  state,  eNOS  is  localised  to  caveolae  on  the  intracellular  leaflet  of  the 
plasma  membrane  (PM).  When  EC  are  stimulated  by  agonist,  eNOS  is  activated  and 
translocates  to  the  cytosol  where  it  converts  L‐arginine  to  L‐citrulline  and  nitric  oxide. 
Phosphorylation  at  Ser1177  and  de‐phosphorylation  of  Thr495  are  associated  with  eNOS 
activation,  leading to caveolar dissociation and cytosolic translocation. A mechanism for 
decreased  NO  availability  may  involve  disruption  of  iCa
2+  signalling.  eNOS  activation, 







Bk  has  been  shown  to  activate  eNOS by  dephosphorylating  eNOS  at  Thr495  and weakly 




To  study  the  eNOS  protein  HUVEC  were  seeded  from  primary  cells  in  6‐well  tissue 
culture  plates.  HUVEC  were  serum  starved  for  one  hour  and  lysed  on  ice  in  Radio‐
Immunoprecipitation Assay  (RIPA) buffer supplemented with protease and phosphatase 
inhibitors as indicated in chapter 2. Protein was estimated by the BCA assay (Pierce) and 




captured  by  the  anti‐eNOS  antibody  and  easily  visualised  by  immunoblotting.  In  figure 
5.8a,  5x  concentrated  loading  buffer  could  be  used  (10  µg  samples)  without  affecting 
migration  in  the  acrylamide  gel  as  indicated  relative  to  samples  loaded  in  2x  loading 
buffer (titration 20 – 0 µg).  
Bk  is  known  to  activate  eNOS by differential  phosphorylation  changes on  Thr495  and 
Ser1177  whilst  there  is  no  evidence  that  thrombin  induces  changes  at  the  threonine 
residue, rather it only phosphorylates Ser1177 alone. Accordingly we examined the ability 
to detect  changes  in  Thr495 phosphorylation by Bk and  thrombin  (Figure 5.8b).  Capture 
time  for  optimal  phosphorylation  of  eNOS  is  between  1‐3  minutes  when  EC  are 
stimulated with  either  Bk  or  thrombin.  Therefore,  HUVEC were  stimulated with  1  or  2 
µmol/L Bk for 1 and 2 minutes (BK1, BK2 respectively; figure 5.8b) (Harris et al., 2001) and 
1 U/mL thrombin for the same time periods (Stahmann et al., 2006). We found no change 
in  total  eNOS  protein  following  either  stimulation.  However  in  this  model,  we  were 
unable  to  detect  Bk‐induced  Thr495  dephosphorylation.  As  expected,  thrombin  also  did 
not alter the Thr495 phosphorylation status. This suggests that our model was not sensitive 
enough  to  detect  such  changes,  possibly  requiring  increased  cell material.  Thus,  in  line 













buffer.  (B)  Detection  of  eNOS  and  phosphorylated  eNOS  at  Thr495. Where:  bradykinin 
(BK), thrombin (T) (1 U/mL), control/untreated (C), (BK1) 1 minute exposure to bradykinin, 














its  activation.  Both  Bk  and  thrombin  stimulate  phosphorylation  of  eNOS  at  Ser1177  in  a 




to  thrombin  (Figure  5.9a).  To  test  the  suitability  of  thrombin  on  eNOS  Ser1177 
phosphorylation, HUVEC were again stimulated with both agonists for 2 minutes and the 
lysates  were  probed  by  immunoblotting  for  native  eNOS  and  phosphorylated  eNOS 
(peNOS)  at  Ser1177.  Bk  is  known  to  only  weakly  phosphorylate  eNOS  at  Ser1177  an 
observation  witnessed  in  our  experiments  (Figure  5.9b).  By  contrast,  thrombin 
stimulation  led  to more  evident  protein  bands  stained  for  peNOS‐Ser1177  compared  to 
control  un‐stimulated  cells.  Due  to  greater  eNOS  responses,  thrombin  was  chosen  to 
study eNOS phosphorylation. HUVEC were then serum‐starved in M199 and subsequently 
stimulated with  thrombin  in either M199 or HBSS suggesting  that peNOS responses did 















































for  60 minutes  and  stimulated  with  bradykinin  or  thrombin  for  2  minutes.  (B)  HUVEC 
were stimulated with bradykinin (1 µmol/L) and thrombin (1 U/mL) for 2 minutes and the 















the  enzyme being  a  limiting  factor. This  closely  reflected  the mean  activity  of  diseased 
patients.  eNOS  activation  was  described  as  increases  in  Ser1177  phosphorylation, 
calculated as a ratio of β‐actin‐normalised, peNOS/eNOS (Figures 5.10). Total eNOS levels 
did  not  differ  between  pASM  pre‐treated  and  untreated  cells.  ASM  alone  appeared  to 
slightly  increase  Ser1177  phosphorylation  following  30  and  60  minute  treatments.  Pre‐
treatment with pASM for 30 minutes caused a 15.8% decrease in Ser1177 phosphorylation 
compared  to untreated cells  thrombin  stimulated cells  (Figure 5.10a). After 60 minutes 
however, ASM pre‐treated HUVEC stimulated with thrombin exhibited an 18% increase in 
Ser1177 phosphorylation compared to untreated, thrombin stimulated cells (Figure 5.10b). 
This differs  in  comparison  to 30 minute  treatments where pASM appeared  to decrease 
Ser1177  phosphorylation  but  could  be  as  a  result  of  the  lower magnitude  of  thrombin‐
induced  phosphorylation.  Ionomycin  caused  a  75%  increase  in  Ser1177  phosphorylation 
compared to unstimulated cells, however, this was 37% lower than thrombin stimulated 
cells (3‐fold increase vs unstimulated cells) (Figure 5.10a). Ionomycin provoked decreased 
eNOS  responses  compared  to  thrombin  which  could  suggest  an  alternate  signalling 
mechanism for thrombin.  Interestingly,  in some cases ionomycin led to decreased eNOS 
phosphorylation  in  ASM‐treated  cells  compared  to  ionomycin  alone,  evident  by  the 
protein band intensity (phosphorylated Ser1177). This may indeed suggest a direct effect of 










against  phosphorylated  eNOS  at  Ser1177.  The  top  panels  of  (A)  and  (B)  show 
representative immunoblots of total eNOS, phosphorylated eNOS and β‐actin. All lysates 









More  experiments  are  needed  to  clarify  the  observations  in  5.2.3.3  including 
experiments  performed  in  Ca2+‐free media  to  question  the  involvement  of  Cer  in  Ca2+ 
influx inhibition. eNOS activation leads to the production of freely diffusible NO from EC. 
Bk  and  thrombin  both  activate  eNOS  leading  to  NO  production  in  a  Ca2+‐dependent 
fashion.  Exogenous  ASM  previously  inhibited  Bk‐induced  Ca2+  signals  in  our  HUVEC 
model.  Bk  has  been extensively  studied  in  receptor‐mediated  eNOS  activation  and was 
used  here  to  study  the  effect  of  exogenous  ASM on NO  production.  HUVEC  in  24‐well 
tissue  culture  plates were  serum  starved  for  1  hour  in  serum‐free  HESFM  and  treated 
with  vehicle,  pASM  (1.25  U/mL),  C2‐Cer  (500  µmol/L)  or  nSMase  (25  mU/mL)  for  30 
minutes.  Nitric  oxide  in  the  media  supernates  was  analysed  in  the  gas  phase  using  a 
Sievers NO  chemiluminescence  analyzer  (Analytix,  Sunderland, UK).  Samples  containing 
nitrates  and  nitrites  alongside  any  NO,  if  present,  are  injected  into  a  reflux  chamber 
containing vanadium (III) chloride (VaCl3) at 95
0C. In the gas phase this reacts with ozone 
to  form  nitrogen  dioxide  (NO2
*).  In  an  excited  state,  the  decay  of  NO2
*  back  to  NO2
‐ 
(nitrite) emits a signal at 600 nm directly proportional to NO concentration (Kleinhenz et 
al.,  2003).  Pre‐treatment  with  pASM  and  nSMase  inhibited  NO  production  by  HUVEC 
stimulated with Bk compared to un‐treated controls whereas HUVEC pre‐treated with C2‐
Cer were not affected  (Figure 5.11).  This data may be  in agreement with  that  in  figure 











nSMase  (25  mU/mL)  or  left  untreated  in  fresh  HESFM  for  30  minutes.  HUVEC  were 
stimulated  with  bradykinin  (1 µmol/L).  Data  are  normalised  to  recordings  of  basal  NO 
production  from  unstimulated  solvent  control  HUVEC.  Data  are  representative  of  one 













SM  metabolites  are  involved  in  housekeeping  reactions  but  many  of  the  pathways 
remain poorly understood. This is highlighted here due to their increasing pluripotency in 
downstream cell signalling. ASM has been shown to have a prominent role in apoptosis as 
ASM‐/‐  mice  showed  defective  apoptotic  responses  to  TNFα  signalling  (Haimovitz‐
Friedman  et  al.,  1997,  Garcia‐Ruiz  et  al.,  2003).  Interestingly,  application  of  exogenous 
ASM  led  to  melanoma  cells  becoming  sensitised  to  irradiation  in  a  dose‐dependent 
manner,  however,  in  vitro,  this  was  evident  only  at  low  pH  (Smith  and  Schuchman, 
2008a). Due to these observations we investigated the effect of exogenous human ASM 
on HUVEC  cytotoxicity  and  apoptosis.  Our  data  showed  that  exogenous  ASM does  not 
cause  necrotic  cell  death  nor  did  it  contribute  to HUVEC  apoptosis. One  explanation  is 
that  intracellular stress responses to ASM come from stimulation of death  ligands (FAS) 
(Sawada et al.,  2002), or  require  co‐stimulation with TNFα. Both  these events however 










deemed  sufficient  to  elicit  significant  Ca2+‐dependent  eNOS  responses  in  HUVEC 











alter  membrane  properties  on  distal  EC  in  vivo,  supporting  the  concept  for  S‐SMase‐
mediated diffuse ECD.  
 




the extracellular  leaflet of  the PM thereby generating Cer  (Jenkins et al., 2010a). Three 
possible mechanisms  exist  for  S‐SMase  access  to  SM  pools  including  1)  secretion  of  S‐





the  most  abundant  lipids  in  the  PM.  The  topology  of  Cer  generation  following  SM 
cleavage  by  ASM  has  been  co‐localised  with  caveolae  where  it  could  alter  membrane 
architecture  in  lipid  rafts  (LR)  (Jin  et  al.,  2008).  Cer  in  LR has been associated with  raft 
fusion creating large platforms found in close proximity to SOC channels such as ICRAC (Li 
and Gulbins,  2007).  The  depressed  agonist‐induced  iCa









acetylsphingosine),  which  can  easily  cross  membranes  (Tornquist  et  al.,  1999).  Most 
definite evidence for ASM/Cer blockade of Ca2+  influx came from the use of ASM‐/‐ cells 
(Lepple‐Wienhues  et  al.,  1999,  Church  et  al.,  2005),  a  mechanism  supported  by  the 
emptying  of  ER  Ca2+  stores  using  the  sarco/endoplasmic  Ca2+  pump  (SERCA)  inhibitor 
thapsigargin and chelating extracellular Ca2+ with ethylene glycol tetraacetic acid (EGTA), 
to show that blockade of Ca2+ influx was abrogated in the absence of ASM (Church et al., 






To  study  the  downstream  effects  of  decreased  iCa
2+  responses,  eNOS  Ser1177 
phosphorylation was used as a marker of  its activation. Different stimuli provoke varied 
eNOS responses (Ca2+‐dependent/independent) and can lead to activation of the enzyme 
by  translocation  or  phosphorylation  (Park  et  al.,  2009b,  Chan  et  al.,  2010,  Pott  et  al., 
2006, Dimmeler et al., 1999). eNOS activation is inhibited by anchorage to the PM at the 
intracellular catalytic domain of  the plasma membrane Ca2+ ATPase  (PMCA). PMCA was 
thought  to  negatively  regulate  eNOS  activity  in  HUVEC  by  increasing  Thr495 
phosphorylation and slightly decreasing Ser1177 phosphorylation, inhibiting NO production 




stimulation,  activating  eNOS  in  a  Ca2+/CaM,  CaMKII  and  AMPK‐dependent  manner, 
independent of Akt activation, depicted in figure 1.4 (Fleming et al., 2001, Motley et al., 
2007,  Thors  et  al.,  2004,  Michel  and  Vanhoutte,  2010).  Bk‐induced  NO  production, 
unaffected  by  PI3K  inhibition,  suggests  that  agonists  of  G‐protein  coupled  receptors 
(GPCR)  evoke  eNOS  responses  independent  of  the  PI3K/Akt/PKB  pathway;  whereas 
CaMKII  inhibition  which,  abolished  Ser1177  phosphorylation  and  decreased  cGMP 
accumulation suggested that CaMKII phosphorylates eNOS at Ser1177 in Bk‐stimulated EC 
(Fleming et al., 2001).  Similarly,  thrombin  is also believed  to work  through a Ca2+/CaM, 
CaMKII pathway that is PKCδ‐sensitive, but is PI3K/Akt independent (Motley et al., 2007, 
Thors et al., 2004, Stahmann et al., 2006, David‐Dufilho et al., 2005). Two pathways may 
therefore  exist  in  thrombin‐mediated  eNOS  activation  including  a)  Ca2+/CaMKII  and  b) 
Chapter 5                                                                 Effects of ASM on endothelial cell function 
  [225] 
AMPK  through  AMP/LKB1  (LKB1  phosphorylates  AMPK)  (Figure  1.4).  Thus,  thrombin‐
mediated  eNOS  activation  may  be  either  Ca2+‐dependent  or  energy‐dependent,  while 




Thrombin  receptor‐mediated  eNOS  activation  requires  both  ER  store  and  SOCE  for 
Ser1177 phosphorylation  (Motley et al., 2007). Thr495 dephosphorylation, another marker 
of  eNOS  activation,  was  not  detected  with  the  required  sensitivity  in  our  experiments 
confirming observations of  greater  Thr495  responses  in  human dermal microvascular  EC 




minutes  of  ASM  pre‐treatment  (Figure  5.10a),  which  appeared  to  increase  after  60 
minutes  (Figure  5.10b).  One  possible  explanation  for  this  is  offered  by  Cer, which was 




however,  again  used  exogenous  C2‐ceramide  that  could  easily  diffuse  across  the  PM 
whereas native,  long‐chain Cer  is more hydrophobic  and would not  readily  incorporate 
into  bio‐membranes  (Chatelut  et  al.,  1998,  Venkataraman  and  Futerman,  2000).  These 





also  led  to  increased  eNOS  translocation  and  phosphorylation  at  Ser1179  also  in  a  Ca2+‐
independent manner (Mogami et al., 2005), suggesting that Cer generation by exogenous 
SMases  could  indeed  increase  eNOS  phosphorylation  through  S‐1‐P  (Barsacchi  et  al., 
2003, Bulotta et al., 2001). 
 
The  precise  mechanisms  of  Bk/thrombin‐induced  NO  regulation  are  still  being 
unraveled.  A  recent  publication  suggested  that  transient  Ser1177  phosphorylation  by 
thrombin  was  not  sufficient  for  significant  NO  production  (Watts  and  Motley,  2009). 
Thr495  phosphorylation  is  known  to  decrease  eNOS  activity  and  NO  production.  This, 
however, was shown to occur after Ser1177 phosphorylation suggesting an auto‐inhibitory 


















without  its shortfalls and repeated attempts  to replicate our  findings were thwarted by 
technical  issues  with  temperature  regulation  as  the  assay  depends  on  low  working 
temperatures (>‐120C).  
Diaminofluorescein  (DAF‐2)  is  a  highly  specific  and  sensitive  NO  probe  (2‐5  nmol/L) 
(Chapter 2; 2.2.12.1) (Nakatsubo et al., 1998). It directly binds NO, which in the presence 





the  required  sensitivity  to  distinguish  between  background  and  agonist‐stimulated  NO 
production (Appendices, figure A4 lower panel).  
 
Another  method  used  for  the  direct  detection  of  NO,  incorporated  an  NO‐specific 







will  be  produced  in  the  cell  monolayer.  Thus,  application  of  agonist  must  be  in  close 




used  in  an  attempt  to  increase  cell  yield  the  latter  having  questionable  physiological 
relevance.  
 
NO production by eNOS  is  a process  tightly  coupled  to  iCa
2+ mobilization  (Nilius  and 
Droogmans, 2001). SMase and Cer can both decrease Ca2+ influx in Jurkat T cells (Church 




signalling  in  Ca2+‐free  conditions  to  observe  direct  Ca2+  influx,  eNOS  activation  and NO 
production. Since Cer has been shown to  increase ONOO‐ production through increased 
































increased  incidence  of  CVD  often  manifesting  as  accelerated  atherosclerosis.  The 
initiating  mechanisms  underlying  the  development  of  atherosclerosis  remain  unclear. 
Vascular  inflammation  in  PSV  and  RA  has  been  shown  to  induce  ECD  and  loss  of  NO 
production.  Ceramide  (Cer)  produced  by  sphingomyelinase  activated  during  vascular 
inflammation is a potent regulator of membrane dynamics altering biophysical properties 
of  the PM,  interfering with Ca2+  influx channels and downstream EC signalling. Thus we 
hypothesised  that  vascular  inflammation  induced  the  secretion  of  SMase,  which  could 
cause diffuse ECD through Cer generation inhibiting Ca2+‐dependent NO production.  
 
This  thesis  investigated  the  presence  and  activity  of  peripheral  blood  S‐SMase  from 




To  our  knowledge  this  study  is  the  first  to  document  raised  S‐SMase  activity  in 
rheumatic disease detected in 4 independent AASV cohorts and an established RA cohort. 
In  a  cross‐sectional  AASV  cohort,  S‐SMase  correlated  with  accumulated  organ/tissue 
damage whilst in serial samples S‐SMase levels fell by 14 weeks following treatment and 
continued  to  fall by at  least 6 months  in patients with established  remission.  In  the RA 
cohort, S‐SMase levels were raised compared to controls and correlated with various CVD 




In  vitro,  key  inflammatory mediators  such  as  IL‐1β  and  TNFα  but  not  IL‐6  induced  the 
secretion  of  active  S‐SMase while  application  of  exogenous  ASM was  able  to  decrease 
iCa
2+ signalling in EC, alter eNOS activation and NO production.   
The  TNFα/S‐SMase  axis  in  chronic  inflammation.  TNFα  is  a  pivotal  inflammatory 
marker  that  has  also  been  shown  to  drive  the  disease  process  in  chronic  rheumatic 
diseases. Models of acute systemic inflammation using LPS have been shown to activate 
S‐SMase  in vivo  through TNFα, while other  inflammatory mediators  including  IL‐1β  and 
IFNγ are capable of directly inducing S‐SMase release in vitro (Wong et al., 2000). IFNγ, IL‐
1β  and TNFα  are present  in  atheromatous disease. We  found  that  TNFα  could directly 
induce  S‐SMase  release  from EC while  its  effect was  blocked  using  anti‐TNFα  antibody 
infliximab; suggesting that  in areas of acute and chronic  inflammation, TNFα‐induced S‐
SMase  release  from  EC  could  act  as  a  secondary  messenger  and  potential  marker  of 
endothelial activation.  
The  specificity  of  the  induction  of  S‐SMase  release  from  EC  is  intriguing.  LPS  causes 
TNFα but also IL‐1β production via the IL‐1 converting enzyme (ICE; caspase‐1), which in 
turn can  induce the release of other  inflammatory cytokines such as  IL‐1β and  IL‐6. LPS 
also  leads  to  IL‐6  production  however,  only  TNFα,  IL‐1β,  IFNγ but  not  IL‐4  or  IL‐6  can 
mediate  S‐SMase  release  from EC  (Kishimoto,  2005, Marathe  et  al.,  1998, Wong  et  al., 
2000,  Feldmann  and  Pusey,  2006).  Data  from  chapter  4  reveal  that  TNFα  is  a  potent 
direct  inducer  of  S‐SMase  secretion  from  EC,  a  process  that  may  readily  occur  in 




cell  states  such  as  monocyte  to  MΦ,  and  drug‐induced  leukemic  cell  differentiation 
mediated  by  transcription  factors  Sp1  and  AP‐2  (Langmann  et  al.,  1999, Murate  et  al., 
2002).  Increased ASM  transcripts were also observed  following  long‐term  incubation of 
DU145  prostate  cells  with  the  chicken  anaemia  virus  apoptin  (Liu  et  al.,  2006)  and  in 
murine models of obesity (Samad et al., 2006, Shah et al., 2008). To date there is limited 
evidence  for  transcriptional  up‐regulation  of  ASM  mRNA  by  IL‐1β which  was  recently 
confirmed  in MCF‐7  cells (Marathe et  al.,  1998,  Jenkins et  al.,  2010a). However,  similar 
findings with TNFα are lacking. This is due to the other adverse signalling events leading 
from TNFα  stimulation  including apoptosis. Given that TNFα  induces a  latent significant 
surge  of  ASM  secretion  after  10  hours,  it  is  logical  to  assume  that  this  may  involve 
induction  of  transcription  while  evidence  exists  for  a  positive  feedback  loop  as  Cer, 
sphingosine  and  S1P  can  upregulate  TNFα  mRNA  contributing  to  the  inflammatory 
process, possibly promoting further ASM activation (Samad et al., 2006).  
Site of action of S‐SMase & physiological significance. How can S‐SMase gain access 
to  SM pools? One option  is  that  S‐SMase  is  secreted  and  internalized  in  non‐host  cells 
(not  secreting) where  it meets  internal  leaflet SM on  the PM. Another option  is  that S‐
SMase  is secreted and hydrolyses outer  leaflet SM. As SM is mostly  found on the outer 
plasmalemmal leaflet, S‐SMase would gain access to an abundant source of SM explaining 
its active secretion (Schuchman, 2010). Downstream metabolites of SM hydrolysis such as 
S1P  were  shown  to  have  pro‐survival  effects  (Spiegel  and Milstien,  2003).  Similarly  S‐




the extracellular space  (Tam et al., 2010). The precise physiological  role of  the S‐SMase 
variant  remains  unclear.  Although  present  in  the  arterial  trees,  venous  predominance 
could provide a role by stunning EC, preventing overt vasodilation and diminishing venous 
flow  restricting  return;  thus  preventing  blood  from  leaving  the  inflammatory  site 
facilitating  local  hypertension,  altering  local  barrier  function  and  adhesion  molecule 
expression.  
The  importance  of  Cer  in  orchestrated  cell  signalling.  SMase  may  hold  a  critical 
position  in  cell  governance whereby  different  variants  exist  in  different  cells  executing 
highly  varied  tasks. A prime example  is  cell  death where Cer generation  is  required  for 
signalling efficiency. Cer alters membrane fluidics causing death receptor clustering which 
provides  a  significant  concentrated  response  rather  than diffuse  signals  across  the PM, 
the resulting signals culminating within the same spatial topology (Grassme et al., 2001, 





no  single  event  contributes  to  vascular  dysfunction.  The mechanisms  behind  the  initial 
step  in atherosclerosis are supported on a variety of platforms  including abnormal  lipid 





et  al.,  2008).  However  to  date  the  initiating mechanism,  if  one  predominates,  has  not 
been elucidated. S‐SMase has been incorporated in an elaborate model shaped by Tabas 
and Williams to describe a process to support the early steps of atherogenesis. This was 
coined  the  ‘response‐to‐retention’  (RTR)  model  (Williams  and  Tabas,  1995)  where 
increased  sub‐endothelial  LDL  retention  could  be mediated  at  least  in  part  by  S‐SMase 
(Tabas, 1999, Tabas et al., 2007).  
Sphingolipids  were  first  associated  with  atherosclerosis  40  years  ago  (Portman  and 
Alexander,  1970).  Sub‐endothelial  lipid  aggregation  is  a  major  contributing  factor  in 
atheroma formation. In the RTR model, the role of S‐SMase lies within facilitation of LDL 
retention  in  the  intimal  layers  of  vessels  (Xu  and  Tabas,  1991).  S‐SMase  alongside 
lipoprotein  lipase  (LpL)  and  secretory  phospholipase  A2  (sPLA2)  are  among  the  studied 
non‐matrix  proteins  involved  in  atheroma  formation with  LpL  and  S‐SMase  thought  to 
work in a synergistic manner in LDL retention (Tabas et al., 1993). Treatment of LDL with 
SMase was  shown  to  increase  LDL aggregation due  to hydrolysis of  LDL‐SM,  facilitating 
uptake by MΦ (Xu and Tabas, 1991, Schissel et al., 1996b). S‐SMase can hydrolyse native 
plasma  LDL  at  acid  pH  only,  but  can  hydrolyse  lesional  LDL  efficiently  at  neutral  pH, 
providing a physiological means behind this  theory  (Schissel et al., 1998a). A causal  link 
for  S‐SMase was provided  in a  recent paper by Devlin et al.,  (2008) whereby Ldlr‐/‐ and 
ASM‐/‐ mice showed decreased arterial lesional areas, lower total cholesterol (unchanged 
HDL‐cholesterol),  and  decreased  LDL  retention  (Devlin  et  al.,  2008).  This  S‐SMase 




is  tightly  involved  in oxidized‐LDL (oxLDL)  induced SMC proliferation (Auge et al., 1996), 
which may  sustain  the  latent  stages  of  atherosclerosis.  A  caveat  however,  comes  from 
Niemann‐Pick disease (NPD) patients who exhibit altered lipoprotein profiles even though 
they  lack  ASM,  lending  support  for  an  alternative  mechanism  behind  accelerated 
atherogenesis involving ECD.  
Although S‐SMase was  convincingly associated with  sub‐endothelial  lipid  retention  it 
does not adequately explain early physiological changes in endothelial responses such as 
decreased  blood  flow.  We  proposed  a  mechanism  that  may  precede  these  lipid 
abnormalities.  A  process  potentially  induced  and  propagated  by  inflammation  and 
immune dysregulation.  TNFα  is  of  particular  interest  as  it  has been  shown  to decrease 
eNOS mRNA  degradation  (Yoshizumi  et  al.,  1993). Wang  et  al.  first  showed  that  TNFα 
impairs endothelial responses to ACh (Wang et al., 1994). Soon after, early studies linked 
the  presence  of  infection  and  acute  inflammatory  responses  to  endotoxin  with  EC 
stunning  (Bhagat et al., 1996). TNFα  is also associated with ECD through  impairment of 




The  SM:Cer  pathway  is  particularly  regulated  by  TNFα,  a  signaling  cascade  that  is 
characterised  by  its  pleiotropism  and  upstream  ubiquity  in  cell  signalling.  Governed 
through  the SMase  family of enzymes,  cells elicit different  responses depending on  the 
stimulus and topology of SMase activation. Our increasing understanding of this pathway 
places  it  central  to  many  pathophysiological  conditions  including  atherosclerosis 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(Alewijnse  and  Peters,  2008,  Smith  and  Schuchman,  2008b).  Cer  generation  in  the  PM 
results  in  the  reorganisation of  PM architecture.  SM hydrolysis  creates Cer‐rich  LR  that 
can aggregate forming larger membrane platforms (Holopainen et al., 1998, Zhang et al., 
2009b) resulting in the clustering and concentration of membrane signaling receptors and 
proteins  involved  in  cell  death,  proliferation  and  differentiation  (Gulbins  and  Grassme, 
2002,  Zhang et  al.,  2009b,  Zhang et  al.,  2008). Our  in  vitro  data also  suggests  that Cer, 
once generated in the PM, may decrease Ca2+ signals for at least 3 hours, consistent with 




CD3  stimulation  in  Jurkat  T  cells  and  TNFα  in  thyroid  cells  (Tornquist  et  al.,  1999, 
Breittmayer et al., 1994) whereas, CD95 stimulation in T cells was shown to block ICRAC in 
an  ASM‐dependent  manner  (Lepple‐Wienhues  et  al.,  1999).  Importantly,  the  Cer 
metabolite  sphingosine  could  also  directly  inhibit  voltage  operated  Ca2+  channels  in 
pituitary cells and ICRAC in basophils (Titievsky et al., 1998, Mathes et al., 1998). Similarly, 
C2‐Cer  also  inhibited  Ca
2+  influx  possibly  due  to  its  ability  to  readily  cross  the  PM, 
suggesting an important requirement for in situ hydrolysis of SM within the PM (Mathes 
et al., 1998). In a recent study from our group, TNFα‐mediated depression of Ca2+ signals 
occured  through  ASM  activation  and  generation  of  Cer,  events  abrogated  in  ASM‐/‐  T 













species  in  SM  closely  interact  with  cholesterol  rings  creating  tightly  packed  structures 
(microdomains,  LR)  that  exist  in  a  more  rigid  state  than  normal  plasma  membrane 
fluidics.  Due  to  the  behaviour  of  Cer,  these  LR  can  fuse  with  other  Cer‐enriched  LR 
yielding larger Cer‐enriched macrodomains or platforms. (B) Cer‐enriched LR can also be 
cholesterol‐free,  arising  from  SM  molecules  not  within  traditional 
sphingolipid/cholesterol‐rich  LR  or  even  from  de  novo  ceramide  synthesis  thus  also 
excluding cholesterol. Cer‐enriched LR are distinct from caveolar‐based LR however, Cer‐
enriched platform formation may occur close to caveolae (A,B). Calcium channels such as 
ICRAC  are  found  in  close  proximity  to  caveolae  thus  S‐SMase‐induced  Cer‐enriched 



















































al.,  2000).  Cer was  previously  reported  to mediate  vasodilation  as  C2‐Cer,  however  the 
authors did not rule out the role of S1P (Johns et al., 1998). The precise effect of Cer on 
eNOS  itself  remains  controversial  and  has  been  suggested  to  activate  the  enzyme  in  a 
Ca2+‐independent manner (Bulotta et al., 2001) possibly through TNFα‐mediated nSMase 
activation  (Barsacchi  et  al.,  2003),  however  since  Cer  inhibits  Akt  kinase  it  may  also 
significantly impair eNOS phosphorylation and therefore inhibit its activation (Schubert et 
al., 2000, Bourbon et al., 2002, Zhou et al., 1998). Since eNOS activation in response to G‐
protein  coupled  receptors  (GPCR)  agonists  is  largely  dependent  on  Ca2+  one  could 
convincingly argue a role for Cer in NO regulation here.  
My  thesis  reveals  for  the  first  time  that  exogenous  ASM  can  directly  decrease  Ca2+ 
mobilisation in EC and provides a hint for altered NO signalling, a classical feature of ECD. 
As a system however, these findings are likely to complement others indicating that Cer 
generation  and  ROS  production  indirectly  diminish  NO  production  (Zhang  et  al.,  2001, 




susceptibility  of  ASM  to  oxidation,  one  may  envisage  ASM  being  activated  by  ROS 
producing  Cer  to  create  LR.  This  would  activate  NADPH  oxidases  increasing  ROS 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generation  thus  further  enhancing  ASM  activation  (Jin  and  Zhou,  2009).  The  most 
important  remark  however  is  that  Cer  is  a  versatile molecule  that  exerts  very  specific 
actions  depending  on  its  topology,  the  SMase  that  produced  it  and  importantly  the 
upstream stimulant of that SMase activity.  
Much  like  Ca2+,  information  about  the  effects  of  Cer  might  be  contained  in  the 
frequency  and  amplitude of  the  intracellular  signal  itself  (Parekh,  2008a).  These  events 
depend on the intracellular topology of Cer generation (PM, nuclear membrane, cytosolic 
cleavage), which may give rise to intracellular messengers or proteins (S1P, sphingosine) 
or  remain as Cer  and  translated  into  specific  responses.  Such  responses  vary  from Cer‐






as  Ca2+  is  vital  for  mitochondrial  function.  Inhibition  of  NO  yields  a  pro‐retentive 
endothelium,  opening  a  place  for  S‐SMase  in  atherogenesis  thus  inhibition  of  Ca2+ 
signalling  from  S‐SMase  may  have  wide‐ranging  effects.  A  further  clue  supporting  an 
alternative mechanism comes from the increased IMT seen in GPA patients, independent 
of  traditional  risk  factors  including  LDL  (de  Leeuw et  al.,  2005). However,  this may  not 




play a  role  in part of  the  initiating mechanism of ECD and propagates atherogenesis by 
interfering with sub‐endothelial lipid deposition.   
Beyond  Ca2+  dependence:  low  anti‐oxidant  capacity  in  chronic  inflammation,  S‐
SMase  and  ECD.  There  is  strong  evidence  for  the  involvement  of  oxidative  stress  in 
chronic  inflammatory  disease  and  CVD.  Both  nSMase  and  ASM  isoforms  have  been 
previously  associated  with  an  element  of  redox‐mediated  amplification  of  enzymatic 
activity (Liu and Hannun, 1997, Liu et al., 1998, Claus et al., 2005, Qiu et al., 2003). GSH 
was first associated as a biological inhibitor of nSMase (Liu and Hannun, 1997), however 
this  was  not  the  case  with  L‐SMase  specifically,  in  which  chemical  reducing  agent 
dithiothreitol  (DTT) was  favorable  (Liu  and Hannun,  1997). However  a  pivotal  paper  by 
Qiu et al. showed that recombinant ASM could be activated by oxidation or mutation of 
its  terminal  cysteine  (Qiu  et  al.,  2003).  To  our  knowledge  this  thesis  outlines  the  first 
example of examining the redox manipulation of native EC‐derived S‐SMase ex vivo and in 
situ.  
Our  investigations  although  not  achieving  the  desired  clarity,  described  an  upward 
shift in S‐SMase activity in the presence of H2O2 suggesting it may also be susceptible to 
regulation  by  oxidative  stress.  This  finding  may  be  of  significance  for  ECD  during 
inflammatory  conditions  with  low  antioxidant  capacity.  Previous  unpublished  material 
from our group found decreased GSH levels in peripheral blood and synovial fluid T cells 
of RA patients. EC, a rich source of ROS (Cai and Harrison, 2000), are likely to also exhibit 
decreased  anti‐oxidant  capacity  and  therefore  loss  of  vascular  function  (Landmesser  et 
al.,  2002).  Increased  ROS  production  by  MΦ  and  neutrophils,  raised  peroxidation 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products  and  decreased  plasma  GSH  are  found  in  RA  and  heart  failure  (Karatas  et  al., 
2003, Seven et al., 2008, Tang et al., 2007, McMurray et al., 1993, Keith et al., 1998). The 
increased  ROS/GSH  ratio  could  predispose  to  increase  S‐SMase  activation  through 
terminal Cys629 oxidation. Cer itself has been shown to increase eNOS expression but also 
lead  to ROS generation  reducing NO bioavailability  in EC  (Li et al., 2002). SM hydrolysis 
leading  to  Cer‐derived  ROS  generation  may  further  contribute  to  ECD  by  ONOO‐ 
formation,  decreased  eNOS‐BH4  availability  and  increased  eNOS  uncoupling.  Critical  to 




Given  the  susceptibility  of  S‐SMase  to  redox‐imbalance,  oxidative  stress  could  be 
expected  to contribute  to ECD by directly diminishing NO  levels; an elaborate  feedback 
loop is formed that involves TNFα, S‐SMase, and Cer production inducing ROS generation 
and/or  upstream  inhibition  of  Ca2+  influx  through  Cer‐mediated  blockade  of  PM  iCRAC 
channels  leading  to  decreased  Ca2+‐dependent  NO  production.  Thus  an  imbalance  of 
cytokine expression and redox dysregulation may contribute to ECD.  
Vascular  inflammation,  S‐SMase  and  accelerated  atherosclerosis.  The  key               
question asks why there is increased cardiovascular mortality in PSV and RA that cannot 





that  the  primary  synovitis  may  obscure  the  vascular  inflammation  often  found  in  RA. 
Rheumatoid vasculitis may be driven by activation of synovial fibroblasts, T cells and MΦ 
in  RA  all  of  which  secrete  TNFα.  To  date  there  are  no  surrogate  markers  for  active 
vascular damage and the effects of S‐SMase and Cer on vascular function have not been 
explored  in  relation  to  disease  activity  in  chronic  inflammation.  This  study  set  out  to 
investigate the presence and activity of S‐SMase  in PSV and RA  in relation to rheumatic 
and  cardiovascular  disease  parameters.  As  a  model,  primary  vasculitis,  the  archetypal 
form  of  idiopathic  vascular  inflammation  has  been  shown  to  feature  enhanced 
atherogenesis.  
S‐SMase  previously  correlated  with  disease  severity  in  CHF  when  compared  to  the 
New York Heart Associated functional class. However this was not the case in our cohorts 
using  the  BVAS  or  DAS‐28  in  AASV  and  RA  respectively.  In  the  CHF  patients,  serum  S‐
SMase levels correlated with impairment of vasodilator responses measured by forearm 
post‐ischaemic  blood  flow  (Doehner  et  al.,  2007).  Interestingly,  local  vascular 
inflammation has been shown to also target distant unaffected vessels. ECD  in PSV was 
shown  to  be  widespread  and  diffusely  present  in  different  vascular  beds.  Filer  et  al., 
(2003) revealed that ECD occurred independently of ANCA status and renal involvement, 
essentially regardless of the site of involvement of the primary vasculitis, suggesting that 
it  could  be  brought  about  as  a  result  of  overt  vascular  inflammation.  Although  anti‐
TNFα and  anti‐IL‐1  treatment  was  shown  to  significantly  improve  vascular  function 
regressing ECD (Booth et al., 2004b, Ikonomidis et al., 2008), this thesis did not reveal an 




group  of  patients  on  infliximab  and  the  presence  of  other  inflammatory  markers  (IL‐
1β, IFNγ).  
Suppression of disease activity (BVAS) in our AASV cohorts was not associated with S‐
SMase  activity.  However  cross  sectional  sampling  was  performed  early  in  the  clinical 
response (w14) where It is known that prolonged treatment is required to prevent early 
relapse even after 1 year. Thus S‐SMase levels may be a marker of endothelial damage as 
supported  by  its  correlation  with  the  VDI  rather  than  of  active  inflammation.  The  RA 
studies in this thesis suggest that S‐SMase correlates with established damage and CV risk 
factors  in RA.  S‐SMase  levels might be best  compared  in  relation  to CVD complications 
that affect PSV. A clue for the lack of relationship between S‐SMase, disease activity and 
pro‐inflammatory  cytokine  levels  is  the apparent prolonged half‐life of  S‐SMase  in  vitro 
(Jenkins et al., 2010a). As its transience in vivo and the kinetics have not been described 
in relation to inflammatory disease, the question arises, what is the half‐life of S‐SMase in 
the  circulation?  If  S‐SMase  is  secreted  during  disease  flares,  and  persists  even  after 
disease  activity  has  clinically  regressed  it  remains  difficult  to  retrospectively  translate 
enzymatic to disease activity.  
 
These data  do not  provide  a  causative  link  of  S‐SMase with  the disease process  but 
provide clues for S‐SMase in clinical disease and EC dysregulation. Thus S‐SMase may be a 
novel  biomarker  directly  relating  to  vascular  damage  and  given  its  source may prove  a 
















expression  of  ASM  in  EC  in  relation  to  the  timing  of  its  secretion  will  help  clarify  its 
association  with  disease  activity  in  clinical  disease.  While  inflammation  is  present  in 
chronic  active  disease,  remission  and  acute  flares  may  affect  S‐SMase  activity. 
Assessment of  the  relationship between TNF,  disease  activity  and ASM will  allow more 
clarity of S‐SMase biology and further validate its use as a diagnostic/prognostic marker. 
 
The  effect  of  S‐SMase  on  spatial  and  temporal  molecule  association  in  the  PM.  It 
remains unknown how S‐SMase accesses pools of SM  in  the PM.  Immunohistochemical 
studies of ASM translocation and secretion would enable us to understand the topology 




LR  would  be  made  possible  through  immunoblotting  for  ASM  with  raft  markers 









Studies  would  focus  on  depleting  intracellular  stores  of  Ca2+  using  thapsigargin  in  an 
extracellular Ca2+‐free medium. Upon addition of Ca2+  into the medium, SOCE would be 
compared between treated and untreated cells with those affected by channel blockade 






Effect  of  ASM  on  adhesion  molecule  expression.  Given  the  importance  of  Ca2+  in 
membrane  dynamics  and  adhesion molecule  expression,  ECD  can  also  be  expressed  as 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media  supernates  from  TNFα  treatment  (100  ng/mL)  HUVEC.  (B)  S‐SMase  detected  by 
immunoblotting in media supernates and (C) S‐SMase activity detected by the thin layer 














18  hours.  DiOC6  dye  was  loaded  prior  to  trypsinisation  (A,  left  panels)  or  following 
trypsinisation (A, right panels). Cells cultured with HESFM (A, top panels), and M199 (A, 
bottom  panels)  for  dye  loading.  (B)  Figures  representative  of  a  typical  experiment  of 
HUVEC  counts  by  flow  cytometry.HUVEC  were  cultured  and  treated  with  serum‐free 








































Exogenous  ASM  (Sigma‐Aldrich)  or  nSMase  (Sigma‐Aldrich)  were  added  to  a  reaction 
mixture  including 62 mmol/L sodium acetate, 0.1%  Igepal  (NP‐40) supplemented with 2 















DAF‐2,  (B)  0.1 µmol/L  DAF‐2,  (C)  1 µmol/L DAF‐2.  Lower  panel,  Selected  experiments 
measuring NO production from HUVEC stimulated with bradykinin (1 µmol/L) compared 
to solvent control (PBS) treated cells and DAF‐2 auto‐fluorescence using 0.1 µmol/L DAF‐
2. For method see 2.2.13.1 . 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